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Abstract
To cope with the rapid changes in the environment, all the cellular processes
must be carefully regulated and this is often achieved by means of the post-
translational modifications. These chemical modifications added to the side
chains of amino acids in protein sequences have a variety of consequences,
ranging from the stability to the change in protein-protein interactions.
One of these post-translational modifications is ADP-ribosylation. ADP-
ribosylation is mainly associated to the regulation of DNA damage repair,
although it is important for the modulation of a large variety of cellular
processes. Being a complex signaling pathway, ADP-ribosylation requires
a likely complex metabolism and a number of transferases and hydrolases
orchestrate its spatial and temporal dynamics. Among the latter, MacroD2
removes the most proximal ADP-ribosyl-moiety from the glutamate of a
substrate protein.
My host lab is interested in the understanding of the modulation of the
DNA damage repair response by focusing on the ADP-ribosyl-hydrolases.
This brought my direct supervisor, Dr. G. Timinszky, to discover a par-
ticular phenomenon associated to MacroD2 protein: when the protein is
tagged with EGFP, upon DNA damage it recruits to the DNA lesion, while
its nuclear signal decreases over time. The work of my PhD aimed to un-
derstand and characterize the strange DNA damage-dependent behavior of
MacroD2.
For my work, I use a combination of microscopy and biochemical technics.
Thus, I show that the decrease in MacroD2 nuclear protein levels is due to
its regulated nuclear export. This behavior of EGFP-tagged MacroD2 con-
struct is also performed by the endogenous protein. I then characterize the
stimulus that triggers MacroD2 nuclear export. Upon DNA damage, mostly
upon formation of double-strand breaks, the kinase ATM, master regulator
of genotoxic stress response, is activated. ATM induces the phosphorylation
of MacroD2 on two specific serine residues located in the MacroD2 intrinsi-
cally disordered C-terminus region. This event triggers the nuclear export
of MacroD2. I also show that MacroD2 nuclear export is able to affect its
own recruitment dynamics at the DNA lesion, suggesting a potential role
in the regulation of the DNA damage response.
Although I defined the events inducing MacroD2 nuclear export, to under-
stand the mechanism with which MacroD2 crosses the nuclear envelope, I
performed a co-immunopurification experiment associated to peptide mass
fingerprinting. By comparing genotoxic stress condition to the control, and
a series of MacroD2 constructs (full-length protein, macrodomain or C-
terminus fragments), it is possible to draw the interactome of the protein
for the specific constructs in the specific conditions. The experiment does
not indicate any candidate that could drive MacroD2 into the cytoplasm.
On the other hand, the co-immunopurification experiment suggests few hy-
potheses about MacroD2 functional roles in the cells. In fact, although little
is known about MacroD2 functions, by combining the analyses on the en-
riched proteins with published studies, I formulate testable hypotheses able
to connect the enzymatic activity of MacroD2 to its genomic association
with autism syndrome.
Zusammenfassung
Alle zellula¨ren Prozesse mu¨ssen genau reguliert werden, um auf plo¨tzliche
Umwelteinflu¨sse reagieren zu ko¨nnen. Dies wird ha¨ufig durch posttrans-
lationale Modifikationen erreicht. Hierbei werden chemische Modifikatio-
nen an Aminosa¨ureseitenketten hinzugefu¨gt. Dies kann viele, verschiedene
Auswirkungen auf Zellen haben, von A¨nderungen der Proteinstabilita¨t bis
zu unterschiedlichen Proteininteraktionen. Eine dieser Modifikationen ist
die ADP-ribosylierung von Proteinen. ADP-ribosylierung wird hauptsa¨chlich
mit der Reparatur von DNA-Scha¨den verbunden, obwohl diese Modifikation
fu¨r eine Vielfalt von weiteren zellula¨ren Prozessen von Bedeutung ist. Da
ADP-ribosylierung ein komplexer Signaltransduktionsweg ist, wird ein ex-
tensiver Metabolismus beno¨tigt, welcher aus mehreren Transferasen und
Hydrolasen besteht. Diese Enzyme bestimmen die o¨rtliche und zeitliche
Dynamik dieses Prozesses. Eines der Enzyme ist MacroD2, das den ADP-
ribose-Rest, welcher u¨ber einen Glutamatrest proximal an ein Substratpro-
tein gebunden ist, entfernt.
Der Arbeitskreis von Dr. G. Timinszky am Department fu¨r physiologische
Chemie der LMU ist daran interessiert herauszufinden, wie die Reparatur
von DNA-Scha¨den modifiziert wird, insbesondere durch ADP-Ribosyl- Hy-
drolasen. Dies fu¨hrte zur Entdeckung eines besonderen Pha¨nomens von
MacroD2 durch meinen direkten Betreuer Dr. G. Timinszky. EGFP-
markiertes MacroD2 rekrutiert zu induzierten DNA-La¨sionen, wobei das
nuklea¨re EGFP Signal u¨ber die Zeit geringer wird. Das Ziel meiner Dok-
torarbeit war es, dieses bemerkenswerte Verhalten von MacroD2 nach der
Induktion von DNA-Scha¨den zu verstehen und zu charakterisieren.
In meiner Doktorarbeit habe ich eine Kombination von Mikroskopie und
biochemischen Methoden verwendet. Damit konnte ich zeigen, dass die
Reduktion des nuklea¨ren MacroD2s durch dessen regulierten Zellkernex-
port hervorgerufen wird. Dieses Verhalten von EGFP-markiertem MacroD2
wurde auch bei endogenem MacroD2 nachgewiesen. Ich konnte auch den
Stimulus charakterisieren, der dazu fu¨hrt, dass MacroD2 aus dem Zel-
lkern exportiert wird. Durch DNA-Scha¨den, hauptsa¨chlich durch DNA-
Doppelstrangbru¨che, wird die Kinase ATM aktiviert, welche Signalkaskaden
in der Zelle startet, um auf genotoxischen Stress zu antworten. ATM
phoshoryliert MacroD2 an zwei spezifischen Serinresten in dessen ungeord-
neter, C-terminaler Region. Dies hat den Export von MacroD2 aus dem
Zellkern zur Folge. Ich konnte des Weiteren zeigen, dass der Zellkernexport
von MacroD2 dessen Rekrutierungsdynamik an DNA-La¨sionen beeinflusst.
Dies spricht fu¨r eine potentielle Rolle von MacroD2 in der Antwort auf
DNA-Scha¨den.
Nachdem ich den Mechanismus definieren konnte, der dazu fu¨hrt, dass
MacroD2 aus dem Zellkern exportiert wird, war es wichtig herauszufinden,
durch welchen Mechanismus MacroD2 die Kernmembran passieren kann.
Hierfu¨r habe ich Co-Immunopra¨zipitationen mit anschließender Analyse der
Peptid-massenfingerprints durchgefu¨hrt. Durch den Vergleich von geno-
toxischen Stressbedingungen mit Kontrollbedingungen und durch die Ver-
wendung mehrerer MacroD2 Konstrukte (Vollla¨ngenprotein, Macrodoma¨ne
und C-terminale Doma¨ne) ist es mo¨glich das Interaktom der Proteine mit
MacroD2 fu¨r verschiedene Konstrukte und Bedingungen zu definieren. Diese
Experimente zeigten jedoch keinen Kandidaten, welcher MacroD2 aus dem
Zellkern in das Zytoplasma exportieren ko¨nnte. Andererseits konnten mehrere
Hypothesen u¨ber funktionelle Aufgaben von MacroD2 in Zellen aufgestellt
werden. Obwohl wenig u¨ber Funktionen von MacroD2 bekannt ist, konnte
ich, durch die Kombination der Analyse von angereicherten Proteinen und
publizierten Ergebnissen, pru¨fbare Hypothesen aufstellen. Diese Hypothe-
sen verbinden die enzymatische Funktion von MacroD2 mit genomweiten
Assoziationsstudien u¨ber das Autismus Syndrom.
To Nonna Maria,
whose fierce spirit has prompted me
to aim to self-improvement
and to finally complete this journey.
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1Introduction
Life demands adaptation to new stimuli, from the outside world as well as from the
inside. Every cellular process consists of a series of enzymatic reactions performed by
a large number of proteins. All these processes need a great deal of coordination: a
multi-step pathway must take place in a controlled manner, in the right proportion,
at the right time and in the right place. It is indeed a complex task for the cell to
organize everything. Therefore, for each pathway, a regulatory system that accurately
fine tunes the different steps in that pathway has evolved.
Each process needs to be adjusted according to the variable conditions inside and
outside of the cell. When the environment changes rapidly, the cell response needs to
be equally fast. This fast response cannot rely on the synthesis of new proteins, since
all together transcription, transcript processing and translation are relatively slow.
To generate an appropriate quick response, other types of regulation have evolved.
For example, post-translational modifications, which are covalently-attached chemical
groups, can affect the activity or the stability of the target protein. Another means
to achieve the regulation of a pathway is to modulate the localization of the proteins
within the cell. Either alone or in combination, these two strategies of regulation can
change the activity of a specific pathway and adjust its functionality to the momentary
needs of the cell.
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1.1 Post-translational modifications in modulating cellu-
lar processes
Many eukaryotic proteins are regulated by means of a chemical modification. The amino
acid side chains of a protein can be modified covalently by a chemical group or even a
small protein, which affects its activity or stability (1). Since the modification occurs
after the synthesis of the protein, it is called a post-translational modification. There
are many classes of post-translational modifications and virtually all proteins could
be regulated through them (Figure 1.1). The most well-studied post-translational
modifications are phosphorylation, methylation, acetylation, ubiquitination and ADP-
ribosylation. But many more are at work in the cells.
The first evidence of reversible post-translational modification is described in the
work on the glycogen phosphorylase (2), whose phosphorylation state dictates the ac-
tivation levels of the protein (3). Since then, our knowledge of post-translational mod-
ifications has expanded rapidly and there is an increasing number of types of modifi-
cation and mechanisms regulating protein activity. Despite their diversity, most post-
translational modifications are modulated through three types of protein components:
a “writer”, an “eraser” and a “reader”. The “writer” is an enzyme, like a transferase,
that attaches the modification to the target protein. The “eraser” removes the modi-
fication. The “reader” is a protein that is able to decode the modification and induce
the effect that the modification is calling for (Figure 1.2). This theory was first elab-
orated for the modifications occurring on histone proteins (4). However, this theory is
generally applicable in describing other post-translational modification-based signaling
pathways. Nonetheless, this view may suffer of extreme generalization, as, for example,
the reader function can be dispensable. In fact, in many cases the post-translational
modification is able to produce an effect by changing the structural conformation of
the substrate, in a way that is independent from “reader” factor.
So far, the main body of research describes how one specific post-translational
modification regulates one biological process. But it is becoming clear that the different
pathways do not work as separated blocks and the survival of the cell is accomplished
only when all the processes are coordinated (5). This is the reason why the interactions
of different pathways are the real key to understand how life is so apt to adapt. Only
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Figure 1.1: Different post-translational modifications present similar functional
components - A small selection of post-translational modifications in the cell: phospho-
rylation (a), acetylation (b), methylation (c). Simplified representation of the reactions
that add or remove the post-translational modification. Also shown as an example is one
typical domain that binds the protein substrates only when the specific post-translational
modification is present. P, phosphorylation; Ac, acetylation; Me, methylation. Adapted
from Deribe et al., 2010 (1).
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Figure 1.2: Post-translational modifications dynamics result from the combi-
nation of three different functions - As originally formulated in the “histone code
hypothesis”, the structure of each post-translational modification is based on three func-
tions: the “writers” set the signal; the “erasers” remove the signal; the “readers” decode
the signal. Adapted from Baker et al., 2008 (4).
by knowing how the network of different processes is interconnected, we can actually
understand the system, and maybe one day control it.
1.2 ADP-ribosylation: regulation and functions
ADP-ribosylation is a post-translational modification discovered already in 1963 (6).
Although in the early years it was mainly referred as enzymatic activity of bacte-
rial toxins, like diphtheria toxin, it then became clear that ADP-ribosylation is a re-
versible post-translational modification implicated in the regulation of several cellular
processes, such as genomic stability (7), chromatin structure (8), transcription (6), cir-
cadian rhythm (9), and RNA metabolism (10). ADP-ribosylation is a very dynamic
post-translational modification, whose high turnover is due to the presence of several
“writers” and “erasers” (Figure 1.3). ADP-ribosylation is very complex, since the
modification can comprise of a single moiety up to 200-long-units chain, which can
be linear or branched. So far, the single ADP-ribosyl-modification works in a distinct
manner, when compared to the long-chain regulatory activity (11). However, the pos-
sible combinations for the long chain, such as the number of moieties in the chain
and the presence of branching, may exponentially increase the coding abilities of this
post-translational modification.
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Figure 1.3: ADP-ribosylation shows a complex metabolism - Protein substrates
are initially modified with the addition of one ADP-ribose moiety. This signal can be
reversed or used as starting point for a long chain that is linear or branching. Several
enzymatic activities ensure that the protein is reverted to the mono-ADP-ribosylated or
unmodified state. Adapted from Barkauskaite et al. 2013 (12).
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1.2.1 Human ADP-ribose transferases are diverse in structure and
function
In humans, ADP-ribosylation is carried out by different classes of transferases. Ac-
cording to the recently proposed nomenclature, ADP-ribose transferases (ARTs) are
divided into two groups (13), depending on which protein structure they adopt: the
first and most studied group consists of the eighteen ADP-ribosyltransferases diphtheria
toxin-like proteins (ARTDs), most of which were previously known as poly(ADP-ribose)
polymerases (PARPs); the second group consists of the five C2 and C3 toxin-like ADP-
rybosyltransferases (ARTCs). Besides the ARTDs and ARTCs, SIRT2, SIRT4 and
SIRT6, belonging to the family of the de-acetylase sirtuins, were also reported to act
as ADP-ribosyl-transferases (14, 15, 16, 17).
The ARTs transfer an ADP-ribose moiety from nicotinamide adenine dinucleotide
(NAD+) onto the target protein and release nicotinamide as by-product (Figure 1.4;
(6)). Many residues that accept ADP-ribose have been described so far. These are:
glutamate (18), aspartate (18), lysine (19), arginine (20), asparagine (21), cysteine (22),
diphthamide (23) and phospho-serine (24) residues.
The complexity of ADP-ribosylation signaling is due to the fact that the modifica-
tion itself shows a certain degree of complexity. While most enzymes can only perform
the transfer of one ADP-ribose moiety, and therefore are called mono(ADP-ribose)
transferases (MARTs), some can attach other moieties to the first, granting the pos-
sibility to create a chain up to 200 units, thus the former name of PARPs (6). The
chain can be linear, if the new moiety is attached to the adenine-proximal ribose unit
through a 2′-1′′-O-glycosidic bond. Also, the PARPs can attach the new moiety at the
nicotinamide-proximal ribose, thus creating a 2′′-1′′′-O-glycosidic bond and forming a
branch (25). The branching happens every 20-50 ADP-ribose units per chain in both
in vitro and in vivo experiments (25, 26, 27, 28).
The eighteen human ARTDs are further classified according to their enzymatic
activity (Figure 1.5). ARTD1, ARTD2, ARTD5 (TNKS1) and ARTD6 (TNKS2)
generate poly(ADP-ribose) (PAR) (11). The others can only transfer a single mono-
ADP-ribose (MAR) onto target proteins, with the exception of ARTD9 and ARTD13
that are inactive. Additionally, the sirtuins SIRT2, SIRT4 and SIRT6 have been shown
to be themselves mono-ADP-ribosyl-transferases (14, 15, 16, 17).
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Figure 1.4: ADP-ribose can be attached in a linear or a branched fashion -
MARTs or PARPs use NAD+ as donor for both the MARylation and PARylation. For a
linear chain, two ADP-ribose molecules are connected through a 2′-1′′-O-glycosidic bond.
Every 20-50 ADP-ribose units, the branching of the chain takes place with the formation
of a 2′′-1′′′-O-glycosidic bond.
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Figure 1.5: Domain architecture of the human ARTDs - List of the eighteen ARTDs
with their domain composition. ART: catalytic core for ART activity; HD: linking helical
subdomain; WGR: conserved central motif (W-G-R); BRCT: BRCA1 carboxy-terminal
domain; SAM: sterile alpha motif; ARD: ankyrin repeat domains; VIT: vault protein inter-
alpha-trypsin; vWA: von Willebrand type A; WWE: named after three conserved residues
(W-W-E); Macro: macrodomain; ZF: zinc finger domains; SAP: SAF/Acinus/PIAS-DNA-
binding domain; MVP-ID: Major-vault particle interaction domain; HPS: Histidine-proline-
serine region; RRM: RNA-binding/recognition motif; UIM: ubiquitin interaction motif;
TPH: Ti-PARP homologous domain. GRD: glycine-rich domain; CBD: caveolin-binding
domain. Adapted from Hottiger et al., 2010 (13)
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ARTD1/PARP1 is the most studied member of the ARTDs. ARTD1 a 116 kDa
enzyme, is one of the few ARTs that is activated by binding specific DNA-damage
related structures. ARTD1 is composed of many structural domains: two homologous
zinc-finger domains (ZnF1 and ZnF2); a third zinc finger domain (ZnF3) diverged from
the previous two; a BRCA1 C-terminus (BRCT) motif with the auto-modification
domain; a WGR (Trp-Gly-Arg) motif; a catalytic domain containing the linking helical
subdomain (HD) and the conserved catalytic signature (HYE) in the real catalytic
fragment (CAT) (Figure 1.6 (29)). So far, crystallization of the whole protein has
been elusive, but through crystallization of ARTD1 fragments it has been possible
to define how the enzyme binds the damaged DNA and how the binding enhances
the enzymatic activity (30, 31, 32, 33, 34, 35). According to several studies, the ZnF1,
ZnF3, WGR and CAT domains are necessary for DNA-dependent activity on DSB (29).
However, Ali et al., 2012 showed that in vivo recruitment of the ARTD1 fragment to
DNA lesions is dependent on a functional ZnF2 upon UV-laser microirradiation (33).
This observation is explained by the role of ZnF2 in the recognition of DNA single-
strand-breaks, largely induced by UV laser (30).
Human ARTD1
a
b
CAT
CAT
Figure 1.6: Domain architecture and activation of ARTD1 - ARTD1 is the best
characterized ARTD. In a, the domain composition of the human ARTD1. In b, surface
rapresentation of ARTD1/DNA structure. Adapted from Langelier et al., 2012 (34).
The most recent mechanism for ARTD1 activation suggests that the ZnF3 and the
WGR domain relay the DNA damage binding to the catalytic domain (34, 35). When
the ZnF domains bind a DNA lesion, a conformational switch in the WGR domain
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makes the HD subdomain to move away from the CAT domain, which then increases
its catalytic processivity. ARTD2 and ARTD3 have the same allosteric regulation
between the HD and CAT domains, although the binding domain and the activating
DNA molecule are different from ARTD1.
Since ARTD1 is so well studied, many examples are described, where ARTD1 ac-
tivity is modulated by post-translational modifications from other enzymes: SET7/9-
dependent methylation (36), SIRT6-induced MARylation (37, 38) and cyclin-dependent
kinase 2 (CDK2)-dependent phosphorylation (39) are all able to induce ARTD1. ARTD1
is also phosphorylated by DNA-PK (40, 41) and by ataxia-telangiectasia-mutated (ATM)
(42, 43, 44), although it is not clear if there is a functional role for these modifications.
Little is known about the structural details of the other ARTD enzymes (45). And
even less is known about the structure of the MARTs. ARTD10 has been the first
MART to be studied in detail and the definition of its catalytic mechanism suggested
that the sequence requirement for the MARylating activity and for the polymerase
activity are different (46).
The MART activity of the sirtuins has been described in a number of paper, but
little is known about their functional role or their substrates. SIRT2 was the first
human sirtuin found to have MART activity in in vitro experiments (14), although other
enzymatic activities, such as deacetylation and demyristoylation, might be prevalent
in the cellular environment (47). SIRT4 is localized in the mitochondria and has been
shown to MARylate the glutamate dehydrogenase (GDH) and modulate in this way its
enzymatic activity (16). Last but not least, SIRT6 has been shown to be recruited to
DNA lesions and to MARylate ARTD1 (37, 38). This modification would increase the
polymerase activity of ARTD1.
1.2.2 The ADP-ribose recognition modules relay the encoded message
Post-translational modifications are often recognized by specific recognition modules.
So far, seven ADP-ribose recognition modules have been identified (Figure 1.7 (8,
12)). These are able to recognize specific or common features of MAR and PAR.
The first identified were the linear PAR-binding motifs (PBMs) (48). Then, in rapid
succession, more modules have been discovered: WWE domain (49), macrodomain
(50) and PAR binding-zinc finger (PBZ) (51). The following domains to be discovered,
FHAs and BRCTs, were previously associated to the recognition of phosphorylation.
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These specific domains seems to have diverged from the canonical phosphorylation-
binder FHA and BRCT domains and a combination of in vitro and in vivo assays
showed for them a better affinity for ADP-ribosylation (52, 53). Similar story occurred
for the single-strand DNA binding domain OB. The authors were able to show binding
for the ADP-ribosylation in place of DNA molecules (54).
Being very diverse binding modules, they can recognize different features of the
ADP-ribose molecule, as different immunoglobulins from a polyclonal antibody recog-
nize several epitopes. For example, WWE domain binds at the linkage between two
different ADP-ribose moieties, making it the perfect reader for PAR (55). On the other
hand, macrodomain is binding the most terminal potion of the ADP-ribosyl-residue.
Therefore, it can bind either the end of a PAR chain or a single MAR (56).
1.2.3 PARG and ARH3 degrades the poly-ADP-ribose into mono-
ADP-ribose
In every type of signaling, the timely removal is essential for proper regulation. There-
fore, in humans there are a number of enzymes that negatively regulate the levels
of ADP-ribosylation, even though they are much fewer compared to the pool of the
transferases (12).
The PAR glycohydrolase (PARG) and ADP-ribose hydrolase 3 (ARH3) degrade
PAR by hydrolyzing the O-glycosidic ribose-ribose bonds and release ADP-ribose (57,
58). In particular, PARG removes preferentially one moiety at the time, but can also
remove the whole chain all together (59). Conversely, the crystal structure of ARH3
suggests that it can only remove the last ADP-ribose of the chain (60, 61). However,
they are ineffective on the protein-linked mono-ADP-ribose, so that their final products
are mono-ADP-ribosylated proteins.
Surprisingly, the two proteins show different structures in the catalytic domain, since
the first possess a catalytic macrodomain, while the latter belongs to the dinitrogenase
reductase-activating glycohydrolase-related protein family (62, 63). PARG activity is
essential to a proper regulation of ADP-ribosylation, due to the lethality at the embryo
stage in PARG-/- mice and to the pronounced neural overproduction of PAR associated
with neurodegeneration in Drosophila (64, 65). ARH3 activity is also important for
proper cell function upon oxidative stress (66).
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Keun Woo Ryu et al. Chem Rev 2015; 115(6):2453-81
Figure 1.7: The different PAR-binding modules - Each PAR binding module
can recognize distinct features of the PAR molecule. a) The PBZ domain (blue) uses
a zinc-coordinated fold that recognise the 2′′-1′-O-glycosidic bond between two ribose
units, shown in the boxes with crystal structures of APLF and CHFR binding analogues.
The macrodomain (red) binds the terminal ADP-ribose residue of PAR or mono-ADP-
ribosylated protein. The WWE domain (green) recognize the iso-ADP-ribose residue.
Human RNF146 WWE domain in complex with iso-ADP-ribose is shown as example. b)
A table summarizing all the different PAR binding modules, the PAR element recognized
and some example factors. From Ryu et al., 2015 (6).
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Until recently, ADP-ribosylation was not a completely reversible modification, since
the enzymes removing the most proximal ADP-ribose moiety attached to the acidic
residues were still unknown. In 2013, three different papers characterized the enzymatic
activity of MacroD1, MacroD2 and TARG1, the human mono-ADP-ribosylhydrolases
(56, 67, 68).
1.2.4 MacroD1, MacroD2 and TARG1: the ultimate “erasers”
ADP-ribosyl-arginine hydrolases in animal species were already known since the middle
1980s (69). These activities, however, were only able to remove the final moiety from
other amino acid residues a part from arginine. Therefore, the mono-ADP-ribosyl
hydrolase activity acting on acidic residues was still missing. MacroD1, MacroD2 and
TARG1 can reverse protein MARylation by hydrolyzing the ester bond between ADP-
ribose and glutamate or aspartate (56, 67, 68). These three proteins belong to the same
protein family, since they share the same catalytic domain, the macrodomain (Figure
1.8). The same domain is present also in PARG, even though modified in key residues
so that PARG cannot perform this last removal step (see 1.2.3; (62)).
The macrodomain is a globular domain presenting a combination of 5 α-helices
and 6 β-sheets (Figure 1.9; (50, 70)). The macrodomain is a very conserved mod-
ule, spread throughout the whole evolutionary arc, from archeobacteria, bacteria to
vertebrates. It is also represented in some virus classes, arguing for a primordial role
in the anti-viral response and a successively exchange between hosts and viruses (70).
Also, the number of macrodomain-containing genes within an organism well correlates
with its complexity, even though it is not always true. Among the model organisms
in research, macrodomains are present in mouse, frog, fruit fly, chicken, zebrafish and
roundworm, as well as many others. Remarkably, budding yeast has not ARTDs but
two macrodomains, probably successively reintroduced (70).
The macrodomain has been first found as an unknown sequence of the histone
variant MacroH2A (71). Independently, by an unbiased genomic approach in yeast,
it was found that this same sequence could hydrolyze a byproduct of tRNA splicing,
the ADP-ribose-1′′-phosphate (72). But at the time there was no connection with
MacroH2A, as well as no crystal structure nor protein family. In 2005 the crystal
structure of the macrodomain from the Archaeoglobus fulgidus protein Afl1521 was
published, matching the folding of the previously unknown sequence with the yeast
13
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H2A Macro MacroH2A11 372
H2A Macro MacroH2A21 372
MacroSNF2_N HELICc ALC11 797
MacroMacro PARP cat ARTD9/PARP9/BAL11 854
Macro Macro Macro PARP catWWERRM ARTD8/PARP14/BAL21 1801
Macro Macro PARP cat ARTD7/PARP15/BAL31 678
Macro SEC14 GDAP21 497
Macro MacroD11 325
Macro MacroD21 448
Macro TARG11 152
MacroRegulatory domain Accessory domain PARG1 976
Figure 1.8: Macrodomain family members in humans - Domain structure of the
human macrodomain proteins. Domain abbreviations: H2A, core histone H2A-like do-
main; HELICc, helicase conserved C-terminal domain; Macro, macrodomain; PARP cat,
poly(ADP-ribose) polymerase catalytic domain; RRM, RNA recognition motif; SEC14,
named after yeast SECretory protein 14 (Sec14p); SNF2-N, SNF2 helicase family N-
terminal domain; WWE, domain is named after a conserved tryptophan/glutamate-
containing motif. Adapted from Rack et al., 2016 (70).
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a b c d
Figure 1.9: How the macrodomain folds and binds to the ADP-ribose - a)The
topological representation of the macrodomain shows the organization of the central six-
stranded -sheet (red) flanked on both sides by five α-helices (green). However, some
macrodomains have additional α-helices or β-strands. b-d) The ribbon and surface rep-
resentations of three human macrodomains, MacroH2A1.1 (b), MacroD2 (c) and TARG1
(d). The structures show the binding of ADP-ribose (b,c) or the lysyl-ADPr intermediate
(d). In the magnifications, details on the coordination of the adenosine moiety by a con-
served phenylalanine and/or asparagine residue as well as by the substrate-binding loops
1 and 2 (red) is depicted in the magnifications. From Rack et al., 2016 (70).
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protein (50). Along with the folding, the macrodomain was identified as a ADP-ribose-
1′′-phosphate hydrolase, as well as a PAR-binding module. MacroH2A was next shown
to bind O-acetyl-ADP-ribose, a byproduct of Sirtuins de-acetylase activity, and that
this ability was lost according to the splicing isoform of MacroH2A (73).
It took some time to show that macrodomains from the human MacroD1 and
MacroD2 were able to hydrolyze O-acetyl-ADP-ribose as well, suggesting a role of
macrodomain proteins in the regulation of histone acetylation (74). In the meantime,
the crystal structure and the O-acyl-ADP-ribose hydrolase activity of C6orf130/TARG1
were confirmed (75). Two years later, several groups finally showed the mono-ADP-
ribose hydrolase activity of MacroD1, MacroD2 and TARG1 (56, 67, 68).
The three mono-ADP-ribose hydrolases share the macrodomain structure. But they
greatly differ in other elements. TARG1 is the smallest of the three proteins, only 17
kDa. It has most of the protein sequence overlapping with the macrodomain and it is
more related to the ALC1-like folding than to the MacroD protein folding (70). When
tagged with EGFP, TARG1 is found in the whole cell, therefore it seems there is no
restriction in its localization (68). The small size should not affect the free movement
of TARG1 within the cell. The catalytic activity of TARG1 requires the formation
of a stable intermediate of the target protein bound to the enzyme. This mode of
action is slightly different from the other two enzymes of the group, consistent with the
fact that TARG1 is in a different phylogenic branch (68, 70, 75). The only described
interactors of TARG1 are ARTD1 and ARTD10, so far (68). Also, TARG1 is shown
to recruit to DNA damage sites upon UV-laser microirradiation and it is dependent
on the ADP-ribose binding ability of the macrodomain. TARG1 activity is associated
with neurodegeneration (68), similarly to PARG (65). Thus, the regulation of ADP-
ribosylation appears to be particularly necessary in the brain.
MacroD1 is a slightly bigger protein, with 35.5 kDa molecular weight. Aside the
macrodomain, MacroD1 presents an N-terminal sequence with a mitochondrial tar-
geting sequence (MTS) (76). Its mitochondrial location suggests that the MacroD1
enzymatic substrates could be all mitochondrial proteins. Studies have shown that
MARylation occurs in mitochondria: for example, SIRT4 negatively regulates GAPDH
activity by MARylation (16). Also, one of PARG isoforms presents a MTS (12). There-
fore, regulation of mitochondrial processes could be mediated by ADP-ribosylation.
However, in vitro tests on the MAR-hydrolase activity of MacroD1 were performed on
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ARTD1 and ARTD10, whose main location is not in the mitochondria. Additionally,
the work of W. Han group shows that MacroD1 (called by them LRP16) is co-activator
of the estrogen receptor α and androgen receptor, as well as being involved in the NF-
κB regulation (77, 78, 79). It is still unknown how these functional interactions can be
consistent with the mitochondrial localization.
The catalytic mechanism proposed for MacroD1 and MacroD2 is different com-
pared to the mechanism of TARG1. MacroD1 and MacroD2 are proposed to perform
a substrate-assisted catalysis (56). The macrodomain would adapt its conformation
to better accommodate the substrate, so that the pyrophosphate of the ADP-ribose
would activate a water molecule for a nucleophilic attack against the glutamate of the
substrate, leading to the release of the ADP-ribose.
1.2.5 The elusive nature of MacroD2
MacroD2 is the third member of the macrodomain mono-ADP-ribosyl hydrolases.
MacroD2 is the biggest of the three, with 448 amino acids length and 50 kDa molec-
ular weight. As the other two members, it has a macrodomain that is located in
the N-terminal portion of the protein (see Uniprot page http://www.uniprot.org/
uniprot/A1Z1Q3). The C-terminal portion is instead not annotated and includes a
compositional biased sequence for glutamic acid between the aa 247 and 388. In the
evolution of macrodomains, MacroD1 and MacroD2 functions were probably performed
by one gene only, until when there has been a duplication event at the beginning of the
vertebrate clade (80).
Previous molecular studies on MacroD2 have focused on the macrodomain alone
(56, 67). In fact, before my PhD, I worked on the recruitment of MacroD1, MacroD2
and TARG1, as shown in Jankevicius et al., 2013 and Sharifi et al., 2013 (56, 68).
Thus, I showed that the MacroD2 macrodomain is able to recruit to the DNA damage
sites upon laser microirradiation, as it is also true for other macrodomains, namely
MacroH2A1.1 variant, MacroD1 and TARG1 (56, 68, 81). The recruitment of MacroD2
was dependent on ADP-ribosylation, since both ARTD inhibition and mutation in the
MacroD2 ADP-ribose-binding pocket (MacroD2 G188E mutant) prevent MacroD2 from
localizing at DNA lesions (56). Also, the recruitment of MacroD2 was different from
MacroH2A1.1, a sole reader of the mark. In fact, while MacroH2A1.1 recruited in a
sharp peak, MacroD2 showed a bimodal curve (Figure 1.10). These results suggested
17
1. INTRODUCTION
that MacroD2 recruited in a first peak, but only upon conversion of the PAR into
MAR by PARG it was able to reside longer at the DNA damage site. To confirm the
hypothesis, when I depleted PARG by RNAi-mediated knock-down, the first peak was
lost and the overall recruitment was strongly decreased (56).
Jankevicius et al. Nat Struct Mol Biol 2013 20(4):508-14 
Figure 1.10: MacroD2 macrodomain recruits to DNA lesions - Recruitment of
EGFP-MacroD2 and mCherry-MacroH2A.1.1 macrodomains to sites of laser-induced DNA
damage. The focus of laser microirradiation is indicated with a yellow circle. Scale bar,
10 µm. Quantification of accumulation to the damage site. From Jankevicius et al., 2013
(56).
The characterization of MacroD2 macrodomain activity defined as possible sub-
strates ARTD1, ARTD10 and Histone H1 (Figure 1.11; (56, 67)). As mentioned
before, MacroD2 enzymatic activity adopts the substrate-assisted catalyst mechanism
described for MacroD1 (56).
Additionally, MacroD2 successfully removes the modification from glycogen syn-
thase kinase β (GSK3β) both in in vitro and in vivo experiments (Figure 1.11; (67)).
GSK3β is an enzyme involved in the regulation of several pathways, involved in prolif-
eration and apoptosis, cell morphology and motility, as well as to diabetes and several
18
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Rosenthal et al. Nat Struct Mol Biol 2013 20(4):502-7
Figure 1.11: MacroD2 removes MAR from ARTD10 and GSK3β in vitro -
Coomassie blue (CB) staining and autoradiography (32P) results of in vitro assays with
tandem-affinity purification (TAP)-tagged ARTD10 and GST-GSK3β coupled to beads.
MacroD2 macrodomain removes MAR from both purified ARTD10 and GSK3β, while the
macrodomains 1 and 2 from mouse ARTD8 do not. From Rosenthal et al., 2013 (67).
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neuropathologies (82, 83). GSK3β has been shown to be in vitro and in vivo MARy-
lated by ARTD10 and this modification results in the decreased activity of the kinase
(84). Thus, ARTD10 and MacroD2 could represent an independent pathway, impor-
tant for the fine-tuning of GSK3β activation levels. But more experiments awaits to
test this hypothesis.
Overall, MacroD2 cellular function is still unclear. There are many hints suggest-
ing MacroD2 to be involved in many processes, but no real evidence. For example,
initial MacroD2 association with Kabuki syndrome has been proved wrong (85, 86).
Still with some controversy, MacroD2 is often associated with autism syndrome, so
that it has also been referred as one of the autism-associated prototypical genes in
genome-wide association studies (87, 88, 89, 90, 91, 92, 93). In addition, MacroD2 has
been associated to other neurological related diseases, as attention-deficit hyperactivity
disorder (ADHD) or major depressive disorder (89, 94, 95). Other association studies
were linking MacroD2 to the temporal lobe volume (96) and to brain connectivity in
patients with neurological and psychiatric disorders (97). Therefore, MacroD2 function
might have an important role in the development of brain functions, as well as in their
protection. As confirm, the MacroD2 knockout mouse shows a number of behavioral
and neurological phenotypes (International Mouse Phenotyping Consortium), firmly
indicating the functional role of MacroD2 in the brain. What would be its molecular
role in the brain is still to define.
MacroD2 overexpression was shown to induce tamoxifen resistance in estrogen re-
ceptor α positive breast cancers (98). Considering the abovementioned interaction be-
tween MacroD1 and the same pathway (77), the authors did actually test and exclude
that MacroD1 overexpression is involved in the formation of the resistance. Multiple
studies found the deletion of MacroD2 gene in association with colorectal cancer, sug-
gesting that MacroD2 could be a tumor-suppressor gene (99, 100, 101, 102). However,
it has also been proposed that the MacroD2 gene locus is fragile (94, 103), thus maybe
erroneously found in diverse genome-wide association studies (94, 104, 105, 106, 107,
108, 109). In conclusion, if these many phenotypes associated with MacroD2 indi-
cate a true relationship and not a coincidence, it is still unknown. And how MacroD2
enzymatic activity could explain such phenotypes, is still an open question.
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1.2.6 ADP-ribosylation regulates several aspects of DNA damage re-
pair
Since its discovery, most efforts in studying ADP-ribosylation signaling function have
focused on its involvement in DNA damage response (DDR) (Figure 1.12; (8)). DNA-
depentent ARTDs, namely ARTD1, ARTD2 and ARTD3, are differentially involved
in this response, even though most studies characterize just ARTD1 activity in the
different DDR pathways (110).
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Figure 1.12: ADP-ribosylation is involved in several DNA repair pathways -
Different types of DNA damage types activares ARTD1 and others transferases. In grey,
some factors that are activated by ADP-ribosylation or recruited to DNA lesions in a PAR-
dependent manner. In the lower boxes, the output repair pathways that are influenced by
ADP-ribosylation signalling.
Many different types of lesions occur on DNA. Single-strand breaks (SSB) arises
either because of endogenous factors, like reactive oxygen species (ROS), or because
of failure in the enzymatic activity of type I topoisomerases (111). These enzymes
are involved in DNA replication and transcription and their role consists in allowing
the denaturation of the DNA double strand, in order to access to the information
kept within: thus, type I topoisomerases nick the sugar-phosphate backbone of one
strand while creating the covalent intermediate of a phospho-tyrosine. As the whole
21
1. INTRODUCTION
DNA molecule has relaxed, adjusting its physical tensions, the topoisomerases ligate
the ends back together. But when there is an abortive ligation or a malfunction in
topoisomerase I activity, the DNA molecule gets an unresolved SSB.
SSBs are also formed as natural process in the repair of other types of lesions.
Oxidative damage, alkylation, methylation, deamination or hydroxylation of a DNA
base are recognized as lesions, since they could interfere with the DNA- or RNA-
polymerase processing and create a base-pairing mismatch. For this reason, the base
excision repair pathway (BER) is initialized. The BER starts with the detection and
excision of the damaged base by DNA glycosylases, which remove from one to eight
nucleotides of the same strand and generate a SSB (112, 113).
Even if ARTD2 is also involved to SSB repair (114), ARTD1 has been described as
an important factor in the induction of BER response, although its actual contribution
to the repair efficiency is controversial (115, 116). Depletion of ARTD1 affects repair
of lesions derived from uracil or 8-oxoguanine, inducers of abasic sites. Also ARTD1
and PARG depletion were relevant in SSB repair upon treatment with H2O2 in chicken
DT40 or A549 human lung carcinoma cells (117). The importance of ARTD1 activity is
probably due to its function in recruiting downstream BER factors due to the formation
of the PAR scaffold. In fact, many proteins involved in the pathways have been found
enriched in PAR-binding proteins or as ADP-ribosylated proteins (53, 118, 119, 120,
121, 122, 123, 124, 125, 126). Therefore, depletion of ARTD1 is affecting the speed of
the repair process but not its successful completion (127, 128, 129).
Other types of DNA lesions that require a more invasive repair pathway, the nu-
cleotide excision repair (NER), do still belong to the SSBs: cyclobutane pyrimidine
dimers (CPDs), (6-4) pyrimidine-pyrimidones photoproducts (6-4PPs) are induced by
UV-C light and consists of bulky adducts distorting the DNA molecule, so that the
entire nucleotide is required to be exchange (130). These DNA lesions are shown to be
strong activators of ADP-ribosylation, arguing for its role in the NER pathway (131).
ARTD1 interacts with damaged DNA binding 2 (DDB2), the factor that recognizes the
malignant photoproducts (130, 132, 133, 134). ARTD1 activity on one side helps the
rearrangement of the chromatin by the recruitment of the chromatin remodeler ALC1.
On the other side, PARylation helps DDB2 to retain at the DNA lesions, although it
is not required for its initial recruitment (133). ARTD1 strongly interacts also with
xeroderma pigmentosum-complementation group A (XPA), another factor for one NER
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sub-pathway (48, 135, 136). ARTD1 activity is important for the recruitment of XPA
to DNA lesions, but the interaction of the two factors might provoke the release of both
ARTD1 and XPA from the DNA.
Although less frequent than the SSBs, the double-strand break (DBS) is the most
dangerous type of lesion, since it can generate important rearrangements in the genome
if not repaired in time (137). DSBs can have an endogenous origin, like in case of
collapse of DNA replication fork or in case of cell-specific genome editing, as in meiosis
in the gamete formation or in V(D)J recombination and class-switch recombination
for the immune cell maturation (138). In addition, exogenous factors can also induce
DSBs, such as ionizing radiation, radiomimetic chemicals and type II topoisomerase
inhibitors (137, 138, 139).
DSBs are repaired by a variety of pathways, whose activation is defined in the
very early onset of the response. The two most studied DSB repair pathways are
the homologous recombination (HR) and the classical non-homologous end-joining (c-
NHEJ). But other pathways can also take place, like the single-strand annealing (SSA)
and the alternative end-joining (alt-EJ) (140). The c-NHEJ pathway consists of the
fast re-ligation of the broken DNA ends. It occurs throughout the whole cell-cycle
but it is the preferential repair in G0/G1 and late G2 phase (141). Even if c-NHEJ
inhibits big translocations and chromosome rearrangements, it brings micro-mutations
at the re-ligation point, defining it as an error-prone pathway (142, 143, 144, 145). The
main factors involved in this pathway are the DNA-dependent protein kinase catalytic
subunit (DNA-PKcs), Ku70 and Ku80, XRCC4 and the Ligase IV (140).
If the broken DNA ends are immediately resected and present 3 single-strand over-
hangs, c-NHEJ is blocked and one of the other three pathways can take place. The
homology-driven repair, another name for the HR, is generally activated after repli-
cation, because it requires a homologous sequence for the restoration of the original
information. Since the most preferred homologous sequence is the sister chromatid,
HR occurrence peaks in mid-S phase (141). Main factors of this slow pathway are the
replication protein A (RPA), which avoids degradation of DNA single strand by coating
it, and the recombinase RAD51.
The last two pathways, SSA and alt-EJ, are highly mutagenic and also required a
different degree of DNA resection. SSA is a homology-driven repair process exploiting
nucleotide repeats (140). Since one of the repeats is deleted during the repair, the loss
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of genetic information makes it an error-prone pathway. The interaction between RPA
and RAD52 allow the repair by SSA. Lastly, the alt-EJ was at first described as a
backup pathway for the c-NHEJ. The alt-EJ employs a different set of factors: in fact,
the repair is mediated by most of the factors that works in the BER pathway, such as
ARTD1, XRCC1 and Ligase III (138).
ARTD1 recognizes DSBs and its clear that ADP-ribosylation is interacting with
different DSB repair pathways, even though the underlying mechanism is not totally
clear (8, 29). Also, the study of ARTD1 for DSB repair is tightly connected with the
story of the PARP inhibitors (PARPi) (146). In 2005 two studies in parallel showed
that inhibition of ARTD1 in cancer cells defected in BRCA genes − genes involved
mainly in HR completion, causing these cell lines to be called BRCAness cells − leads
to their death (147, 148). These studies envisioned for the first time a synthetic-
lethality strategy for treatment in cancer with tumor-suppressor gene deficiency. Since
then, more and more sophisticated PARPi molecules were designed and tested mainly in
ovarian and breast cancer patients with BRCAness background, alone or in combination
with other cytotoxic compounds (146). Unfortunately, it is not clear what is the real
meaning of this synthetic lethality. More recent studies suggest that PARPi induces
a stalled ARTD1-DNA intermediate that can be processed only by HR pathway (149,
150).
ARTD1 negative regulates HR by counteracting the accumulation of RAD51 (151).
Such an activity of ARTD1 affects the sister chromatid exchange (152), the intra-
and the extrachromosomal recombination (151, 153, 154). However, some proteins
involved in HR are found enriched in pull-downs of PARylated proteins in the presence
of genotoxic stress (118, 119). Even more factors present a PAR-binding module,
suggesting that their recruitment could be dependent on ARTDs activity, at least at
some stage of the damage response (51, 52, 53, 54, 118, 119, 155, 156, 157, 158, 159).
A similar concept is true also for the c-NHEJ pathway: some studies showed in-
teraction between repair factors and PARylation, mainly because of the presence of
PAR-binding modules (48, 53, 118, 119). Because of their PBMs, DNA-PKcs and
Ku70 recruit to DNA damage in a PAR-dependent manner (48). They form a complex
together with ARTD1 at the DNA lesion (40, 41, 48, 160, 161, 162, 163). However,
it is not clear what are the effects of such an interaction. Maybe the PARylation of
DNA-PK stimulates the kinase activity (41, 160). Similarly, the DNA-PK-mediated
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phosphorylation of ARTD1 fails to have a clear effect on the activity of the ADP-ribose
trasferase (40, 41). However, in many studies, ARTD1 and DNA-PK activities coop-
erates, for example in double knock-out mice for DNA repair or in the case of V(D)J
recombination in B cells (164, 165, 166). Also, DNA-PK and ARTD1 interaction is
shown to be relevant in the unresected stalled DNA-replication fork (167), as well as
in the inhibition of the ribosomal RNA synthesis (168).
But the most important role of ARTD1 in DNA damage response is associated with
the alt-EJ pathway (138). First defined as backup pathway, it has now emancipated
as an alternative pathway, whose activation is mainly due to the location of the DNA
damage and the poor accessibility of other pathways factors. In fact, the alt-EJ is
activated in the lack of c-NHEJ factors, like the Ku proteins (162), given the shear
competition that ARTD1 and the Ku proteins have for the DNA ends (169, 170, 171,
172). The alt-EJ is particularly prone to cause translocations and major genomic
rearrangements and requires XRCC1 and Ligase III for the accomplishment of the
repair (173, 174).
In conclusion, ADP-ribosylation has definitely a role in the early phase of the re-
sponse, helping the general recruitment of factors involved in different DSB repair
pathways. However, it might be that the location of the DNA lesion in the genome
might preferentially activate different pathways and, similarly, the involvement of ADP-
ribosylation might change accordingly. As last comment, the role of MARylation in all
DNA damage responses is still obscure. For example, ARTD10 interacts with PCNA
and ARTD10-depletion induced sensitivity to hydroxyurea and UV, both inducing
stalled replication forks (175). But we still miss a complete picture of the involve-
ment of MARylation in DNA damage response.
1.2.7 ADP-ribosylation regulates also other cellular processes
Beyond the DDR, the eighteen human ARTDs are collectively involved in almost ev-
ery cellular process. In a recent study that compares the location and the knock-
down-induced effects on morphology of each ARTD, the authors showed, although just
in a macroscopic way, how ADP-ribosylation influences different aspects of cellular
life, ranging from cell cycle defects to cytoskeletal defects (176). Among the eighteen
ARTDs, ARTD1 is the most studied, above all in relation to DNA damage repair. But
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fragmented studies show the involvement of ARTD1 and many other transferases in a
vast variety of cellular processes.
For example, many studies involving ARTD1 explore its function in gene expression,
as modulator of chromatin compaction status. Since the early time of ADP-ribosylation
field, PARylation on histones was shown to relax the chromatin and make it more
accessible (177, 178). In fact, the generation of a PAR chain, long and rich in negative
charges, is bound to have dramatic effects on the activity of the target protein or its
affinity for other molecules. Thus, the modification and consequent eviction of H1 is the
most favorable explanation for the chromatin relaxation (179). The eviction process is
shown also for other chromatin factors, like the histone chaperone complex FACT or
the histone demethylase KDM5B (180, 181). But PAR formation on chromatin induces
also the recruitment of other proteins, such as the chromatin remodelers (8). ALC1
has a macrodomain that allows the recruitment to DNA and, if bound to PAR, induces
the activation of the remodeling activity (Figure 1.13,1; (182)). PARylation is also
inducing the recruitment of SMARCA5 and CHD4, two major components of other
chromatin remodeling complex, respectively the ISWI family complexes and the NuRD
complex (157, 183, 184). Of course, by regulating the accessibility of different factor to
the genomic information, ARTD1 holds the key for the proper regulation of almost all
processes that take place in the cell.
Other studies also focusing on ARTD1 showed that PARylation on a target pro-
tein can induce the recruitment of PAR-binding E3 ubiquitin ligases, so that ADP-
ribosylation can be read as mark for protein degradation. RNF146/Iduna and CHFR,
two E3 ligases, have a WWE and a PBZ domain, respectively (159, 185). Once re-
cruited, the E3 ligases ubiquitylate the PARylated target and mark it for degradation.
It is not clear if all the PARylated proteins are actually target of this degradation
pathway. It might be that the E3 ligases require an additional signal to activate their
ligase activity. However, this mechanism has been shown for axin, a component of the
Wnt signaling (186), mediated by ARTD5 activity (Figure 1.13,2; (187)), as well
as for ARTD1 itself, to avoid DNA damage-induced hyperactivation (Figure 1.13,3;
(185, 188)). Hyperactivation of ARTD1 and PARylation are connected to a particu-
lar form of caspase-independent programmed cell death, thus called parthanatos (189).
The parthanatos is based on the release of free PAR chains, which transmits as sec-
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Figure 1.13: The many roles of ADP-ribosylation in the cell - MARylation and
PARylation have been connected with several signaling pathways and cell processes. An
overview on some described functional interactions: 1 ) upon DNA damage, ARTD1 acti-
vated recruits chromatin remodelers, like ALC1, for relaxation of the chromatin and mod-
ulation of gene expression and repair; 2 ) ARTD5 release the negative feedback loop of Wnt
signaling activation by PARylating axin, negative regulator of the pathway, and targeting it
to degradation; 3 ) ARTD1 targets itself to degradation by PARylation-mediated ubiquiti-
lation and prevents its own hyper-activation, which brings to the AIF-mediated cell-death,
also known as parthanatos; 4 ) ARTD10 MARylates GSK3β, which normally inhibits the
activation of Wnt signaling by targeting β-catenin for degradation; 5 ) ARTD10 also inhibits
NF-κB signaling by affecting the positive signaling mediated by NEMO; 6 ) upon IL-4 cy-
tokine signaling, ARTD8 activity co-activates STAT6-responding genes; 7 ) ARTD9, maybe
together with ARTD8, affects STAT1-dependent gene expression; 8 ) ARTD15 controls the
unfolded protein response (UPR) by modifying IRE1α and PERK; 9 ) when different types
of stress arise, PARylation is generally involved in the modulation of RNA metabolism and
temporary block of RNA interference; 10 ) PARylation, mediated for example by ARTD1,
modulates different DNA damage repair pathways. Adapted from Bu¨tepage et al., 2015
(11)
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ondary messenger the death signal to the mitochondria and leads to the release of the
apoptosis-inducing factor (AIF) (190)
Apart from the omnipresent ARTD1, other transferases were found to be involved
in interesting cellular processes. ARTD10, for example, might be involved in the regu-
lation of the Wnt signaling, since it modifies the glycogen synthase kinase 3 β (GSK3β)
in vitro (84). In normal condition, the GSK3β kinase is assembled in a complex lo-
cated at the cellular membrane and its activity results in the degradation of β-catenin,
the activating transcription factors for the Wnt-responsive genes (Figure 1.13,4).
When Wnt molecule binds the receptor outside the cellular membrane, β-catenin is
not phosphorylated, thus not degraded, and can activate the Wnt-responsive genes,
which lead to proliferation. Therefore, if MARylation is able to decrease the activity of
GSK3β, the β-catenin would consequently be stabilized. Unfortunately, the authors of
the previous studies did not show if the MARylation of GSK3β was actually affecting
Wnt signaling. However, in vitro and in vivo experiments indicated GSK3β as one of
the few substrates of MacroD2 activity (67), further suggesting a functional role of the
MARylation for the regulation of this enzyme. Nonetheless, the regulation of β-catenin
protein level is just one of the functions ascribed to GSK3β: for example, as the name
of the protein suggests, it regulates the glycogen synthesis, therefore this could open a
possible connection between MARylation and metabolism (191, 192).
ARTD10 has been also shown to negatively regulate the activation of NF-κB path-
way, which activates pro-inflammatory genes in response to cytokines like IL-1β and
TNFα or genotoxic stress (Figure 1.13,5; (11, 193)). The study performed by Lu¨scher
group showed that ARTD10 can modifies one of the positive regulators of the pathway,
NF-κB essential modulator (NEMO) (194). This interaction interferes with the K36-
polyubiquitination of NEMO, which helps maintain the signaling induced. The result is
the renewed inhibition of NF-κB-dependent transcriptional activation. Thus, ARTD10
and MARylation could represent a checkpoint for the total activation of the inflam-
matory response. On the other hand, ARTD1 activity has been shown to help NF-κB
activation by promoting NEMO nuclear export, as well as by acting as co-activator of
the NF-κB transcription factors at the promoters (195, 196, 197). This opposite effect
between MARylation and PARylation shows that MARylation is not just a step of the
formation of PAR chains, but a real independent signal.
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Other transferases are also involved in the regulation of signaling pathways. Few
studies have described how ARTD8/PARP15/BAL2 co-activates with STAT6 the ex-
pression of specific cytokines, which are important for the humoral immunity (Figure
1.13,6; (198, 199, 200, 201)). The macrodomains of ARTD8 are necessary for the
interaction with STAT6, but the exact reason is not yet clear (199, 200). Also, the
MART activity is required for ARTD8 function (198, 200). In fact, ARTD8 is pro-
posed to function as a transcriptional switch, by repressing or activating the expression
according to the interaction with STAT6 (201).
The inactive ARTD9/PARP9/BAL1, instead, is involved in another immune response-
related pathway, the interferone-γ (INFγ)-dependent STAT1 pathway (Figure 1.13,7;
(202, 203)). In Camicia et al., 2013, the authors state (but not show) that STAT1 is
modified by ARTD8 and ARTD10 in vitro. However, they could not reproduce such a
result in vivo, probably due to lack of a proper tool for the detection of MARylation in
the cell (202). However, they showed that in diffuse large B-cell lymphoma ARTD9 in-
teracts via its macrodomains with both MARylated isoforms of STAT1 (STAT1α and
STAT1β). As consequence, STAT1α activates two proto-oncogenes genes (interefer-
one responsive factor 2 (IFR2) and B-cell CLL/lymphoma 6 (BCL6)), while STAT1β
negatively regulates transcription of the INFγ-dependent tumor-suppressor IRF1.
ARTD15/PARP15 regulates the activation of the Unfolded Protein Response (UPR)
(Figure 1.13,8). ARTD15 is a tail-anchored protein embedded in the membrane of
endoplasmic reticulum (ER) and facing the cytosol (204). When in the ER there is
abundance of unfolded proteins, the UPR is activated in order to temporally block
protein synthesis and to express chaperones that will assist in the folding of the al-
ready synthetized but denaturated proteins. Jwa and colleagues showed that ARTD15
MARylates IRE1α and PERK, the two kinases involved in the activation of the UPR.
Such a modification could induce decreased affinity for their inhibitor, the binding im-
munoglobulin protein (BiP), and activate the UPR. Although BiP is ADP-ribosylated,
it is not clear which ADP-ribosyltransferase might modify it, since BiP resides within
the ER lumen (205).
Lastly, proteomic studies of PAR-binding proteins or PARylated proteins showed
enrichments in RNA biology-related classification terms (10, 118, 118, 206). In addition,
several studies showed effects of ARTDs in all the key steps of RNA metabolism (10).
For example, several splicing factors, which are members of the hnRNPs, contains
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PAR-binding modules (207). Upon formation of PAR due to heat-shock stress, some
splicing factors are sequestered from the mRNAs under maturation (208). Therefore,
induction of ADP-ribosylation can have important consequences on the maturation of
RNA transcripts (Figure 1.13,9).
But ADP-ribosylation affects life of RNA molecules also in the cytoplasm. Mono(ADP-
ribosylation) of eukaryotic elongation factor-2 (eEF-2) dissociates the ribosomal com-
plex and blocks protein synthesis, as performed also by the cognate A fragment of
diphtheria toxin (209, 210). This regulation occurs also upon inflammatory response,
since cells treated with interleukin-1 β (IL1β) show increased levels of modified eEF-2
(211). Also, ADP-ribosylation affects the translation of mRNAs also by regulating
the RNA-interference machinery. Interestingly, all the members of the Ago family are
modified and the ADP-ribosylation affects their affinity towards the target mRNA,
leading to a negative regulation of the microRNAs (212). Interestingly, in the same
paper PAR is shown to be required for the formation of cytoplasmic stress granules,
where RNA-binding proteins accumulate together with mRNA molecules. Even so far
away from the chromatin, PAR shows to be precious for its scaffolding properties.
In conclusion, while PARylation has been studied since 50 years, only recently
MARylation has gained a spotlight. In fact, limitations in the detection of the specific
MARylation on the proteins has so far limited the possibility to define the subset of
physiological processes regulated by this signal (11). However, the development of
techniques that combine genetics, organic chemistry and mass-spectrometry has begun
to explore the network connected to specific ARTDs (213, 214). In these studies, a
specific ARTD is mutated so that it can use as donor of ADP-ribose a special NAD+
derivative. The power of this tool is then to define both the complete list of substrates
of the specific transferase, but also to provide the yet unknown sequence requirements
for the modification. Therefore, in the next years more comprehensive understanding
of the MARylation network will arise.
1.2.8 Upon DNA damage MacroD2 shows a double behavior
Dr. Gyula Timinszky, the direct supervisor of my PhD project, has worked on ADP-
ribosylation and macrodomain proteins since the professional relationship with Prof.
A.G. Ladurner started. Before my arrival at the lab, Dr. Timinszky was comparing the
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behavior of different macrodomains upon DNA damage, by using a live-cell imaging
approach.
Most of the macrodomains are able to recruit to the DNA damage sites because of
their ability to bind ADP-ribosylation. For example, when MacroH2A1.1 macrodomain
is expressed as fragment tagged with EGFP, it recruits to the microirradiation-induced
DNA lesions with a very fast dynamic (56, 81). Similarly, this recruiting behavior has
been successively shown for the three macrodomain ADP-ribosyl-hydrolases, MacroD1,
MacroD2 and TARG1 (56, 67, 68).
Aside the published work, Dr. Timinszky discovered that, in contrast of the
other macrodomain proteins tested, the EGFP-tagged full-length form of MacroD2
showed the decrease of the nuclear signal upon DNA damage. This behavior was
proved for few conditions, like different DNA-damage inducing compounds or upon
UV-microirradiation (Figure 1.14). This phenomenon might be explained either by
regulated nuclear transport or by a regulated form of protein degradation.
0 min 1 min 2 min 4 min 12 min
EGFP-MacroD2
Figure 1.14: MacroD2 nuclear protein level decreases upon DNA damage - Laser
micro-irradiation experiment on HeLa cells expressing EGFP-MacroD2. Yellow arrows
show the focus point of the laser microirradiation. The experiment was performed by Dr.
Gyula Timinszky.
Dr. Timinszky decided also to probe for possible inducers of the phenomenon. In a
set of experiments, he showed the involvement of ataxia-telangiectasia-mutated (ATM)
kinase in the induction of MacroD2 signal decrease. ATM is a key regulator of the DNA
damage response and the activation of the cell-cycle checkpoint (215). Dr. Timinszky
showed also that, if MacroD2 signal decreased in the nucleus, the inhibition of the
kinase restores the initial distribution of the signal, arguing also for the reversibility of
the process (Figure 1.15).
The sudden discovery of the double MacroD2 behavior upon DNA damage is an
intriguing open question that can add more to the regulation and function of this still
unknown protein. Moreover, the interaction between ADP-ribosylation metabolism
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Before
ATM inhibitor
5 min 15 min 30 min
Figure 1.15: ATM inhibition results in reversal of MacroD2 signal decrease
in the nucleus - Cell were pre-treated for one hour with camptothecin, yellow arrows
indicate those cells that responded to the drug. Then, they were imaged upon treatment
with ATM inhibitor KU55933. The experiment was performed by Dr. Gyula Timinszky.
and ATM-signaling, and its possible role in the DNA damage response, urges for a
more detailed understanding of MacroD2 functions in the cell.
Since MacroD2 responds to ATM activation, I will give a summary about ATM
kinase, its modes of activation and its protein family (see Section 1.3). Finally, since
I could show that MacroD2 new behavior is explained by regulated nuclear export, I
will give an overview on the nuclear transport and the basic features of its regulation
(see Section 1.4).
1.3 ATM and the PI3K-like kinases
Ataxia-telangiectasia mutated (ATM) is a key regulator of the DNA damage response
and it belongs to the PI3K-like kinse family. The amount of studies about this kinase
family is massive, since most of the members are involved in DNA damage and tumor
development.
1.3.1 ATM is the protein behind the ataxia-telangiectasia disease
ATM received its name from the autosomal recessive disorder ataxia telangiectasia
(A-T) (216, 217). This disease presents several symptoms, among which the dilata-
tion of blood vessel (telangiectasia), neurodegeneration in the cerebellum that affects
movement and coordination and general immunodeficiency (215). Also, A-T patients
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are predisposed to cancer, especially lymphomas, and are very sensitive to ionizing
radiation (218).
ATM is a big protein, 350 kDa in weight and 3056 residue long. ATM belongs to the
PI3K-like kinase (PIKKs) family, related to the lipid-kinase PI3K. Unlike their cousins,
PIKKs transfer phosphate group exclusively onto serines or threonines of protein targets
(219). For some members of the family, ATM among them, the modified serine or
threonine must be followed by a glutamine, forming the so called SQ/TQ motif (220).
ATM is located mainly in the nucleus (221), even though many studies showed presence
of ATM in the cytoplasm of neuronal cells of mouse and human cerebellum or in
differentiated neuronal cell lines (222, 223, 224, 225). One report suggested that ATM
might export together with NEMO upon stress-dependent activation of the NF-κB
pathway (226).
1.3.2 ATM is a master regulator of the DNA damage repair
Cells lacking ATM activity present increased genomic instability and sheer sensitivity to
DNA damage-inducing agents, in particular to irradiation or radiomimetic compounds
(227, 228). This sensitivity was soon linked to the important function that ATM has
during DNA damage response, in particular upon DSB repair (215). In fact, ATM-
dependent regulation is important for the overall DNA repair process, the cell-cycle
checkpoint regulation and the definition of the cell fate: survival over apoptosis (229).
In addition, upon DNA damage, ATM activity immediately restructures most of cellular
processes through a powerful amplification of the signal, mediated by ATM itself and
its associated kinases: Chk1, Chk2 and Mk2, kinases that are activated by ATM to
relay the SOS signal everywhere in the cell (230).
It is not clear how ATM is activated in the very first place upon DSB (Figure
1.16). ATM might have the ability to bind damaged DNA (231), but it seems to be
not a strong interaction and it requires help from other proteins (232). Thus, some
factor must be sensing the presence of DSB and transfer the message to ATM itself,
in order to initiate the system. The best candidate is the complex MRN, formed by
Mre11-Rad50-Nbs1 (233, 234, 235): in fact, Mre11 is recruiting to irradiated foci with
a fast dynamics and independent from ATM (236). Patients lacking Mre11 present
most of A-T symptoms, above all the sensitivity to irradiation, thus this disease is
called A-T-like disorder (ATLD). The mutation of Nbs1, on the other hand, induces
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the Nijmegen breakage syndrome (NBS), which among diverse symptoms shows strong
radiosensitivity. The similarities are probably due to the fact that the MRN complex
is important for the initial activation of ATM and for its binding to DNA (232, 237).
It is suggested that the MRN complex is able to bind the DNA ends, slightly open the
DNA molecule and predispose it to the interaction with ATM (232).
After the initial activation of ATM mediated by the MRN complex (232, 237), more
steps are required to the full activation. In the absence of DNA damage, two ATM
molecules constitute a dimer, whose positioning inhibits the binding and modification
of substrates (238). Upon DNA damage, the two molecules auto-phosphorylate in
trans on S1981 and this is enough to dissociate the dimer. In addition, the histone
acetylase TIP60, constitutively binding the C-terminus of ATM, acetylates ATM on
position K3016 and fully activates it (239). TIP60 is also involved in a positive feedback
loop, since ATM induces the Chk2 kinase, whose activity helps TIP60 remain active
(240, 241, 242).
Once ATM is activated, it can perform its main role of amplification of the signal.
ATM phosphorylates the histone variant H2AX (γH2AX), which is used as recruitment
platform for repair factors, forming visible irradiation-induced foci (243). One of the
first factors recruited and modified by ATM is the mediator of DNA damage checkpoint
protein 1 (Mdc1) (244, 245). In fact, Mdc1 is important for the setup of a positive
feedback loop by binding the γH2AX with its BRCT domain, ATM with the FHA
domain and interacting with Nbs1 via a Ck2-dependent phosphorylation event (246,
247, 248). Modification of Mdc1 by ATM helps its oligomerization and therefore the
formation of the foci (249).
This recruiting environment enhances ATM chances to encounter and modify its
almost thousand substrates (42, 44, 250, 251). Mass spectrometry approaches showed
an intricate network, mainly involved in DNA repair, but also regulating transcrip-
tion, mRNA processing, chromatin remodeling, cell-cycle regulation. ATM-mediated
modifications on the kinases Chk1, Chk2 and Mk2 are able to achieve the maximum
amplification of the response (252, 253, 254). Other described modified proteins are
Nbs1, Rad50, Kap1, the cohesin subunits Smc1 and Smc3 and the tumor suppressor
p53 (44).
The tumor suppressor p53 was the very first identified target of ATM activity
(255, 256, 257). In cells undergoing DNA damage in G1 phase, the G1/S checkpoint
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Figure 1.16: ATM is activated by double-strand breaks - a) In normal conditions,
ATM is in a dimeric inactive form. But upon DSB, ATM becomes active.b) ATM activates
itself by autophosphorylation, which induces the release from the dimer. ATM is then able
to interact with the MRN complex at the DNA lesion- The interaction further activates
ATM, that in turn modifies many effectors: histone H2AX, p53, BRCA1 and Chk2 and
others. The start of the signaling cascade leads to the repair of the DNA damage, the tem-
porary arrest of the cell-cycle and the modulation of the metabolism, with the temporary
standby of energy-consuming processes. In extreme case, ATM initiates the cell-death pro-
gram or the entrance to senescence. c) The phosphorylation of the histone H2AX recruits
Mdc1, which induces the further activation of ATM and the spreading of the histone mark.
Adapted from Mare´chal et al. 2013 (230).
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is activated and cells are prevented to start the DNA replication, due to the possible
problems that the replication machinery can encounter in the presence of unrepaired
DSBs (258). The DNA-induced phosphorylation on S15 mediated by ATM is one of the
sequential events that lead to the stabilization of p53, which acts as transcription factor
and induces the cell-cycle checkpoint (259). ATM has a guardian role throughout the
cell cycle. Mutations in ATM impair both the S-phase and the S/G2 checkpoints. In
both, ATM modifies the breast cancer type 1 susceptibility protein (BRCA1) in two
sites, whose mutation affects either one or the other checkpoint initiation (260, 261,
262).
Recent studies have also connected ATM activation with NF-κB signaling (226).
Upon DNA damage, ATM performs one of the three post-translational modifications
required to target the NF-κB essential modulator (NEMO) from the nucleus to the
cytoplasm. Such a regulated localization is important for the phosphorylation and
dissociation of the NF-κB inhibitory complex, thus leading to the activation of the
inflammatory response (193). Thus, while ARTD10 MARylates NEMO, repressing the
activation of the pathway (194), ATM induces it by leading NEMO into the cytopasm.
Therefore, induction of the inflammatory pathway represents another condition when
several signals must be integrated to obtain an organic response.
1.3.3 ATM is activated also in MRN-independent manner
Apart from the previously described MRN-dependent activation of ATM, other activa-
tion modes have been discovered in the recent years (229, 263). Upon hypotonic stress
or cloroquine treatment, the ATM INteracting protein (ATMIN) binds ATM, as shown
by colocalization in immunofluorescence experiments (264). ATM and ATMIN asso-
ciation induces the ATM-mediated phosphorylation on p53. Also, ATMIN competes
with Nbs1 for the same binding site on ATM, therefore ATMIN-dependent and MRN-
dependent activation pathways are mutually exclusive (265). The interaction between
ATM and ATMIN is abrogated by a ubiquitylation event performed by the E3 ligase
UBR5 upon DNA damage (266). Thus, this event shifts the equilibrium of the ATM
species towards the interaction with Nbs1 and the initiation of the DDR.
Hypoxia is also able to activate ATM (267). The study from the Hammond group
showed that the activation of ATM is independent of Nbs1 and the foci formation, since
ATM stays in a diffuse nuclear form. However, they showed that Mdc1 is required for
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the amplification of the signal. Later, ATM-activation was confirmed and linked to the
phosphorylation and stabilization of hypoxia-inducible factor 1-α (HIF-1α) (268).
A MRN-independent mode of activation of ATM is also achieved upon oxidative
stress (263, 269). It was already clear that both A-T cell lines and mouse models
showed higher levels of ROS if compared with normal cells (270, 271, 272). Therefore,
it was suggested that the absence of ATM induces oxidative stress in neurons. This
chronic stress could explain the degeneration in the cerebellum of A-T patients. This
hypothesis is partially confirmed with the higher sensitivity that A-T cells have for
oxidative agents (273, 274).
The mechanism of the activation is quite peculiar, since it involves two ATM
molecules that keep the dimeric structure, which is actually enforced by the forma-
tion of disulfide bonds (275). Therefore, in contrast to the inactive, non-covalent dimer
of the inactive form, Paull and colleagues found an ATM dimer form that is actually
active. The most relevant disulfide bond, out of the many forming within the dimer,
utilizes the C2991. Mutation of this cysteine into alanine affects only the hydrogen
peroxide-induction of ATM but not the canonical MRN-dependent pathway (275).
To sum up, the activity of ATM has the critical role in coordinating many processes
that take place in the cell and in driving to the most successful resolution of the
crisis: by stopping activities like cell-cycle progression and DNA transcription, by easing
the access to the DNA lesion with a suitable recruitment platform and relaxation of
the chromatin, by readjusting the cellular metabolism for a less DNA damage-prone
environment.
1.3.4 ATR and DNA-PK also belong to the PIKK family
The PI3K-like kinase family is composed in total by six members and all are specialized
in the response to different stimuli (276). For the DNA damage repair response, two
other members are activated beyond ATM: ATM and Rad3 related (ATR) and DNA-
dependent protein kinase (DNA-PK). ATR activity is induced upon DSBs that are
associated to replication fork (277). The resection of the DSBs and the formation of
RPA-coated single-strand DNA induces the activation of ATR in complex with ATRIP
(278). On the other hand, c-NHEJ is regulated by DNA-PK catalytic subunit (DNA-
PKcs), in association with the Ku70/Ku80 dimer (279).
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The DNA-PK holoenzyme is composed by three components: the DNA-PKcs,
around 350 kDa in size; Ku70; Ku80 (Figure 1.17, panel a; (279)). The latter
two factors form the clamp that recognizes the DNA double strand and help the re-
cruitment of the DNA-PKcs to the DSB. A low-resolution structure shows how the
kinase binds directly the DSB ends with the help of the Ku70/Ku80 dimer (280). Also,
the DNA-PKcs phosphorylates itself in several sites, behaving similarly to ATM (281).
However, different groups of auto-modification induce distinct effects, like negatively
regulating the interaction with the Ku proteins or modulating the enzymatic activity
(282, 283).
DNA-PK modifies a series of effectors involved in the c-NHEJ (279). In addition,
DNA-PK modifies the histone H2AX, even though this event is linked to particular
conditions, like hypotonic stress combined to irradiation and mitosis regulation (284,
285). As I mentioned above, DNA-PK interacts with ARTD1. Even though they
might interact upon DSB repair, their interaction is important for the DSB-dependent
induction of transcription of estrogen-responsive genes (286). DNA-PK is also involved
in the transcription of other classes of genes, like the androgen-responsive (287) or the
insulin-responsive ones (288).
As third DSB-dependent kinase, ATR role is so important that the homozygous
mutation of ATR brings embryonic lethality in mice and cell death in human cells (230).
ATR is activated upon formation of long stretches of ssDNA, as in the case of DSBs and
with stalled replication forks (Figure 1.17, panel b). Due to the common SQ/TQ
motif and the connection to the HR regulation, the targets of ATM activity found by
mass spectrometry experiments are actually shared with ATR (42), although the two
subsets of ATM and ATR targets change according to the DNA damage type (289).
While ATM is more relevant for the G1 checkpoint, ATR is more active in the intra-S
and G2/M checkpoints, by phosphorylating its main effector, Chk1 (252, 290, 291).
However, since the role of ATM is shown in all checkpoints, it is possible that for each
case the two kinases cooperate to properly amplify the response.
The other three members of the PIKKs are activated upon other stimuli. Sup-
pressor in morphogenesis in genitalia 1 (SMG-1) is involved in the non-sense mediated
decay, a quality control pathway for the mRNAs (292). The mechanistic target of
rapamycin (mTOR, previously known as FRAP) is instead activated upon metabolic
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Figure 1.17: The activation of DNA-PK and ATR by double-strand breaks
- a) When DSBs occur (1), the Ku70/Ku80 dimer is recruited to the ends of the DNA
lesion. The Ku dimer recruits DNA-PKcs (3), forming the DNA-PK holoenzyme. In the
complex, the Ku proteins shift along the DNA to allow DNA-PKcs to bind the DNA ends.
DNA-PK is finally active (4), auto-phosphorylates and leads to the recruitment of c-NHEJ
factors (as example, XRCC4, XLF, PNKP, DNA Ligase IV) (5). The activation induces
also DNA-PKcs to disattach from the DNA. b) RPA molecules coat ssDNA, also in the
proximity of the replication fork (1). RPA induces the independent recruitment of inactive
ATR via ATRIP, and of the 9-1-1 complex (2). ATR gets activated and modifies the 9-1-1
complex (3). The modification leads to the recruitment of the TopBP1 protein, which
further enhances ATR activity (5). ATR modifies other targets, for example Chk1 and
p53. Adapted from Jette and Lees-Miller 2015 and Mare´chal et al. 2013 (230, 279).
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stimuli (293). mTOR is responding to different pathways, like insulin and growth fac-
tors, and induces proliferation. It is the catalytic subunit of two different complexes,
with different components: mTORC1 induces ribosome genesis and lipid synthesis, in
response of a favorable energetic environment; mTORC2, instead, positively regulates
the actin cytoskeleton, cell size and cell progression. The last member of the PIKK fam-
ily is transformation/transcription domain-associated protein (TRRAP) and, although
it is catalytically inactive, it is a component of a histone acetyltransferase complex
specialized in the activation of mitotic checkpoint genes (294).
1.4 The nuclear transport
When a stimulus occurs, survival requires a fast but accurate response. As mentioned
above, this is easily achieved by post-translational regulation of mediators of the re-
sponse. Another way to switch on or off the activity of a protein in a fast manner
is to regulate its location in the cell. An enzyme, for example, might be restricted
to a compartment, secluded from its substrates, and released only at the moment of
need. Considering that within the eukaryotic cell there are many membrane-enclosed
compartments, the regulation of the function can take advantage of this evolutionary
feature.
The preliminary work performed by my supervisor Dr. Timinszky indicated that
MacroD2 nuclear signal is depleted upon DNA damage. During my PhD project, I
showed that this depletion is explained by the regulated nuclear export of MacroD2.
The nuclear transport is not a trivial problem for the cell, but mechanisms have evolved
to exploit a probably energetic-disadvantage into a regulatory opportunity.
1.4.1 The mechanism of nuclear transport
The presence of a distinct compartment where to keep the genetic information and the
related processes was one of the major breakthroughs in the evolution of the eukaryotic
cell. The nucleus is separated from the cytoplasm by the nuclear envelope. This
is a double-bilayer membrane connected with the endoplasmic reticulum. The nuclear
envelope is fenestrated by giant protein complexes, the nuclear pore complexes (NPCs),
which allow the passage of molecules between the nucleus and the cytoplasm. Each
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vertebrate cell has around 4000 NPCs embedded in the nuclear envelope, allowing a
constant traffic between the two compartments (295).
More than simple channels, NPCs are complexes formed by multiple copies of 34
proteins, called nucleoporins (296). These make a passage in the points where the inner
and the outer membranes of the nuclear envelope fuse. In X. laevis, the giant structure
is around 120 MDa in total weight, a diameter of 126 nm and a height of 71 nm within
the envelope, excluding the accessory elements on the cytoplasmic and nuclear face
(297). In fact, on the nuclear side eight rod-shapes proteins connect to a distal ring
and form the so called nuclear basket; likewise, on the cytoplasmic face there are eight
flexible protrusions, completing the structure. The overall structure is conserved across
all eukaryotic clades (298).
The conduit across the envelope is full of unstructured tails of the nucleoporins,
rich in phenylalanine-glycine (FG) repeats. These repeats weakly interact with each
other, forming a hydrogel in the center of the pore that form the permeability barrier
for the passage (299). The diameter of the conduit is a controversial issue, since even
if it is calculated to be 2.5-5 nm (300), it can accommodate particles up to 40 nm in
diameter (301). The NPC allows the indiscriminate passage of ions and metabolites.
Macromolecules smaller than 5nm in diameter (roughly 40 kDa in size) can also dif-
fuse freely (300). This is a rough estimation, since slightly bigger macromolecule but
with an elongated shape still show free passage. On the other hand, bigger macro-
molecules require assisted transport, mediated by the nuclear transport receptors, a
class of proteins that bind their cargo and help the cross beyond the NPC (302).
The nuclear transport receptors bind or release the protein cargos depending on
the binding with the small GTP-binding protein/GTPase Ran (Figure 1.18). Ran
converts guanosine triphosphate (GTP) into guanosine diphosphate (GDP): the confor-
mation of Ran changes according to the guanosine species it is binding at the moment.
However, the enzymatic activity is not efficient. To this end, Ran needs to associate
with the GTPase-activating proteins (GAPs), which enhance the conversion from GTP
to GDP; and with the guanine nucleotide exchange factors (GEFs), which induce the
release of the GDP and the bind with the next GTP molecule. By positioning GAPs
and GEFs in the cytoplasm and in the nucleus, respectively, it is possible to create a
directionality in the conformational change: RanGAPs, like RanBP1, are associated to
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the cytoplasmic protrusions of the NPC, while RanGEFs, like RCC1, are sitting on the
chromatin (303).
The nuclear transport receptors are divided into two classes: the importins bind the
cargo in the cytoplasm and release it in the nucleus upon binding with the Ran-GTP;
on the other hand, the exportins bind the cargo in the nucleus in a trimeric complex
with Ran-GTP. This complex dissociates in the cytoplasm when Ran is activated to
convert the GTP into GDP. Ran is then transported back into the nucleus by binding
with the nuclear transport receptor NTF2. This nucleocytoplasmic cycle, thus, even if
it offers many regulatory options, is energy-dependent (302, 303).
The importins and exportins belong together to the karyopherin β superfamily
(304). Most karyopherins bind their cargos directly, while other times adaptor proteins
are required between the nuclear transport factor and the cargo. The importin β,
for example, binds the cargo through the interaction with the karyopherin importin
α (305). While the importin α/β complex accounts for the import of most proteins,
there are other importins that have a more specialized subset of cargoes. Similarly,
the exportin 1 (Xpo1/CRM1) is the one that helps the export of the vast majority of
cargoes. Other exportins have few other specialized targets, for example exportin t
carries the tRNAs into the cytoplasm (306).
The karyopherins recognize special sequences on the cargo protein, called nuclear
localization signal (NLS), in case it induces the nuclear import, and nuclear export
sequence (NES), if it is able to drive the nuclear export. These sequences are generally
located in unstructured loops and the presence of such sequences helps with the predic-
tion of the general localization of the protein, even though the accessibility of a specific
sequence can be constantly modulated. Importin α recognizes an NLS sequence that
consists of either one stretch of basic residues or two basic stretches connected via a
short linker, in which case it is called a bipartite NLS (307). Apart from the most classi-
cal NLS, other sequences have been described, like the so called PY-NLS recognized by
the adapter importin β2 (308, 309). Regarding the export signal, exportin 1 recognizes
an 8- to 15- residues leucine/hydrophobic-rich motif (310). It is also worth to mention
that the cargos can also interact with other partners, conferring to proteins without
any localization sequence the ability to cross the nuclear envelope. This mechanism is
called “piggy-backing” (302).
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Figure 1.18: The assisted nuclear transport cycle - The nuclear tranport is illus-
trated: 1 ) The importin binds its cargo in the cytoplasm and crosses the nuclear envelope;
2 ) in the nucleus the Ran-GTP (red) molecule binds the importin, induces the release of
the cargo and drives the importin back to the cytoplasm; 3 ) the RanGAP enhances Ran
GTPase activity and the Ran-GDP (yellow) releases the importin, which is free to bind the
new cargo; 4 ) in the nucleus, the exportin interacts with Ran-GTP (red) which allows the
interaction with the exporting cargo; 5 ) the complex formed by exportin-Ran-GTP-cargo
crosses the nuclear envelope; 6 ) in the cytoplasm, the conversion of Ran-GTP (red) into
Ran-GDP (yellow) incudes the disassembly of the complex and the exportin is free for
a new round; 7 ) Ran-GDP (yellow) is transported back by the transporter NTF2; 8 ) in
the nucleus, a RanGEF induces the release of GDP and the binding with the new GTP,
regenerating the Ran-GTP (red) for the nuclear transport.
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1.4.2 Regulation of protein localization
The localization of the protein across the different compartments depends on a series
of factors. If the protein is smaller than 40 kDa, or if it has a more suitable shape,
it can freely pass through the permeability barrier of the NPC and equally distribute
between the nucleus and the cytoplasm. However, the size will impact on the speed
with which the protein will equilibrate, even though the equilibrium will be eventually
reached. On the contrary, the localization can be tightly regulated if the proteins need
the help of the nuclear transport receptors. Thus, the overall distribution is defined by
many factors. First of all, the concentration of free karyopherins and how the transport
system itself is saturated can impact on the speed of the process. On the other hand,
the accessibility of the cargo localization signal is often modulated (302).
In some occasions, an interaction partner can mask the signal upon binding, af-
fecting the interaction between the cargo and the karyopherin, like in the case of the
inhibitor IκBα that masks the NLS of NF-κB (311, 312). The regulation can also be
due to an allosteric change in the protein conformation, which the cargo adopts upon
binding with an interactor: when the fatty-acid binding protein 5 (FABP5) binds to
its ligand, it undergoes a conformational change so that a tertiary non-linear nuclear
targeting signal is formed (313).
In other cases, the protein can be trapped in one specific compartment, due to a
stable interaction with an immobile component, such as cytoskeleton, chromatin or
the cellular membrane. This means that the pool of protein available for the nuclear
transport is reduced and the modulation of the export consists mainly in modulating
the interaction with the cellular component. This is the case of the Ca2+-dependent
induction of calmodulin nuclear import (314). On the other hand, some proteins, like
Notch receptor, are generally anchored in a particular compartment and the release
and translocation is triggered by a protease, which cleaves away their anchor (315).
Last but not least, the modulation can occur also co-transcriptionally, by performing
an alternative splicing that might introduce (or remove) a localization signal in (or from)
the protein sequence. In the case of the Nek2 kinase, the splicing of three alternative
variants changes the presence and even the strength of the NLS, making Nek2C isoform
mainly nuclear, Nek2B mainly cytoplasmic and Nek2A equally distributed (316).
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Most often, however, the modulation occurs via post-translational modification.
The post-translational modifications might affect the interaction between the cargo and
the transporter. For example, upon DNA damage response ATM or ATR phosphorylate
p53, next to its NES, preventing its interaction with exportin 1 and leading to its
accumulation in the nucleus (256, 257, 317). Likewise, the estrogen receptor α is
also phosphorylated upon p38MAPK activation and the modification affects the NES
recognition, leading to nuclear accumulation (318). Even if the phosphorylation is
the most common post-translational modification that affects nuclear transport, other
post-translational modifications can occur as well. The p300 acetylates the NLS of the
RecQ protein-like 4 (RECQL4) helicase, preventing it to localize in the nucleus (319).
Post-translational modifications could also actively induce the translocation, al-
though these cases are not very frequent. The best known cases occur in the MAP
kinases signal cascade: p38MAPK and p42MAPK are phosphorylated in two different
sites and the phosphorylation induces the recognition of the NLS by the importin 7,
leading to the accumulation in the nucleus and the activation of nuclear targets (320).
On the other hand, post-translational modification-dependent nuclear export occurs
in case of the androgen receptor (AR). While it is translocated into the nucleus upon
androgen-binding, the AR nuclear export is enhanced when other signaling pathways
are active: p38MAPK or c-Jun induce the phosphorylation on S650, next to the NES of
the AR, thus increasing the interaction with the exportin 1 (321). Similarly, upon stress,
p38MAPK induces the p38 regulated/activated protein kinase (PRAK, also known as
MAPKAPK5) nuclear export (322). Several types of cellular stress induce also the
phosphorylation of the kinase MK2 on the threonine 317, which induces a change in
conformation and increases the accessibility of its NES, leading to the accumulation in
the cytoplasm (323). Remarkably, a series of three different post-translational modifica-
tions are necessary to export NF-κB-inhibitor NEMO: ubiquitination, ATM-dependent
phosphorylation and finally SUMOylation (193, 226).
Sometimes, however, the post-translational modification-dependent accumulation
in the cytoplasm is caused by the fact that the protein tightly interacts with residents
of the cytoplasm and its nuclear import is therefore impaired. This is true for the
ubiquitin E3-ligase COP1, whose activity leads to the nuclear export and degradation
of p53. COP1 is phosphorylated upon DNA damage and the mark is recognized by
the chaperone 14-3-3σ in the cytoplasm (324). Also other proteins get trapped in
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the cytoplasm due to the interaction with the 14-3-3 proteins, namely FOXO1 (325) or
FOXO4 (326, 327). In the case of the nuclear factor of activated T-cells (NF-AT), GSK3
modifies the protein and the phosphorylated form is trapped in the cytoplasm, although
it is not clear if it is due to interaction with other factors (328). Upon Ca2+ signaling,
calcineurin dephosphorylates NF-AT and induces its nuclear import (329, 330).
1.5 Integration of the signals: the key to the success
In conclusion, to achieve fast adaptation to all the inputs that are constantly collected,
cells need to be able to change rapidly the pathway usage and the specific protein ac-
tivity. For example, the complex machinery that is employed for the repair of DSBs
requires an accurate calibration of its activation, as well as the block of all the physi-
ological processes that might negatively impact the repair. The easiest way to achieve
such a complex result is to send out a signal that can tune the activity of many pieces
of the clockwork at the same time: post-translational modifications are information
theory applied to biochemistry, the clever way with which the cells have coped with
the daunting task of adaptation.
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As a post-translational modification, ADP-ribosylation presents stunning dynamics
and an elevated level of complexity. It is involved in virtually every process in the cell,
either directly, as a regulatory mechanism of single steps of a process, or indirectly,
by its involvement in the regulation of chromatin accessibility. Only recently have
appropriate tools been developed to thoroughly study this modification, bringing a
new Renaissance to the field.
Although the presence of tools to detect PARylation has directed most of the efforts
in the understanding its functional role, still little is known about the actual extent
of regulation mediated by MARylation. However, recent studies suggest a similar
extensive involvement of MARylation signaling in cellular life. In 2013, it was possible
to define the last enzymes that complete the whole metabolism of ADP-ribosylation,
with the discovery of MacroD1, MacroD2 and TARG1 (56, 67, 68). But their actual
functions are still far from being defined.
MacroD2 is the largest of the three proteins. The localization of the EGFP-tagged
version of MacroD2 overlaps with that of TARG1, but MacroD2 contains an additional
protein sequence that suggests a different function or regulation as compared to the
smallest brother. The MacroD2 gene, as distinct from MacroD1, is first found in the
vertebrates, probably due to a duplication event followed by a fusion with an additional
unknown sequence, which is present only within vertebrates with more than 50 % of
identity. Therefore, the presence of MacroD2 as gene correlates with high complexity,
and the association studies with deficiencies in neural function suggest that it might
indeed have a specific function that appeared only recently in evolution.
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During a short internship at the Timinszky group, before starting the PhD, I helped
characterize the recruitment dynamics of the MacroD2 macrodomain, then included in
the Jankevicius et al., 2013 work. Before that point, published studies on MacroD2 had
mainly shown only broad associations with disease. The characterization of MacroD2
enzymatic activity has been a remarkable step forward, but it is still unclear how it is
connected with the greater picture. Therefore, the serendipitous discovery of a second
MacroD2 behavior upon DNA damage - the decrease of its nuclear signal - represented
a thrilling opportunity to add more pieces to the puzzle.
Already at that time, preliminary experiments showed that HeLa cells transfected
with mEGFP-MacroD2 full-length manifest a decrease in the fluorescent signal in the
nucleus in certain conditions, like Topoisomerase poisons camptothecin and etoposide,
or UV laser micro-irradiation (Figure 1.14). Additionally, preliminary data showed
a possible induction of MacroD2 export by ATM, and the reversibility of this process
(Figure 1.15).
I joined the group and this particular project with the aim of characterizing this
MacroD2 behavior: the decrease of nuclear levels. In general, such a behavior could
show a form of regulation for the MacroD2 function, either by activation of a degra-
dation pathway or by active translocation across the nuclear envelope. Therefore, I
thought that by dissecting the behavior that Dr. Timinszky had discovered, I would
be able to understand the mechanism inducing it, which could consequently provide
more insight on the cellular function of MacroD2. In addition, since the preliminary
experiments showed that the induction of the MacroD2 special behavior is probably
due to ATM-signaling, this project allowed me to explore a probable integration node
between two massive regulatory systems upon DNA damage response, namely the ADP-
ribosylation-mediated and the ATM-mediated signaling.
For these reasons, my PhD project had two main goals.
1. Aim I: characterize the decrease of MacroD2 nuclear protein levels
upon DNA damage
To better understand the phenomenon of decrease of MacroD2 nuclear protein
levels I intend to use a combination of live-cell microscopy and biochemical ap-
proaches. Firstly, I need to define if the decrease of MacroD2 nuclear signal is due
to regulated nuclear export or to the activation of a degradation pathway. Next,
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I intend to define the overall conditions that robustly induce the phenomenon, as
well as the contribution of ATM or other kinases of the PI3K-like kinase family.
I also intend to define the requirements for the phenomenon at the level of the
MacroD2 protein sequence. Lastly, the decrease of MacroD2 nuclear levels also
needs to be proved for the endogenous protein.
2. Aim II: identify candidates for the regulation of MacroD2 upon DNA
damage and for MacroD2 cellular function
In parallel to Aim I, I intend to define the interactome of MacroD2 protein in the
presence and absence of genotoxic stress. By means of an unbiased approach, this
proteomic strategy can suggest testable hypotheses concerning two aspects: the
protein factors that might be involved in the regulation of the decrease in nuclear
levels, and the function of MacroD2 in cells. In fact, by performing the experiment
under conditions that induce the new behavior of MacroD2, I can define proteins
that might help MacroD2 regulation. On the other hand, both the control and
genotoxic conditions could show factors involved in cellular processes that are
possibly regulated by MacroD2 enzymatic activity.
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3ATM kinase induces MacroD2
nuclear export
3.1 Introduction
MacroD2 is one of the three ADP-ribosyl-hydrolases recently found in humans (56,
67). These proteins share the same catalytic domain, known as the macrodomain,
which enables them to remove the most-proximal ADP-ribose from the target protein,
completely reversing the ADP-ribosylation modification. The MacroD2 macrodomain
has been shown to recruit to DNA lesions upon laser microirradiation experiments (see
Figure 1.10). However, the exact role of MacroD2 during the DNA damage response
is still unknown.
As mentioned in the Section 1.2.5 of the Introduction chapter, preliminary exper-
iments showed that the nuclear signal of EGFP-tagged MacroD2 full-length protein
decreases upon DNA damage (see Figure 1.14). This serendipitous discovery sug-
gests two different possibilities: either upon DNA damage MacroD2 is degraded in a
regulated manner, or the protein subcellular localization changes, with a net trans-
port into the cytoplasm. In both cases, it proposes that MacroD2 could be regulated,
either at the protein levels or in its subcellular localization. Moreover, other experi-
ments showed that the depletion of the MacroD2 signal in the nucleus is blocked upon
treatment with a specific ATM kinase inhibitor (See Figure 1.15).
Although little is still known about MacroD2 function in the cell, the hypothesis
that MacroD2 is regulated upon DNA damage can provide more insight into under-
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standing ADP-ribosylation’s function during the repair response, both at the DNA
lesion and in the rest of the cell. Also, the possible involvement of ATM kinase brings
ADP-ribosylation into the arena with one of the master regulators of DNA damage
repair. Therefore, I decided to characterize this particular regulation of nuclear signal
MacroD2, by understanding its nature and by dissecting the process of its induction.
3.2 MacroD2 exports from the nucleus upon DNA dam-
age
A necessary first control experiment was to test if the EGFP itself could be the cause
of the decrease of MacroD2 nuclear protein levels. To do this, I transfected HeLa
cells stably expressing mCherry-H2B with either EGFP-tagged full-length MacroD2
or EGFP. The cells were then imaged upon UV-laser microirradiation and the images
were analyzed with an automatic approach (see Methods 6.8). By comparing the
ratio of the nuclear signal over the cytoplasmic signal, I observed a consistent decrease
of EGFP-MacroD2 signal in the nucleus. This behavior was not observed with EGFP
alone, excluding that the EGFP tag could be the cause of the phenomenon (Figure
3.1).
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Figure 3.1: Nuclear EGFP-MacroD2 signal is depleted in the nucleus - a)UV-
microirradiation experiments using HeLa cells stably expressing mCherry-H2B and trans-
fected with mEGFP-MacroD2 or mEGFP constructs. Scale bar, 10 µm. b) 50−100
cells were quantified from three independent experiments (see Methods 6.8). Nu-
clear/cytoplasmic ratio was calculated using CellProfiler 2.0 (331), and the mCherry signal
was used for the nuclei segmentation. Error bars, 95 %CI.
I then aimed to understand whether the amount of DNA damage correlates with
the extent of MacroD2 signal decrease. Thus, I tested how the increasing amount
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of DNA damage that I inflicted on the cells by changing the energy of the 355 nm
laser affected the extent of the MacroD2 nuclear signal decrease. Increasing amounts
of DNA damage initiate the DNA damage response in a more robust manner and
enhance the amplification of the signaling cascade. The increase in response is used to
show that phenomenon is due to a biological process, as customary in DNA-damage
research field, and not due to an artifact, which would instead show no correlation.
Thus, I performed the experiment on U2OS cells stably expressing mYFP-MacroD2
full-length and mCherry-H2B and used two different energy amounts to induce DNA
damage (see Methods 6.8). The speed of depletion of MacroD2 nuclear signal was
proportional to the amount of laser energy irradiated and, consequently, to the amount
of DNA damage that was induced, confirming the presence of a DNA damage-dependent
response (Figure 3.2).
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Figure 3.2: MacroD2 nuclear signal depletion occurs with a DNA damage
dosage-dependent manner - a)Microirradiation live-cell microscopy using U2OS cells
stably expressing the mYFP-MacroD2 full length and the mCherry-H2B constructs. Arbi-
trary medium and high laser energy values are used to induce different amounts of damage
to the cell. Scale bar, 10 µm. b) 50−100 cells were quantified from three independent
experiments (see Methods 6.8). Nuclear/cytoplasmic ratio was calculated using Cell-
Profiler 2.0 (331), the mCherry signal was used for the nuclei segmentation. Error bars,
95 %CI.
UV-laser microirradiation induces different types of DNA damage lesions accord-
ing to the amount of energy delivered (332). Therefore, it is impossible to define the
exact amount of the various DNA lesions that are generated with this experimental
setup. To gain better insight into MacroD2’s response to these different types of dam-
age, I decided to test the MacroD2 decrease in nuclear signal in the presence of small
molecule compounds, which cause specific types of DNA damage. For single-strand
breaks (SSBs), I chose the drug camptothecin. Camptothecin blocks the activity of the
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class I of topoisomerases, enzymes that are important for the process of replication and
transcription (111). During these processes, the topoisomerase I nicks a single strand
in order to release the surplus of topological energy of the DNA molecule in a controlled
manner. Therefore, by not allowing the topoisomerase to perform the ligation step, the
camptothecin drug induces SSBs in DNA.
I found that when camptothecin is used, MacroD2 nuclear signal depletion is lim-
ited to only a subset of cells, as shown in preliminary experiments (see Figure 1.15).
Since only a fraction of cells responds to the treatment, I hypothesized that the exclu-
sive generation of SSBs does not induces the phenomenon. Since in S-phase, SSBs are
converted into double-strand breaks (DSBs) upon replication (111), the few respon-
sive cells upon camptothecin treatment might be in S-phase, when their SSBs have
been converted into DSBs. Therefore, if only SSBs are generated, the cell-cycle could
influence the decrease of MacroD2 nuclear protein levels.
To test this hypothesis, I synchronized U2OS stably expressing mEGFP-MacroD2
via aphidicolin treatment, which blocks cells at the G1-S interphase (see Method
6.7.4). Shortly after release, the cells were treated with camptothecin and imaged.
I then checked the percentage of cells responsive to the camptothecin treatment, in
synchronized and not synchronized cells (Figure 3.3). Indeed, the number of cells
showing MacroD2 nuclear signal depletion increased when cells were synchronized and
released in S-phase. Therefore, SSBs may be poor inducers of the decrease of MacroD2
nuclear levels, compared to DSBs.
To test whether DSBs are the cause of the MacroD2 nuclear depletion, I used
the etoposide compound in the same assay. Unlike camptothecin, etoposide targets
class II topoisomerases, whose activity consists in interrupting the DNA phosphate
backbone at both strands. The drug freezes the topoisomerase molecule before the
ligation, thus forming DSBs. I tested the MacroD2 nuclear signal depletion in U2OS
stably expressing mYFP-MacroD2 and mCherry-H2B upon etoposide and DMSO con-
trol treatment (Figure 3.4). In contrast to the camptothecin experiment, the response
upon etoposide treatment was robust and strong, suggesting that DSB formation acti-
vates the signaling pathway that leads to the depletion of the nuclear MacroD2 signal.
Since etoposide strongly induces the nuclear MacroD2 signal depletion in a reproducible
manner, I used this treatment for further tests regarding the MacroD2 nuclear signal
depletion.
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Figure 3.3: Double-strand breaks induce MacroD2 decrease in nuclear signal
better than single-strand breaks - Percentage of cells showing MacroD2 nuclear signal
depletion in U2OS cells stably transfected with mEGFP-MacroD2, synchronized or not
with aphidicolin and treated with camptothecin 50 µM. Cells analyzed from one experi-
ment, three imaging fields. Error bars, SD.
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Figure 3.4: Etoposide strongly induces MacroD2 nuclear signal depletion -
a)Live-cell imaging using U2OS-mYFP-MacroD2 full length+mCherry-H2B cells treated
either with DMSO or etoposide 10 µM. Scale bar, 10 µm. b) 50−100 cells were quantified
from three independent experiments (see Methods 6.8). Nuclear/cytoplasmic ratio was
calculated using CellProfiler 2.0 (331), and the mCherry signal was used for the nuclei
segmentation. Error bars, 95 %CI.
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The next step was to determine whether MacroD2 nuclear signal depletion is due
to degradation upon DNA damage, in contrast to the hypothesis that it is caused by
nuclear export. Therefore, I performed a cyclohexamide chase, to test whether the
depletion of MacroD2 is due to protein degradation (see Methods 6.10). Cyclo-
hexamide is a compound that blocks the translation elongation step of the ribosomal
complex, impairing the cellular protein synthesis. Once the protein synthesis is blocked
by cyclohexamide, the protein levels of MacroD2 can be compared in the presence and
absence of DNA damage, in order to show if there is induction of the MacroD2 protein
degradation upon DNA damage response. Thus, I treated U2OS cells stably-expressing
mYFP-MacroD2 with cyclohexamide or ethanol as negative control. After 30 minutes
I treated the same cells either with DMSO or etoposide to induce DNA damage. Then,
I collected the cells over a 24 hours time period (0, 45 minutes, 2 hours, 4 hours and
24 hours for both cyclohexamide and ethanol treatments). The following immunoblots
were used for quantitative analysis (Figure 3.5). Since I did not observe significant
changes in EGFP-MacroD2 protein levels upon etoposide treatment in the timescale of
our microscopy studies (45 minutes), I concluded that the MacroD2 nuclear depletion
is not due to regulated protein degradation.
In addition to the cyclohexamide chase, to investigate if the observed nuclear de-
pletion of MacroD2 upon DNA damage is due to nuclear export and not to protein
degradation, I tracked the nuclear and cytoplasmic intensity of EGFP-tagged MacroD2
expressed in HeLa cells upon UV-laser microirradiation. Over time, the MacroD2 nu-
clear intensity is reduced almost to the half of the initial reading, while the cytoplasmic
intensity increases by 15 % (Figure 3.6). This disparity in fluorescence changes be-
tween the two set of intensities is compatible with the difference in the volume between
the nuclear and the cytoplasmic compartments. This experiment further excludes that
MacroD2 nuclear depletion is explained by its regulated degradation. Instead, it con-
firms that MacroD2 is exported from the nucleus upon DNA damage.
Since the ectopically-expressed EGFP-MacroD2 construct is reproducibly export-
ing, I wanted to test if the endogenous MacroD2 is also exporting. To this end, I needed
a working antibody, since the commercially-available antibodies for MacroD2 fail to de-
tect the correct protein size via immunoblot. An anti-MacroD2 serum was prepared
by the in-house animal facility, where the rabbits have been immunized with purified
V5-MacroD2 macrodomain prepared by G. Jankevicius. To increase the purity and the
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Figure 3.5: Etoposide treatment does not reduce the total mYFP-MacroD2
protein levels in 30 minutes - a)Cyclohexamide chase experiment (see Methods
6.10). U2OS-mYFP-MacroD2 full length+mCherry-H2B cells were pretreated with cy-
clohexamide (CHX) or ethanol (V) for 30 minutes. At time 0, either DMSO or etoposide
(10 µM) was added. Cells were then collected over a 24 hours time period. Immunoblot
decorated with anti-GFP or anti-actin. b) Quantification of (a) from four independent
experiments. Statistics performed with unpaired non-parametrical Mann-Whitney test.
Error bars, SEM.
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Figure 3.6: The cytoplasmic signal of EGFP-MacroD2 increases upon UV-
lased microirradiation - DNA damage was induced with UV-microirradiation (high
laser energy) on HeLa cells stably expressing mCherry-H2B and transfected with mEGFP-
MacroD2. The quantification of nuclear and cytoplasmic intensity over time was performed
by means of the software Fiji (http://fiji.sc/Fiji) (see Methods 6.8.4). One cell is
shown as example
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specificity of the antibody, I performed the affinity-purification of the seventh bleed of
anti-MacroD2 serum, following the standard protocol generally used in the department
(see Methods 6.11). The elution step was performed with three different buffers
(citrate, glycine and phosphate buffer) and I tested their performance by immunoblot
with different amounts of purified V5-MacroD2 macrodomain protein (Figure 3.7).
As expected, the antibody recognize the macrodomain of MacroD2 and the best per-
forming batch was the one obtained by the glycine elution, which was always used for
my subsequent experiments.
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Figure 3.7: Anti-MacroD2 serum was purified by affinity-purification - V5-
MacroD2 macrodomain was coupled to CNBr-Sepharose 4B beads. The affinity-column
prepared was then used to purify the serum. Three types of buffers (citrate, glycine and
phosphate buffer) were used for the elution steps (see Methods 6.11). A western blot
with 5 ng and 25 pg of purified V5-MacroD2 macrodomain, used also for raising the an-
tibody, was used to define the purification quality. MacroD2 macrodomain runs at the
height of 25 kDa.
To test the specificity of the antibody, I pre-cleared the anti-MacroD2 antibody
by incubating it with recombinant MacroD2 full-length protein. I then used the pre-
cleared antibody for an immunoblot with different cell lysates (U2OS mYFP-MacroD2
full-length; U2OS; HeLa mCherry-H2B; HEK293 TREx) and purified MacroD2 full-
length recombinant protein (Figure 3.8) in comparison to the non-cleared antibody.
Upon pre-clearing, both the endogenous and recombinant MacroD2 bands showed a
reduction in intensity. However, the unspecific band around 110 kDa became stronger,
possibly due to a larger amount of secondary antibodies available for the recognition
of those bands.
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Figure 3.8: Anti-MacroD2 antibody specifically recognize endogenous and re-
combinant MacroD2 - Cell lysates (U2OS mYFP-MacroD2 full-length; U2OS; HeLa
mCherry-H2B; HEK293 TREx; for each, 30 µg loaded) and 200 ng purified MacroD2
full-length were run for a western blot (see Methods 6.9). The primary antibody (anti-
MacroD2) has been previously incubated for one hour at 4 ◦C with 1 mg/mL purified
MacroD2 full-length or water. For the non-cleared antibody section of the membrane,
both short and long exposition are shown; for the pre-cleared antibody section, only long
exposition is shown. * is unspecific band
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To further confirm that the band at 70 kDa is specific for MacroD2, I treated U2OS
cells for RNAi-mediated depletion, by using control or MacroD2-targeting siRNA (see
Methods 6.7.3). Then, I performed a western blot from the cell lysates (Figure
3.9). The 70 kDa band is not present in the knock-down samples, indicating that this
band is MacroD2.
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Figure 3.9: RNAi-mediated knock-down of MacroD2 confirms the partial speci-
ficity of anti-MacroD2 antibody - U2OS cells treated either with siRNA against
MacroD2 or negative control. Collection of cells and lysate preparation at 72 hours post
transfection. Immunoblot with anti-MacroD2 and anti-GAPDH, used as loading control.
The presence of the unspecific band around 110 kDa makes this a not ideal antibody.
Nonetheless, being the best tool available, this antibody was used to test endogenous
MacroD2 nuclear export by immunofluorescence microscopy (see Methods 6.8.2).
To this end, I compared the wild-type U2OS to the U2OS MacroD2 knock-out cell line
generated by G. Mo¨ller by means of the CRISPR-Cas system (333). Cells were treated
with DMSO or etoposide for 1 hour, fixed and processed according to the protocol. In
wild-type U2OS, the nuclear signal showed depletion after 1 hour etoposide treatment,
while the knock-out cells did not (Figure 3.10). The export is clearly detectable,
showing the physiological nature of the regulation of MacroD2 localization upon DNA
damage. However, this antibody does not show the specific localization of MacroD2,
because of the impurities still present after the purification.
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Figure 3.10: The endogenous MacroD2 exports from the nucleus upon one
hour etoposide treatment - a)Immunofluorescence experiment with anti-MacroD2 anti-
body and Hoechst dye on U2OS and U2OS MacroD2-/- cells treated either with DMSO or
etoposide 10 µM for 1 hour. Scale bar, 10 µm. b) Quantification of (a) in three indepen-
dent experiments (see Methods 6.8.2). Nuclear/cytoplasmic ratio was calculated using
CellProfiler 2.0 (331), the Hoechst signal was used for the nuclei segmentation. Statistics
performed with unpaired non-parametrical Kolmogorov-Smirnov test. Error bars, Tukey
fences.
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3.3 The C-terminal region of MacroD2 drives the nuclear
export
MacroD2 has no known nuclear localization signal (NLS) nor a nuclear exporting se-
quence (NES). Indeed, several online predicting programs, such as NLS mapper, NL-
Stradamus, SeqNLS, NES Finder 0.2, Net NES 1.1and LocNES, fail to detect any
localization sequence with satisfactory confidence (data not shown). Therefore, it is
possible that its mode of export could differ from those of other exporting proteins.
When observing the protein sequence, MacroD2 protein consists of an annotated
N-terminal globular macrodomain (aa 59-240) and a long C-terminal region with un-
known function. The globular macrodomain recognizes with high affinity mono-ADP-
ribosylated protein and removes the modification (56, 67). The C-terminus, instead,
is not annotated and the only sequences with more than 50 % identity are from other
vertebrate MacroD2 genes via BLAST search. Therefore, I tested which part of the
MacroD2 protein is sufficient for the regulated nuclear export. I expressed in HeLa
cells EGFP-tagged MacroD2 full-length, macrodomain or the C-terminal region. Then,
I treated the cells with etoposide and imaged using live-cell imaging (Figure 3.11).
Both the full-length and the C-terminal constructs exported, while the macrodomain
alone did not. This indicates that the C-terminal region of MacroD2 is responsible for
its nuclear export.
Due to the lack of localization signals, I decided to explore the protein sequence
and structure of MacroD2. Although the structure of the MacroD2 macrodomain has
been already solved (56), the C-terminus region has never been studied. Online pre-
dictions for the protein secondary structure, such as PredictProtein, indicate that the
C-terminal stretch should be unstructured, with high likelihood being exposed to the
cell environment (Figure 3.12; (334)).
To confirm this prediction, I expressed and purified MacroD2, as a full-length and
C-terminal region (244-488) constructs (see Methods 6.12). Although the C-terminal
region is predicted to be unstructured, the construct was soluble and purified without
precipitation (Figure 3.13). Also, the MacroD2 C-terminal region runs at the height
of 50 kDa, even though its length would account for 25 kDa. This behavior is probably
due to the compositional bias of the C-terminal sequence, as it is also shared by the
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Figure 3.11: The C-terminal region is sufficient for MacroD2 nuclear export
- Live-cell imaging of tagged mEGFP-MacroD2 constructs (full-length, macrodomain or
C-terminal region) in HeLa-mCherry-H2B cells treated either with DMSO or etoposide 10
µM (see Methods 6.8). Scale bar, 10 µm.
26 52 78 104 130 156 182 208 234 260 286 312 338 364 390 416
4481
Exposed Buried Strand Helix Disordered
Figure 3.12: The C-terminal portion of MacroD2 is predicted to be unstruc-
tured - Predictions of MacroD2 secondary structure. Sequence of MacroD2 Isoform 1 of
Uniprot was analysed with the online software PredictProtein (334). The first line shows
prediction for each residue to be exposed or buried; the second line shows prediction for
the presence of helices or strands of β-sheets; the third line shows prediction of disorder.
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MacroD2 full-length protein. The constructs were then further purified by a size-
exclusion column.
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Figure 3.13: The MacroD2 C-terminal region is expressed and purified - His-
TEV-MacroD2 C-terminal construct was expressed in E. coli and purified. The construct
runs at the height of 50 kDa, even though its length would account for 25 kDa. In the
Coomassie-stained gel, the different steps of the purification are shown.
I then analyzed the three purified proteins (full-length and C-terminus purified by
me, macrodomain purified by G. Jankevicius) by circular dichroism, with the help
of Dr. F. Kamp, LMU (see Methods 6.13). Circular dichroism is generally used
to investigate the secondary structure of the proteins by analyzing the change in the
circularly polarized light that passes through a solution with the pure protein. Although
it is not as accurate as a crystal structure, circular dichroism can show which is the
predominant secondary structure of the protein that is being analyzed.
The spectrum of the macrodomain showed a predominant presence of α-helices,
given to the strong positive value around 190 nm and the negative (and almost parallel
to the x-axis) portion of the curve in the interval 209-222 nm (Figure 3.14). This
result is consistent with the percentages calculated from the crystal structure, with 37
% of α-helices and almost 15 % of β-sheets.
The result also confirmed the prediction for the structure of the C-terminus, since
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Figure 3.14: The MacroD2 C-terminal region is unstructured - Circular dichro-
ism experiment on purified MacroD2 full-length, macrodomain and C-terminal region
constructs (5 µM; 20 mM phosphate buffer pH 7.3). In the box, examples for the α-
helix (alpha - green), β-sheet (beta - blue) and random coil (random - red) spectra
(http://www.fbs.leeds.ac.uk/facilities/cd/images/1.png)
the C-terminal fragment showed a strong unstructured behavior, as shown by the deep
negative valley at 198 nm and the almost positive value at 212 nm (335). The full-length
construct showed mostly similarities to the macrodomain folding pattern. Nonetheless,
it has a lower content of α-helices and the presence of random coils when compared to
the macrodomain alone, explaining the shift towards negative values in the portion of
the curve between 190 and 205 nm.
3.4 ATM kinase activity induces MacroD2 nuclear export
As previously mentioned, preliminary experiments showed that ATM kinase activity
could induce MacroD2 nuclear export (see Figure 1.15). Cells were pre-treated with
camptothecin and then treated with an ATM inhibitor KU55399. The few cells re-
sponding to the camptothecin with MacroD2 nuclear export showed a net import of
the protein upon treatment with ATM inhibitor.
ATM belongs to the PI3K-like kinases (276, 336). This class of kinases consists of
six members: ATM, ATR, DNA-PK, SGM-1, mTOR and TRRAP. Of these, ATM,
ATR and DNA-PK play an important role in the DNA damage response by regulating
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the early phase of factor recruitment, cell-cycle checkpoints and the choice of repair
pathway to activate (276). Since all three are involved in DNA damage repair regula-
tion and might even share a subset of common targets, I wanted to define which was
the specific contribution of each of the kinases to MacroD2 export, by using specific
small molecule inhibitors: KU55933, VE-821 and NU7441 for ATM, ATR and DNA-
PK, respectively. Therefore, I pre-treated U2OS stably expressing mYFP-MacroD2
full-length with these inhibitors for 30 minutes before performing the imaging upon
laser microirradiation (see Methods 6.8). The ATM inhibitor successfully inhibited
MacroD2 nuclear export, while ATR and DNA-PK inhibitors did not. In fact, the inhi-
bition of ATR minimally enhances the export (Figure 3.15). This might be explained
by the fact that inactivation of ATR could lead to the increased activation of ATM,
since less competition would take place at the DNA damage site.
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Figure 3.15: Among the PI3K-like kinases, only ATM induces MacroD2 nuclear
export - a) Microirradiation live-cell microscopy of U2OS cells stably expressing mYFP-
MacroD2 full length and mCherry-H2B constructs, pretreated with KU55933 10 µM, VE-
821 1 µM, NU7441 1 µM or DMSO for 30 minutes. Medium laser energy was used. Scale
bar, 10 µm. b) 50−100 cells were quantified from three independent experiments (see
Methods 6.8). Nuclear/cytoplasmic ratio was calculated using CellProfiler 2.0 (331),
and the mCherry signal was used for the nuclei segmentation. Error bars, 95 %CI.
To confirm ATM involvement in the induction of MacroD2 nuclear export, I per-
formed a similar experiment using etoposide. I pre-treated U2OS cells stably expressing
mYFP-MacroD2 full-length with either DMSO or ATM inhibitor for 30 minutes. Then,
I performed the experiment by adding DMSO or etoposide while imaging (see Meth-
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ods 6.8). The experiment showed that ATM inhibition blocks MacroD2 export also
when DNA damage is induced by etoposide (Figure 3.16).
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Figure 3.16: ATM inhibition blocks MacroD2 nuclear export upon etoposide
treatment - a)Live-cell imaging of U2OS-mYFP-MacroD2 full length+mCherry-H2B cells
pre-treated with either DMSO or KU55933 10 M for 30 minutes, and treated either with
DMSO or etoposide 10 µM. Scale bar, 10 µm. b) 50−100 cells were quantified from three
independent experiments (see Methods 6.8). Nuclear/cytoplasmic ratio was calculated
using CellProfiler 2.0 (331), and the mCherry signal was used for the nuclei segmentation.
Error bars, 95 %CI.
While small molecule compounds are a very powerful tool, the main drawback for
their use is the chance in affecting other proteins that might share some similarity with
the main target. For this reason, it is advisable to confirm the functional interaction
with at least another approach. Thus, to further validate the involvement of ATM, I
wanted to perform the siRNA-mediated knockdown of ATM.
To check the efficiency of the knock-down, I performed an immunblot with whole
cell lysate from U2OS cells treated with siRNA against ATM or a control siRNA for
72 hours (see Methods 6.7.3) and probed it with anti-ATM antibody and anti-
GAPDH as loading control. The RNAi treatment drastically reduced ATM protein
levels (Figure 3.17). Hence, the residual expression of ATM implies that a residual
ATM enzymatic activity could still be activated and may generate an intermediate
phenotype, rather than the complete block of MacroD2 nuclear export.
To test the MacroD2 nuclear export upon ATM-knockdown, I imaged U2OS cells
expressing EGFP-MacroD2 C-terminal region upon etoposide treatment (see Meth-
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Figure 3.17: RNAi against ATM successfully reduces ATM protein levels -
Immunoblotting with anti-ATM in U2OS-mYFP-MacroD2 full length+mCherry-H2B cells
treated either with siRNA against ATM or negative control siRNA 72 hours post transfec-
tion (see Methods 6.7.3). GAPDH is used as loading control.
ods 6.7.3 and 6.8). The export dynamics of the C-terminal region construct was
reduced by half when ATM is depleted in cells (Figure 3.18). As expected, given
that the ATM knock-down was incomplete, the experiment showed residual export of
MacroD2 C-terminus region.
I then performed the same experiment with U2OS cells stably expressing MacroD2
full-length construct. In this case, the reduction of MacroD2 nuclear export was mini-
mal and restricted to the time-window of 15-25 minutes after etoposide addition (Fig-
ure 3.19).
I then wanted to check if the reduced effect of ATM knock-down on MacroD2 full-
length nuclear export is restricted to the etoposide treatment. Therefore, I tested the
U2OS stably expressing MacroD2 full-length upon UV-microirradiation (see Methods
6.8). Also in this condition, MacroD2 full-length nuclear export only minimally changes
between the two conditions (Figure 3.20). I detected a minor difference in the export
speed of the ATM-depleted cells compared with the control in case of high laser energy,
while such a difference was lost when I applied a modest amount of DNA damage.
So, while the ATM inhibitor successfully blocked the nuclear export of MacroD2,
the RNAi-mediated treatment showed more contrasting results. These could be ex-
plained either by the residual presence of ATM, due to the incomplete depletion of
the protein, or by a possible redundancy with other kinases, that appears clearly only
upon specific conditions, such as the decreased activity of ATM. Thus, to further test
the involvement of ATM in the induction of MacroD2 nuclear export, we acquired two
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Figure 3.18: siRNA-mediated knock-down of ATM reduces the nuclear export
of the MacroD2 C-terminus fragment - Quantification of live-cell imaging experiments
with U2OS cells stably expressing the mEGFP-MacroD2 C-terminal region+mCherry-H2B,
pretreated for 72 hours with siRNA against ATM or negative control siRNA, and treated
with DMSO or etoposide 10 µM. 50−100 cells were quantified from two independent exper-
iments (see Methods 6.8). Nuclear/cytoplasmic ratio was calculated using CellProfiler
2.0 (331), and the mCherry signal was used for the nuclei segmentation. Error bars are 95
%CI.
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Figure 3.19: ATM-depletion minimally affects the export of the MacroD2 full-
length construct - Quantification of live-cell imaging experiments with U2OS cells stably
expressing the mYFP-MacroD2 full-length, pretreated for 72 hours with siRNA against
ATM or negative control siRNA, and with DMSO or etoposide 10 µM. 50−100 cells were
quantified from two independent experiments (see Methods 6.8). Nuclear/cytoplasmic
ratio was calculated using CellProfiler 2.0 (331), and the mCherry signal was used for the
nuclei segmentation. Error bars are 95 %CI.
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Figure 3.20: The nuclear export of the MacroD2 full-length construct upon
laser microirradiation is marginally affected by the ATM knock-down - a) Quan-
tification of live-cell imaging experiments with high UV-laser energy. b) Quantification of
live-cell imaging experiments with medium UV-laser energy. For (a) and (b), 50−100 U2OS
cells stably expressing the mYFP-MacroD2 full-length and mCherry-H2B, pretreated for
72 hours with siRNA against ATM or negative control siRNA, were quantified from three
independent experiments (see Methods 6.8). Nuclear/cytoplasmic ratio was calculated
using CellProfiler 2.0 (331), and the mCherry signal was used for the nuclei segmentation.
Error bars are 95 %CI.
new cell lines, the G-361 (ATM+/+) and the HT-144 (ATM-/-). These two cell lines are
both melanoma cells with similar, although not identical, genetic background. To check
for the expression of ATM, I tested their cell lysates by immunoblots with anti-ATM
antibody (see Methods 6.9). ATM band was clearly detected in G-361 samples,
however, it was absent in HT-144 sample lanes (Figure 3.21). This result confirms
that HT-144 is a knock-out cell line for ATM.
Then, to test whether MacroD2 can export in the cell line without ATM kinase, I
transfected G-361 and HT-144 cells with EGFP-MacroD2 full-length and imaged the
cells upon UV-laser microirradiation (see Methods 6.8). While in the ATM+/+ G-
361 cell line MacroD2 exports as expected, in the ATM-/- HT-144 cell line MacroD2
nuclear export is not blocked (Figure 3.22). This result indicates that another kinase
could replace ATM in the induction of MacroD2 nuclear export.
Due to similarities between the different members of the PI3K-like kinases family,
it is plausible that some redundancy between these kinases is shown upon specific
conditions. To determine whether one of the other PI3K-like kinases might replace
ATM in the induction of MacroD2 nuclear export when ATM is absent, I transfected
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Figure 3.21: ATM-/- cells do not show ATM band at the immunoblot - Im-
munoblotting with anti-ATM using cell extracts of G-361 and HT-144 cells prepared in
triplicate. GAPDH is used as loading control.
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Figure 3.22: MacroD2 shows residual nuclear export in ATM-/- cells - Microir-
radiation live-cell microscopy of G-361 (ATM+/+) and HT-144 (ATM-/-) cells transfected
with mEGFP-MacroD2 full-length construct. The focus of the laser micro-irradiation is
indicated with yellow arrowheads (see Methods 6.8). High laser energy was used. Scale
bar, 10 µm.
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HT-144 cells with EGFP-MacroD2 full-length and mCherry-H2B. I pretreated the cells
with DMSO, ATM inhibitor (KU55933), ATR inhibitor (VE-821) or DNA-PK inhibitor
(NU7441) for 30 minutes before inducing DNA damage by UV-microirradiation (see
Methods 6.7.3 and 6.8). While the ATM and the ATR inhibitors did not affect the
nuclear export of MacroD2, DNA-PK inhibition resulted in the decrease of MacroD2
nuclear export. These results suggest that in ATM-/- HT-144 cells the role of ATM in
inducing MacroD2 upon UV-laser microirradiation is taken over by DNA-PK (Figure
3.23).
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Figure 3.23: In ATM-/- cells DNA-PK induces MacroD2 nuclear export - a)
Microirradiation live-cell microscopy of HT-144 (ATM-/-) cells transfected with mEGFP-
MacroD2 full-length and mCherry-H2B constructs. Cells were then pretreated with DMSO,
KU55933 10 µM, VE-821 10 µM or NU7441 1 µM for 30 minutes (see Methods 6.8).
High laser energy was used. Scale bar, 10 µm. b) Quantification of an example cell.
Nuclear/cytoplasmic ratio was calculated using CellProfiler 2.0 (331), the mCherry signal
was used for the nuclei segmentation.
The redundancy in ATM activity could represent a back-up mechanism that is
frequently activated, given the importance of the task of this kinase. On the other
hand, it might occur only upon specific conditions. Therefore, to test whether this
redundancy is not restricted to UV-laser microirradiation, the EGFP-MacroD2 nuclear
export was tested in ATM-/- HT-144 upon etoposide treatment (see Methods 6.7.3,
6.8 and 6.8.6). U2OS cells were used as positive control of the MacroD2 nuclear
export. Unlike with the UV-laser, MacroD2 nuclear export was completely inhibited in
HT-144 cells (Figure 3.24). Therefore, upon etoposide treatment, MacroD2 nuclear
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export is exclusively induced by ATM kinase. Such a result show that a specific DNA
damage type might activate a specific pathway, which is able to induce the nuclear
export of MacroD2 in a contained extent.
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Figure 3.24: MacroD2 nuclear export is blocked when ATM-/- cells are treated
with etoposide - Quantification of live-cell imaging experiments with U2OS and ATM-/-
HT-144 cell, transiently transfected with EGFP-MacroD2 full-length and pre-treated with
Hoechst, then treated with etoposide 10 µM. 50−200 cells were quantified from two inde-
pendent transfections (see Methods 6.7.3, 6.8 and 6.8.6). Nuclear/cytoplasmic ratio
was calculated using CellProfiler 2.0 (331), the Hoechst signal was used for the nuclei
segmentation. Error bars are 95 %CI.
3.5 MacroD2 macrodomain marginally modulates its nu-
clear export
In the Section 3.4, I showed that ATM induces MacroD2 nuclear export and that ATM
can be replaced by other kinases according to the type of pathway that is activated.
I also showed that the RNAi-mediated depletion of ATM affects the MacroD2 nuclear
export in different ways, depending on the construct that has been transfected, either
full-length MacroD2 or its C-terminal region (see Figures 3.18 and 3.19).
Since the ATM knock-down is performed in the same way in the two experiments,
the difference in MacroD2 behavior should not be caused by a difference in ATM
activity. However, the two MacroD2 constructs, the full-length and the C-terminal
fragment, differ by the presence (or absence) of the macrodomain. It is then important
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to define whether the macrodomain affects the nuclear export of the whole protein.
The macrodomain presents three features:
1. it is able to bind mono-ADP-ribose, which occurs at DNA lesions;
2. it has a mono-ADP-ribosyl-hydrolase activity, upon binding to modified targets;
3. it is a globular domain of 25 kDa, which might hinder the passage through the
NPC by affecting the MacroD2 physical properties.
I then decided to test how these different features could affect MacroD2 nuclear ex-
port. Assuming that the recruitment to the DNA damage site is important for ATM to
get close to MacroD2, I should see a decrease in its nuclear export dynamics by affect-
ing MacroD2 recruitment. Thus, I pre-treated U2OS cells stably expressing MacroD2
full-length in the presence of DMSO or olaparib, a strong inhibitor of ARTD1, ARTD2
and ARTD3 (337). Olaparib treatment, thus, hinders the PAR formation at the DNA
lesions. Successively, I tested the MacroD2 nuclear export dynamics upon UV-laser mi-
croirradiation (see Methods 6.7.3 and 6.8). As consequence, the olaparib-treated
cells showed no recruitment of MacroD2 to the DNA damage site (Figure 3.25). Yet,
MacroD2 nuclear export dynamics was not affected. Therefore, the recruitment of
MacroD2 to the DNA lesion is not important for MacroD2 nuclear export.
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Figure 3.25: The recruitment to DNA lesions does not affect MacroD2
nuclear export - a)Microirradiation live-cell imaging of U2OS-mYFP-MacroD2 full-
length+mCherry-H2B cells pretreated with either DMSO or olaparib 2 µM. Yellow cir-
cle show the microirradiation focus. High laser energy was used. Scale bar, 10 µm. b)
50−100 cells were quantified from three independent experiments (see Methods 6.8).
Nuclear/cytoplasmic ratio was calculated using CellProfiler 2.0 (331), and the mCherry
signal was used for the nuclei segmentation. Error bars, 95 %CI.
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To investigate if the abolishment of the binding to the ADP-ribose or the acquired
binding to PAR could affect the dynamics of MacroD2 nuclear export, I used two
published mutants. Previous studies on MacroD2 macrodomain have defined a series
of mutation that might affect the binding or the catalytic activity (56). For example,
the G188E mutation completely abolishes the binding of ADP-ribose. Additionally,
the G100E+I189R+Y190R mutant no longer has catalytic activity, but is still able to
bind the ADP-ribose. Moreover, this mutant is no longer selective for the mono-ADP-
ribosylation, but gains the ability to bind PAR as well (G. Jankevicius, unpublished).
Therefore, I transiently expressed these mutants in comparison to the wild-type in
HeLa cells stably expressing mCherry-H2B and performed UV-laser microirradiation
experiments(see Methods 6.8).
The MacroD2 nuclear export dynamics of the three constructs were similar but not
equal (Figure 3.26). The MacroD2 G188E mutant that cannot bind any ADP-ribose
was exported marginally faster than the wild-type construct. This minimal difference
between the ADP-ribose-binding deficient mutant and the wild-type construct in the
export rate is quite striking if compared to the total overlap upon olaparib treatment.
This distinction could be explained by the fact that the MacroD2 macrodomain inter-
acts with mono-ADP-ribosylation, while the main targets of olaparib are ARTD1 and
ARTD2, which are poly-ADP-ribosyl-transferases. Therefore, affecting the binding of
the macrodomain with any type of ADP-ribosylation induces a slightly faster export.
On the other hand, the MacroD2 G100E+I189R+Y190N mutant that is capable to
bind PAR as well as MAR is consistently marginally slower than the wild-type, maybe
due to the increase in binding events that this protein can undergo.
The MacroD2 macrodomain is 25 kDa in size, as is EGFP. To test whether the size
of the protein affects the export rate, with the help of J. Preißer, a C-terminal construct
in a vector containing two EGFP in series was generated. This construct has a similar
molecular weight compared to EGFP-MacroD2 full-length. Thus, by comparing the
nuclear export of these two construct, two outputs are expected: one option is that the
EGFP-EGFP-MacroD2 C-terminal construct behaves like the EGFP-MacroD2 full-
length, meaning that the size but not the macrodomain affects the nuclear export. In
the other scenario, where the EGFP-EGFP-MacroD2 C-terminal exports as the same
fragment with only one EGFP attached, the macrodomain affects the nuclear export by
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Figure 3.26: The macrodomain ability to bind ADP-ribose marginally af-
fects the MacroD2 export rate - Quantification of microirradiation live-cell imaging
of mEGFP-MacroD2 constructs (full-length wild type, full-length G188E or full-length
G100E+I189R+Y190N) in HeLa cells stably expressing mCherry-H2B. 50−100 cells were
quantified from three independent experiments (see Methods 6.8). Nuclear/cytoplasmic
ratio was calculated using CellProfiler 2.0 (331), and the mCherry signal was used for the
nuclei segmentation. Error bars, 95 %CI For the microirradiation, high laser energy was
used..
sourcing possible interactions. I thus transfected EGFP-MacroD2 full-length, EGFP-
MacroD2 C-terminus and EGFP-EGFP-MacroD2 C-terminus constructs in HeLa cells
stably expressing mCherry-H2B (Figure 3.27).
The export dynamics of EGFP-EGFP-MacroD2 C-terminus shows a shape that
is very similar to the one of the MacroD2 full-length construct. However, the two
constructs shows a difference in the overall speed, maybe due to the fact that the
EGFP-EGFP-MacroD2 C-terminus cannot bind any ADP-ribosylation and therefore it
is faster in being exported. On the other hand, the EGFP-C-terminus construct shows
a completely different export dynamics, suggesting that the main difference between
the full-length and the C-terminus constructs is indeed just the size.
As shown previously (see Figures 3.18 and 3.19), the RNAi-mediated depletion
of ATM affects the dynamics of nuclear export of the MacroD2 C-terminus fragment,
but only marginally the dynamics of the full-length protein. To test if these differences
in behavior are indeed due to the presence of the macrodomain, four U2OS stable
cell lines expressing EGFP-MacroD2 full-length, EGFP-MacroD2 full-length (G188E),
EGFP-MacroD2 C-terminus or EGFP-EGFP-MacroD2 C-terminus were treated for 72
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Figure 3.27: The EGFP-EGFP-MacroD2 C-terminus construct shows the same
dynamic of export of the full-length protein - Quantification of microirradiation
live-cell imaging of mEGFP-MacroD2 constructs (EGFP-MacroD2 full-length, EGFP-
MacroD2 C-terminus or EGFP-EGFP-MacroD2 C-terminus) in HeLa cells stably express-
ing mCherry-H2B. Around 50 cells were quantified from three independent experiments
(see Methods 6.8). Nuclear/cytoplasmic ratio was calculated using CellProfiler 2.0 (331),
and the mCherry signal was used for the nuclei segmentation. Error bars, 95 %CI. For the
microirradiation, high laser energy was used.
hours with ATM siRNA or a negative control siRNA (see Methods 6.7.3). On the
third day, cells were pre-treated with Hoechst to stain the nuclei and imaged (see
Methods 6.8 and 6.8.6). The DNA damage was induced by etoposide treatment,
since the Hoechst treatment, necessary for the nuclei segmentation, is not compatible
with my settings of UV-laser microirradiation. In the control treatment, MacroD2 full-
length and C-terminus construct showed the same behavior that was seen previously
(see Figure 3.28, panel b).
The EGFP-MacroD2 full-length G188E mutant also behaves as shown previously,
being slightly faster than the EGFP-MacroD2 full-length. On the contrary, the EGFP-
EGFP-MacroD2 C-terminus construct maintains its previously shown behavior only in
the initial phase of the export dynamics, since it exports up to 20 minutes with a rate
that is intermediate between the full-length and the C-terminus construct; successively,
the C-terminus protein with two EGFP attached slows down in the export, becoming
slower than the full-length (see Figure 3.28, panel a). Since this experiment has been
performed upon etoposide treatment and not UV-laser, it is possible that this change
might have slightly changed the export rate of the different constructs, although the
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EGFP- Full-length wild-type - control siRNA
EGFP- Full-length wild-type - ATM siRNA
EGFP- Full-length (G188E) - control siRNA
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EGFP- C-terminus - control siRNA
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EGFP-EGFP- C-terminus - control siRNA
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Figure 3.28: The partial depletion of ATM mostly affect the dynamics of the
MacroD2 C-terminus only - Quantification of microirradiation live-cell imaging of four
U2OS stable cell lines (EGFP-MacroD2 full-length, EGFP-MacroD2 full-length (G188E),
EGFP-MacroD2 C-terminus and EGFP-EGFP-MacroD2 C-terminus) treated with ATM
siRNA or control siRNA for 72 hours. Before imaging, cells were treated with Hoechst.
Upon imaging, DNA damage was induced by using Etoposide 10 µM. 300−600 cells were
quantified per each condition (see Methods 6.8 and 6.8.6). a) The eight conditions are
shown for the total length of the experiment (80 minutes). b) Close-up of a, with the four
cell lines treated with control siRNA. c) Close-up of a, with the four cell lines treated with
ATM siRNA. Both a and b show the first portion of the experiment, up to 50 minutes.
Nuclear/cytoplasmic ratio was calculated using CellProfiler 2.0 (331), and the Hoechst
signal was used for the nuclei segmentation. Error bars, 95 %CI. For the microirradiation,
high laser energy was used.
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two controls (full-length and C-terminus) were behaving as expected.
When comparing the control treatment with the ATM knock-down, the results show
that the construct showing the most relevant decrease in export rate was the EGFP-
MacroD2 C-terminus, while EGFP-MacroD2 full-length, EGFP-MacroD2 full-length
(G188E) and the EGFP-EGFP-MacroD2 C-terminus constructs were less affected (see
Figure 3.28, panels a and c). The result further supports the hypothesis that the
length of the construct is the main factor influencing the export dynamics of MacroD2.
3.6 ATM induces the phosphorylation of MacroD2 C-terminal
region upon DNA damage
Upon DNA damage, ATM kinase modifies mediators and effectors of the repair process,
creating a signaling cascade of phosphorylation events (276, 338). In particular, ATM
activates other kinases, like Chk1 and Chk2, whose main role is to stop cell-cycle
progression until the DNA lesion is resolved (252, 339, 340).
Therefore, I tested if MacroD2 is phosphorylated upon DNA damage as well. In
HEK293 lysate I added the purified EGFP-tagged MacroD2 C-terminal fragment to-
gether with (32P)γ-ATP (see Methods 6.14). In control samples I also added ATM
inhibitor KU55933. I then induced DNA damage in the samples by adding Benzonase
nuclease and incubated for 40 minutes. I then purified EGFP-MacroD2 C-terminus
protein by GFP-trap and ran the samples on a gel, which was stained with Coomassie
and then analyzed for the radioactive content.
In the autoradiograph, I could see increased phosphorylation of the C-terminal
fragment in the sample incubated with Benzonase, as DNA damage inducer (Figure
3.29). On the contrary, when the reaction buffer was supplemented with the ATM
inhibitor KU55933, the radioactive signal was reduced. This means that upon DNA
damage MacroD2 is phosphorylated either directly or indirectly by ATM kinase activity.
To look at the DNA damage-induced phosphorylation of MacroD2 in more detail,
we started a collaboration with Dr. A. Schmidt at the Zentrallabor fu¨r Proteinanalytik,
LMU. By checking the sequence annotated on Uniprot, the MacroD2 protein sequence
presents several residues that might accept phosphorylation. Thus, we adopted a mass
spectrometry-based phospho-proteomics approach to measure the abundance of phos-
phorylated peptides from MacroD2 (see Methods 6.15). U2OS cells stably expressing
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Figure 3.29: MacroD2 is phosphorylated in the C-terminal region - a)Coomassie
and autoradiography of purified mEGFP-MacroD2 C-terminal domain added to HEK293
cell lysate, which has been treated or not with benzonase and KU55933, spiked with
(32P)γ-ATP and successively immunopurified. b) Quantification of IP results from three
independent experiments (see Methods 6.14). Error bars, SEM.
mYFP-MacroD2 full-length and mCherry-H2B were treated for 1 hour with DMSO or
etoposide. MacroD2 proteins were then purified by using GFP-trap and treated for
mass spectrometry by Dr. Schmidt. In three biological replicates we achieved a pro-
tein coverage of 70 %. Some sites showed increased phosphorylation upon etoposide
treatment as compared with control, such as S292, S415 and S426 (Figure 3.30, Ta-
ble 3.1). Additionally, there were cases, like the phosphorylation in the aa 307-317
stretch, that is present only in the DMSO-treated cells. Other cases showed the same
enrichment level in both treatments, arguing for the irrelevance of these particular
modifications in MacroD2 nuclear export.
In particular, the phosphorylated version of the peptide 402-417 is more enriched
upon etoposide treatment (Figure 3.31,panel a). In fact, in the spectrum of the
phosphorylated peptide (see panel a,1), the peak is present upon etoposide treat-
ment but absent in the untreated sample. In addition, since the peptide 402-417 is
short, it is certain that the phosphorylation event occurs exclusively on S415, since
the modification is present only for the y-fragments upon the peptide fragmentation
(Figure 3.31,panel b).
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Figure 3.30: MacroD2 residues are phosphorylated upon etoposide treatment
- Abundance of phosphorylated peptides of MacroD2. U2OS stably expressing mYFP-
MacroD2+mCherry-H2B were treated for 1 hour with etoposide 10 µM or DMSO and
immunopurified with GFP-trap. Following treatment, mass spectrometry experiment and
analysis performed by Dr. A. Schmidt. Quantification of three independent experiments.
Error bars, SEM. Statistics performed with paired t-Test with two-tailed distribution.
Sequence Localization Amino acid Localization score
DENGPEEKQSVEEMEEQSQ 268 S 1.00
DGVNTVTVPGPASEEAVE 292 S 1.00
DENITKGGEVT 311 S 0.99
DSTKNEIKIETESQSSYMETEELSSNQE 345 S 0.65
DSTKNEIKIETESQSSYMETEELSSNQE 356 S 0.47
DSTKNEIKIETESQSSYMETEELSSNQE 352 T 0.51
DSTKNEIKIETESQSSYMETEELSSNQE 349 Y 0.59
DTPRMPGKSEGSSDLENTPGPDVEMNSQV 400 S 0.90
DTPRMPGKSEGSSDLENTPGPDVEMNSQV 401 S 0.49
DLENTPGPDVEMNSQV 415 S 1.00
DKVNDPTESQQEDQLIAGAQ 424 T 0.74
DKVNDPTESQQE 426 S 1.00
Table 3.1: Identified MacroD2 phosphorylated peptides - Overview of identified
peptides and position of the phosphorylation. The localization score is the probability that
the particular modification is located on the specific residue and it is calculated by dividing
the (1 − pvalue) of the fragmented ion with the specific modified residues with the sum of
the (1 − pvalue) of all the fragmented ions of the peptide (341).
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Figure 3.31: The serine in position 415 is modified upon etoposide treatment
- a) Extracted ion chromatogram from experiment 3.30, showing aa 402-417 peptide with
phosphorylation of the serine (1), oxidation of the methionine (2) or with both modifications
(3), comparing control treatment with etoposide treatment. b) CID-MS/MS spectrum of
the 402-417 peptide in the phosphorylated and oxidated form (921.37 m/z).
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3.7 Phosphorylation sequence requirements indicates the
direct involvement of ATM
MacroD2 is rich in residues that can accept phosphorylation, as shown for the many
phosphorylation events on serines and threonines occurring on MacroD2 (see Figure
3.30). Importantly, most of these amino acids are located in the C-terminal region of
MacroD2, which has a biased composition towards acidic residues. This biased compo-
sition is favorable for a few classes of kinases, such as PI3K-like kinases, Chk kinases
and Polo-like kinases, although these different classes have specific and more detailed
consensus sequences (342, 343). In the MacroD2 C-terminal region there are four ser-
ines followed by glutamine (S276, S345, S415 and S426), a motif that is recognized by
ATM, ATR and DNA-PK (220). The S415 was a well characterized site phosphory-
lated upon etoposide treatment, as detected by mass spectrometry (see Figure 3.31),
leading to the hypothesis that MacroD2 could be specifically phosphorylated by ATM
and PI3K-like kinases.
To test whether these four SQ motifs are involved in the induction of MacroD2
nuclear export, I generated a EGFP-MacroD2 construct with all four C-terminal region
SQ motifs mutated (mutant 4SA; S276,345,415,426A) with the help of G. Jankevicius
and S. Grau. The mutant 4SA was transfected in HeLa cells stably expressing mCherry-
H2B and tested for the export upon UV-laser microirradiation, in comparison to the
wild-type (see Methods 6.8). The EGFP-MacroD2 mutated in all SQ motifs was not
able to export (Figure 3.32). These motifs are thus necessary for MacroD2 nuclear
export.
To address the specific contribution of each motif, we created four mutants, each
with three of the four serines mutated to alanine, leaving only one SQ motif intact
per construct.The constructs were then tested for the nuclear export upon UV-laser
microirradiation, having been transfected in HeLa cells stably expressing mCherry-
H2B (see Methods 6.8). The experiment showed that the serines S276 and S426 are
irrelevant for the export, because the constructs presenting only these motifs intact did
not accumulate in the cytoplasm (Figure 3.33). On the other hand, S345 and S415
are necessary for the nuclear export. When each of these two serines was left intact,
MacroD2 nuclear export was successful.
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Figure 3.32: Mutation of the four SQ motifs completely abolishes MacroD2
nuclear export - a)Microirradiation live-cell microscopy of HeLa cells stably expressing
mCherry-H2B and transfected with mEGFP-MacroD2 full-length or mEGFP-MacroD2
S276,345,415,426A constructs. For the microirradiation, high laser energy was used. Scale
bar, 10 µm. b) 50−100 cells were quantified from three independent experiments (see
Methods 6.8). Nuclear/cytoplasmic ratio was calculated using CellProfiler 2.0 (331),
and the mCherry signal was used for the nuclei segmentation. Error bars, 95 %CI.
Then, to further confirm the role of the S345 and S415 for the nuclear export of
MacroD2, I generated a EGFP-MacroD2 full-length construct whose S276 and S426
were mutated to alanine, leaving S345 and S415 as serine. As before, I transfected
the mutant and the wild-type constructs in HeLa cells stably expressing mCherry-H2B
and tested their ability to export from the nucleus upon UV-laser microirradiation
(see Methods 6.8). The export dynamics of the MacroD2 S276,426A construct is
indistinguishable from the wild-type (Figure 3.34). Additionally, from Figure 3.33 it
is clearly noticeable that when the S354 and S415 are intact alone in the protein, the
nuclear export does occur but not at the same level of the wild-type protein. Thus,
S345 and S415 are likely working in a cooperative way.
The fact that I could pinpoint two specific residues essential for MacroD2 nuclear
export argues for the presence of two exporting sequences in the C-terminus region.
It is likely that each sequence includes a phosphorylated serine. The serine S415 is
clearly shown to be phosphorylated upon DNA damage (see Figure 3.31). Also S345
was recognized as site during the identification of the phosphorylated sites with mass
spectrometry, although not with the same degree of certainty (see Table 3.1). Indeed,
due to the length of the peptide and, thus, the presence of many residues capable of
modification, S345 was not shown to be the only site able to accept the phosphorylation
within the peptide. Nonetheless, in both cases the mutation of the serine blocks the
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Figure 3.33: S345 and S415 are neccessary for MacroD2 nuclear export
- a)Microirradiation live-cell microscopy of HeLa cells stably expressing mCherry-H2B
and transfected with mEGFP-MacroD2 full-length or different serine triple mutants
(S345,415,426A; S276,415,426A; S276,345,426A; S276,345,415A). For the microirradiation,
high laser energy was used. Scale bar, 10 µm. b) 50−100 cells were quantified from three
independent experiments (see Methods 6.8). Nuclear/cytoplasmic ratio was calculated
using CellProfiler 2.0 (331), and the mCherry signal was used for the nuclei segmentation.
Error bars, 95 %CI.
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Figure 3.34: S345 and S415 are sufficient for the nuclear export of MacroD2
- Quantification of microirradiation live-cell microscopy of HeLa cells stably expressing
mCherry-H2B and transfected with mEGFP-MacroD2 full-length wild type or S276,426A.
50−100 cells were quantified from three independent experiments (see Methods 6.8).
Nuclear/cytoplasmic ratio was calculated using CellProfiler 2.0 (331), and the mCherry
signal was used for the nuclei segmentation. Error bars, 95 %CI. For the microirradiation,
high laser energy was used.
nuclear export. Thus, it is highly likely that the S345 undergoes the phosphorylation
event able to induce the nuclear export, as the serine S415 does. However, more
sequence requirements could be necessary for the activity of these export sequences.
For this reason, I wanted to characterize the contribution of the residues surrounding
the phospho-serine for the export. This piece of information could be in fact very
helpful to define possible interactors that are important for the accomplishment of the
localization.
I initially focused on the sequence surrounding the serine 415 because it was the
best characterized modification in the phospho-proteomics analysis (see Figure 3.31).
First, I tested a series of fragments with decreasing length to find a sequence short
enough for further manipulation, yet, still be able to export. I therefore compared
EGFP-MacroD2 full-length, MacroD2 C-terminal (aa 236-448) and the fragments aa
382-418, aa 402-418 and aa 410-418, all transiently expressed in HeLa-mCherry-H2B
cells and measured the nuclear export upon UV-laser microirradiation (see Methods
6.8). Surprisingly, just a 9-residue-long fragment, namely aa 410-418 (DVEMNSQVD),
is still able to export residually (Figure 3.35). Therefore, I defined this fragment as
the core exporting sequence.
86
3.7 Phosphorylation sequence requirements indicates the direct
involvement of ATM
0 min 5 min 15 min 30 min
MacroD2 full length
MacroD2 (aa236-448) 
MacroD2 (aa382-418) 
MacroD2 (aa402-418)
MacroD2 (aa410-418)
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0 5 10 15 20 25 30
Time (min)
F
lu
o
re
sc
e
n
t 
n
u
cl
e
a
r 
ra
ti
o
MacroD2 full length
MacroD2 (aa236-448) 
MacroD2 (aa382-418) 
MacroD2 (aa402-418)
MacroD2 (aa410-418)
a b
Figure 3.35: The fragment aa 410-418 is sufficient for MacroD2 nuclear export
- a)Microirradiation live-cell imaging of HeLa cells stably expressing mCherry-H2B and
transfected with mEGFP-tagged constructs (MacroD2 full-length, MacroD2 C-terminal
region (aa 236-448), MacroD2 aa 382-418, MacroD2 aa 402-418, MacroD2 aa 410-418). For
the microirradiation, high laser energy was used. Scale bar, 10 µm. b) 50−100 cells were
quantified from three independent experiments (see Methods 6.8). Nuclear/cytoplasmic
ratio was calculated using CellProfiler 2.0 (331), and the mCherry signal was used for the
nuclei segmentation. Error bars, 95 %CI.
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To define to what extent each residue in the sequence is required for phosphoryla-
tion, I adopted a scanning mutagenesis approach. I mutated each residue of the 410-416
stretch to alanine (or aspartate in the case of V411, given to the close similarity be-
tween alanine and valine) within the EGFP-MacroD2 (382-418) fragment. I performed
the mutations in a longer fragment to avoid impairments in the binding of the kinase
due to sequence length. To assay the kinase activity, I used HEK293 cell lysates spiked
with the purified proteins and treated with Benzonase nuclease (see Methods 6.14).
I tested the incorporation of (32P)-phosphate in the His-EGFP-tagged mutagenized
fragments compared to the GST-EGFP-tagged wild-type fragment, which acted as an
internal positive control for phosphorylation (Figure 3.36).
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Figure 3.36: Both S415 and Q416 are required for the phosphorylation -
a)Coomassie and autoradiography of purified GST-mEGFP-MacroD2 (aa382-418) wild-
type and His-mEGFP-MacroD2 (aa382-418) (wild-type or mutant proteins). Purified con-
structs were added to HEK293 cell lysate, which was treated with benzonase and spiked
with (32P)γ-ATP. Successively, immunopurification with GFP-trap. b) Quantification of
(a) in three independent experiments. Error bars, SEM. Statistics performed with un-
paired non-parametrical Mann-Whitney test against the wild-type (see Methods 6.14).
* is p = 0.05; n.s. is p > 0.05.
Different residues appear to have different effects on the phosphorylation, presum-
ably due to a variation in recognition by the kinase. As expected, the mutation of the
serine 415 abolished the incorporation of radioactivity. Additionally, the Q416A muta-
tion totally blocked the modification. This result argued for the direct involvement of
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ATM in the phosphorylation of MacroD2, since ATM, ATR and DNA-PK are the only
kinases that strictly require the glutamine after the serine: among them, ATM seems
to be the main inducer of MacroD2 nuclear export (see Section 3.4; (342)). On the
other hand, other mutations only marginally affected the modification, thus they are
not fundamental for the kinase to recognize the sequence.
After having defined the phosphorylation level of these mutant, I wanted to see
their nuclear export efficiency. Thus, I transfected all the EGFP-tagged mutants of the
aa 382-418 fragment in HeLa cells stably expressing mCherry-H2B and I tested them
in nuclear export assays upon UV-laser microirradiation (see Methods 6.8). As
expected, neither S415A nor Q416A are able to export (Figure 3.37). Interestingly,
the M413A mutant shared the same phenotype.
Since M413A mutant shows no change in incorporation of the (32P)-phosphate
compared to the wild type, this result suggests that the methionine could be essential
in the nuclear export in a step that is downstream of the phosphorylation of the serine,
such as for the recognition of the sequence by the export machinery.
A similar approach was taken to define the sequence requirements also for the S345
site. Together with J. Preißer and M.L. Tran, we determined the shortest sequence re-
quired for the export of a fragment containing the serine 345. We found that the stretch
between K340 and M350 is necessary and sufficient for the export (KIETESQSSYM ):
in comparison with the fragment 410-418 around the serine 415, the 340-350 stretch is
slightly longer (data not shown). Still, to again avoid impairments in the binding, we
performed the scanning alanine mutagenesis in a longer fragment, namely aa 336-372:
the two fragments, aa 382-418 and aa 336-372, were designed to have a comparable
length.
M.L. Tran expressed all the mutants in HeLa cells stably expressing mCherry-H2B
and tested their nuclear export dynamics upon laser microirradiation. Similarly to the
410-418 fragment, S345, Q346 and M350 are necessary for the nuclear export of this
fragment (Figure 3.38). On the other hand, few other mutations also slowed the
export dynamics (Table 3.2). Their residues were mainly located downstream from
the SQ motif.
In both sequences, the mutation of the serine or the following glutamine affected
the nuclear export. Likewise, in both sequences the mutation of a methionine into an
alanine impaired the export, although their position relative to the serine is different:
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Figure 3.37: M413 is also necessary for the nuclear export of the fragment aa
382-418 - a)Microirradiation live-cell microscopy of HeLa cells stably expressing mCherry-
H2B and transfected with mEGFP-MacroD2 (aa382-418) wild-type construct or mutants
(D410A; V411E; E412A; M413A; N414A; S415A; Q416A). For the microirradiation, high
laser energy was used. Scale bar, 10 µm. b) 50−100 cells were quantified from three
independent experiments (see Methods 6.8). Nuclear/cytoplasmic ratio was calculated
using CellProfiler 2.0 (331), and the mCherry signal was used for the nuclei segmentation.
Error bars, 95 %CI.
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Figure 3.38: In the aa 336-372 fragment, S345, Q346 and M350 are necessary
for the export - Quantification of microirradiation live-cell imaging of HeLa cells stably
expressing mCherry-H2B and transfected with mEGFP-MacroD2 (aa336-372) wild-type
construct or mutants S345A, Q346A and M350A. 50−100 cells were quantified from three
independent experiments (see Methods 6.8). Nuclear/cytoplasmic ratio was calculated
using CellProfiler 2.0 (331), and the mCherry signal was used for the nuclei segmentation.
Error bars, 95 %CI. For the microirradiation, high laser energy was used.
Position Wild-type Mutant Export in mutant Significance
340 K A unchanged no
341 I A unchanged no
342 E A unchanged no
343 T A slow yes
344 E A unchanged no
345 S A no yes
346 Q A no yes
347 S A slow yes
348 S A slow yes
349 Y A slow yes
350 M A no yes
Table 3.2: Export dynamics for alanine mutant in the aa 336-372 fragment
- Alanine scanning mutagenesis for the fragment aa 336-372. Each mutant is compared
to the wild-type and the outcome of unpaired non-parametrical Mann-Whitney tests is
shown.
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M413 is in position -2 compared to the S415, while M350 is in position +5 from the
serine S345. In addition, when comparing the two export sequences, all the residues of
the aa 382-418 fragment that are relevant for the definition of the export dynamics were
located shortly upstream from the SQ motif. Conversely, in the aa 336-372 fragment,
the majority of the residues whose mutation affected the nuclear export were located
downstream from the SQ motif.
The inhibition of the MacroD2 nuclear export when the methionine is mutated
into alanine shows that by placing a residue of different nature in that position does
impair the occurrence of the process, but does not prove that the methionine and only
the methionine is required in that position. To test how essential is the methionine,
I mutated the M413 to phenylalanine or isoleucine. These two residues are, in fact,
belonging to the same group of strongly hydrophobic amino acids.
For the experiment, I transfected the mEGFP-MacroD2 (aa388-424) wild-type
and mutants M413A, M413F and M413I constructs in HeLa cells stably expressing
mCherry-H2B. I then tested the export dynamics of these construct upon UV-laser
microirradiation (see Methods 6.8). When comparing the wild-type construct with
its related mutants, it is clear that the mutation of the methionine impairs the nuclear
export, even when it is mutated to strongly hydrophobic residues (Figure 3.39).
In summary, the phosphorylation of the S415 residue within the aa 382-418 frag-
ment is dependent on the presence of the serine and the glutamine. Moreover, for
both the exporting sequences, the mutation of the serine or the glutamine to alanine
blocks the nuclear export. Having the serine followed by a glutamine in both motifs as
sequence requirement, strongly suggests that ATM itself is interacting with MacroD2
and modifying it upon DNA damage.
In addition to the SQ motif, the two sequences share another feature: a methionine,
whose mutation to alanine impairs the nuclear export of MacroD2 fragments. The
mutation of the methionine does not affect the phosphorylation process, as I showed
for the aa 382-418 sequence. However, the relative positions of the methionines and
the SQ motifs change in the two exporting sequences.
92
3.7 Phosphorylation sequence requirements indicates the direct
involvement of ATM
1.2
1.1
1.0
0.9
0.8
0.7
0.5
0 5 10 15 20
Time (min)
F
lu
o
re
sc
e
n
t 
n
u
cl
e
a
r 
ra
ti
o
0.6
aa 388-424 wild-type
aa 388-424 M413F 
aa 388-424 M413I
aa 388-424 M413A
Figure 3.39: Mutation of the M413 to other hydrophobic residues does not
rescue MacroD2 nuclear export - Quantification of microirradiation live-cell imag-
ing of HeLa cells stably expressing mCherry-H2B and transfected with mEGFP-MacroD2
(aa388-424) wild-type construct or mutants M413A, M413F and M413I. 50−100 cells were
quantified from two independent experiments (see Methods 6.8). Nuclear/cytoplasmic
ratio was calculated using CellProfiler 2.0 (331), and the mCherry signal was used for the
nuclei segmentation. Error bars, 95 %CI. For the microirradiation, high laser energy was
used.
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3.8 14-3-3s do not bind MacroD2
As the two sequences in MacroD2 protein necessary for its nuclear export upon DNA
damage have been defined (see Section 3.7), it is possible to address which mechanism
mediates the nuclear export of MacroD2. As shown above, this process is regulated
by means of phosphorylation events, which can modulate the interaction with nuclear
transport receptors or adaptor proteins. As described in Section 1.4.2, it is a common
mechanism that proteins are phosphorylated and such phospho-sites can be recognized
by adaptor proteins, which mediate in turn the formation of the complex with the
export machinery (302, 344, 345).
The best described class of these adaptor proteins are the 14-3-3s (346, 347, 348).
Preliminary analyses of the first biological replicate of the co-immunopurification ex-
periment coupled to peptide mass fingerprinting, which I describe in Chapter 4, showed
the binding of 14-3-3 to MacroD2 full-length and C-terminal fragment upon etoposide
treatment. This preliminary result prompted me to perform validation experiments on
this possible binding candidate for the MacroD2 nuclear export.
14-3-3 proteins are small (28 kDa), abundant and very stable and preferentially
bind phosphorylated serines or threonines that are placed within a consensus sequence
(349, 350). There are three described consensus sequences:
• -R(S/T)XpSXP-
• -RX(F/Y)XpSXP-
• -pSXCOOH
Several proteins have been described to interact with the 14-3-3s in a phosphorylation-
independent manner, such as the anti-apoptotic protein BAX (351), the transcription
factor ChREBP (352) and the viral ADP-ribosyltransferase ExoS (353).
The 14-3-3s might be suitable candidates to drive MacroD2 out of the nucleus for
a number of reasons. First of all, they bind phospho-serines or phospho-threonine. In
the case of COP1, the phospho-site is modified by ATM itself (324). 14-3-3s have been
described several times as intermediate of nuclear export, such as for COP1, Chk1,
FKHRL1, FOXO1, FOXO4, BAD or Cdc25C (324, 325, 346, 354, 355, 356). However,
in most cases the nuclear export is due to the fact that, upon binding, the 14-3-3 masks
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the NLS of the transported protein, thus impairing the nuclear import. Often, the
binding with 14-3-3s require two phospho-sites, since the 14-3-3 proteins adopt either
a homo- or a heterodimer form (350). The two residues that act as binding site for
the 14-3-3s are preferentially located in unstructured sequences, to help in formation
of all possible contacts between the proteins (356). For these reasons, it is feasible
to hypothesize a possible interaction between MacroD2 and a 14-3-3 protein upon
DNA damage. As shown in the previous section, MacroD2 has two motifs undergoing
phosphorylation upon DNA damage, which drive its nuclear export. Both sites are
present in the unstructured C-terminus region of MacroD2.
On the other hand, some other considerations question the involvement of 14-3-3s
in the export of MacroD2. The consensus sequence for the 14-3-3 binding tends to be
incompatible with the one of the PI3K-like kinases, since the 14-3-3s prefers positive
charges, while the PI3K-like kinases prefers sequences rich in negative charges (357).
Therefore, the consensus is theoretically incompatible also with MacroD2 exporting
sequences, being that MacroD2 is rich in acidic amino acids. Still, given the many
elements supporting the hypothesis, it was worthwhile to test the interaction.
For this reason, with the help of J. Preißer, I expressed and purified all seven
human 14-3-3 isoforms (, σ, ζ, β, η, θ and γ) with a GST tag (see Methods 6.16.1)
Additionally, I also purified the 14-3-3 with a mutation of lysine 49 into glutamate.
This mutant is described as unable to bind the phospho-serine, and as such represents
a suitable negative control for a pull-down assay. I used synthetic biotynilated-peptides
in place of MacroD2 protein in order to test the interaction in an in vitro condition:
1. Biotin - G S L S Q R Q R S T S T P N V H (Control peptide - unphosphorylated)
2. Biotin - G S L S Q R Q R S T pS T P N V H (Control peptide - phosphorylated)
3. Biotin - N T P G P D V E M N S Q V D K V
4. Biotin - N T P G P D V E M N pS Q V D K V
5. Biotin - N T P G P D V E A N S Q V D K V
6. Biotin - N T P G P D V E A N pS Q V D K V
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1 and 2 are control peptides that have been previously published (343). The other
four peptides are designed from MacroD2 protein sequence (aa 402-420). Peptides 4
and 6 are phosphorylated at serine 415; 5 and 6 have the methionine 413 mutated to
alanine. Considering that the percentage of phosphorylated MacroD2 over the total
cellular pool is unknown, by adopting synthetic peptides I sought to work in a defined
condition, where all the MacroD2 sequences would be modified.
I then performed the pull-down experiment of the GST-14-3-3 proteins using the
biotinilated peptides conjugated to Streptavidin resin (see Methods 6.16.2). The
Figure 3.40 shows the pull-down experiment of the GST-14-3-3 proteins with the syn-
thetic peptides.
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Figure 3.40: The MacroD2 phosphorylated peptides do not interact with puri-
fied 14-3-3s - Pull-down experiment of purified 14-3-3 (, (K49E), σ, ζ, β, η, θ and γ) and
biotinylated-peptides, phosphorylated or not. Immunoblot of the samples with anti-GST
(see Methods 6.16.2).
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In the negative control EGFP, the signal in most of the lanes suggested a background
binding, while the pull-down of the 14-3-3  (K49E) mutant was not comparable because
of its faint signal in the input. All the 14-3-3 proteins except the σ convincingly bound
the phosphorylated control protein more than the unphosphorylated form. Among
these pull-downs, the 14-3-3 , β, η and θ bound better the unphosphorylated MacroD2
peptide compared to the phosphorylated one, while only the 14-3-3 ζ seemed to bind
more the phosphorylated peptide than the unphosphorylated form, even if very weakly.
When comparing the pull-downs performed with the peptides with the mutated
methionine, the 14-3-3 σ was more enriched in the phosphorylated form compared to
the unphosphorylated one. However, the equal binding for the positive control urged
me to not consider this protein, since published work clearly showed that it should bind
more the phosphorylated control peptide over the unposphorylated (343). This output
was also present for the 14-3-3 β, even though it was a very faint signal. On the other
hand, the 14-3-3 ζ, η, θ and γ showed more enrichment upon the unphosphorylated
version. Finally, the 14-3-3  showed no signal for either pull-downs. According to
these results, no 14-3-3 protein met these three criteria: to bind the control peptides as
expected (2 more than 1 ), to bind the phosphorylated MacroD2 peptide (4 ) more than
the unphosphorylated one (3 ), and to not bind any peptide mutated in the methionine
(5 and 6 ).
I repeated the experiment with a subset of proteins, but the results were not repro-
ducible, possibly due to different amounts of peptides conjugated to the beads across
the different experiments (data not shown). Although the control peptides always
worked consistently, since I did not find a way to define the amount of MacroD2 pep-
tides present until the end of the experiment, I decided to test the interaction with
another approach: a co-immunopurification experiment between 14-3-3 proteins and
the purified MacroD2 C-terminus fragment.
To this end, I added EGFP-MacroD2 C-terminal domain and a selection of the
14-3-3 proteins (, (K49E), ζ and β) to the HEK293 lysate and activated the DNA
damage response by adding Benzonase to the system (see Methods 6.16.3), as done
previously (see Figures 3.29 and 3.36). As mentioned above, the strength of the pull-
down approach with synthetic peptides consisted of having at least 95 % of the molecules
phosphorylated, while in this case I ignore the exact percentage of phosphorylated
protein. However, since I used a large amount of purified proteins in the experiments,
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it may have been possible to detect the interaction between the two partners in this
condition. Nonetheless, the band for the EGFP-MacroD2 C-terminal region did not
appear in any of the pull-downs from samples treated with Benzonase (Figure 3.41).
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Figure 3.41: The MacroD2 C-terminal domain does not interact with 14-3-3, ζ
and β in vitro - Immunoprecipitation experiment of EGFP-MacroD2 C-terminal domain
and GST-14-3-3s (, (K49E), ζ and β) or GST-EGFP. Purified proteins were spiked into
HEK293 cell-extract. DNA damage was induced by adding Benzonase nuclease. Control
immunopurifications were performed with water in place of Benzonase. Co-IP performed
with glutathione beads and interaction tested with anti-GFP.(see Methods 6.16.3)
Although I could not detect any signal, I decided to perform a variation of the
same experiment, using the EGFP-MacroD2 (aa382-418) fragments previously used
(see Figure 3.36). In particular, I added the same above mentioned 14-3-3 proteins
and the MacroD2 fragments, both the wild type and the mutants M413A and S415A
to the HEK293 cell lysate (see Methods 6.16.3). As before, I could not detect
any enrichment of the MacroD2 fragments upon pull-down of the GST-14-3-3 proteins
(Figure 3.42).
As a last attempt to observe the interaction between MacroD2 and the 14-3-3s, I
performed a co-immunoprecipitation experiment of the 14-3-3 with EGFP-MacroD2
or EGFP alone stably expressed in HEK293 cells (see Methods 6.16.4). The 14-3-3
was the isoform identified in the first place in the co-immunopurification experiment
coupled with peptide mass fingerprinting (see Chapter 4). The cells were treated for
one hour with etoposide before harvesting, reproducing the same conditions used for
the co-IP experiment that is described in Chapter 4. However it was observed that even
though MacroD2 was highly enriched, the 14-3-3 was not detectable (Figure 3.43).
To sum up, the multiple attempts at identifying an interaction were unsuccessful
and, therefore, the 14-3-3 identified by the mass spectrometry approach appears to be
a false positive.
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Figure 3.42: The 14-3-3s do not interact with MacroD2 fragments in vitro -
Immunoprecipitation experiment of EGFP-MacroD2 fragment (aa382-418) wild type and
mutants (M413A and S415A) and GST-14-3-3s (, (K49E), ζ and β). Purified proteins
were spiked into HEK293 cell-extract. DNA damage was induced by adding Benzonase
nuclease. Co-IP performed with glutathione beads and interaction tested with anti-GFP
on immunoblot (see Methods 6.16.3).
99
3. ATM KINASE INDUCES MACROD2 NUCLEAR EXPORT
EG
FP
-M
ac
ro
D2
 F
L
EG
FP
-M
ac
ro
D2
 F
L
EG
FP
EG
FP
Anti-MacroD2 
Anti-14-3-3 ε (short exposition)
Anti-14-3-3 ε (long exposition)
Anti-GAPDH
Input IP
Figure 3.43: MacroD2 fails to pull down the 14-3-3 in vivo - Immunoprecipitation
experiment of 14-3-3 protein from HEK293 cell extract. Cells were overexpressing EGFP-
MacroD2 full-length or EGFP alone, treated for one hour with etoposide 10 µM and
immuno-purified by GFP-trap. GAPDH was used as negative control (see Methods
6.16.4).
3.9 ATM activity regulates the recruitment of MacroD2
to DNA lesions
After having characterized MacroD2 nuclear export, the question about the possible
role of this regulation is still open. To this end, I tested if the ATM-induced MacroD2
nuclear export could affect MacroD2 recruitment to sites of DNA damage. Thus, I
transfected EGFP-tagged MacroD2 full-length, MacroD2 macrodomain and MacroD2
C-terminus proteins in HeLa stably expressing mCherry-H2B and performed UV-laser
microirradiation experiments to test their recruitment dynamics (see Methods 6.8).
The recruitment dynamics of the three protein was very different (Figure 3.44).
Both MacroD2 full-length and macrodomain recruited to DNA damage sites, while
the EGFP-MacroD2 C-terminus fragment did not. Moreover, between the two recruit-
ing constructs there was a striking difference in the residency time: the full-length
protein dissipates from the sites of DNA damage faster than the macrodomain only
construct.
To investigate if the MacroD2 nuclear export can affect the recruitment dynamics,
I compared the accumulation of EGFP-tagged wild type MacroD2 with that of the
export-incompetent (4SA - S276,345,415,426A) mutant at the UV microirradiated sites
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Figure 3.44: The macrodomain of MacroD2 is necessary for the recruitment of
MacroD2 to DNA lesions - Recruitment of tagged mEGFP-MacroD2 constructs (full
length, macrodomain or C-terminal domain) in HeLa cells stably expressing mCherry-
H2B. The focus of laser micro-irradiation is indicated with yellow arrowheads. For the
microirradiation, medium laser energy was used. Scale bar, 10 µm.
of DNA damage induced by UV-laser microirradiation. The two constructs were also
compared in the recruitment in the presence of the ATM inhibitor, KU55933, or DMSO
control (see Methods 6.8.5). The recruitment of the wild type MacroD2 construct
treated with DMSO peaked 2 minutes after laser irradiation (Figure 3.45).
Afterwards, the protein amount at the sites of DNA damage - and within the whole
nucleus - decreased, which led to the loss of MacroD2 proteins at the damage site within
5 minutes.
When the cells transfected with the wild-type construct are treated with the ATM
inhibitor, MacroD2 visibly resided at the DNA lesions up to 30 minutes after the laser
microirradiation, as also shown by the quantified levels of the fluorescent signal in the
recruitment area that persist around 1 for the whole experiment. Likewise, the cells
trasfected with the export-incompetent mutant show high recruitment and persistence
of the fluorescent signal at DNA lesions until the end of the experiment (30 minutes),
as shown by both the images and the quantification.
In summary, while the recruitment has no impact on the nuclear export dynamics of
MacroD2 (see Figure 3.25), these results show that MacroD2 nuclear export affects
its recruitment dynamics.
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Figure 3.45: MacroD2 nuclear export affects its recruitment to DNA lesions - a)
Recruitment of tagged mEGFP-MacroD2 constructs (wild-type or S276,345,415,426A mu-
tant) in HeLa cells stably expressing mCherry-H2B, treated either with DMSO or KU55933
10 µM. The focus of laser micro-irradiation is indicated with a yellow circle. For the mi-
croirradiation, medium laser energy was used. Scale bar, 10 µm. b) Quantification of
the recruitment performed on 15 cells from three independent experiments (see Methods
6.8.5). Error bars are 95 %CI.
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3.10 Discussion
This chapter shows that MacroD2 nuclear signal depletion upon DNA damage is ex-
plained by its regulated nuclear export (Figure 3.46). The phenomenon was also
confirmed for the endogenous protein, suggesting a physiological relevance of this form
of regulation.
EXPORT
Cytoplasm
Nucleus
S S
P P
MACROD2
ATM
Figure 3.46: The model of MacroD2 nuclear export - Upon DNA damage, most
likely via DSB formation, ATM gets activated. ATM modifies the unstructured C-terminus
of MacroD2 in two serines: S345 and S415. This event induces the regulated export of
MacroD2 from the nucleus.
Upon DNA damage, the activation of the ATM kinase induces the phosphoryla-
tion of two serines in the MacroD2 C-terminal unstructured region. These two serine
residues (S345 and S415) are both followed by a glutamine, which is a motif that is
directly recognized by ATM, ATR and DNA-PK kinases (220). Since the mutation of
the Q416 showed loss of phosphorylation, a PI3K-like kinase is likely performing the
modification. As long as ATM kinase is available and active, the inhibition of ATR or
DNA-PK does not affect MacroD2 nuclear export. However, in other conditions, such
as ATM knock-out, RNAi-mediated knock-down or activation of ATM-independent
DNA damage reponse pathways, ATM kinase can be replaced in inducing MacroD2
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nuclear export by other PI3K-like kinases, such as DNA-PK.
I then showed that for both exporting sites a short stretch of sequence (10 − 15
amino acids long) is able to target EGFP for nuclear export. These results exclude the
possibility that the modification might unmask a hidden nuclear exporting sequence,
but rather suggest that the phosphorylation induces the interaction of these stretches
with factors that enable the nuclear export. Within each of the two exporting se-
quences, a methionine is essential for the export: in fact, when mutated into alanine,
phenylalanine or isoleucine, the nuclear export of MacroD2 fragments cannot take place.
However, when comparing the two exporting sequences, the residue is not present at
the same position in relation to the phosphoserine.
I then considered the possibility that MacroD2 is exported from the nucleus via
a “piggy-back” mechanism by interacting with a NES-carrying protein. Preliminary
data from a co-immunoprecipitation coupled to peptide mass fingerprinting experiment
suggested a 14-3-3 protein as a viable candidate as an interaction partner. These
chaperone proteins can bind a phosphorylated motif in the cargo protein and cause
the protein to accumulate in the cytoplasm. Although I have performed three different
types of experiments to test their binding, I did not see any interaction. Indeed, a
scientist can only show that a certain phenomenon happens, therefore it is not possible
to show without any doubt that two proteins do not interact: I could spend years,
endlessly changing the experimental procedure and never be sure that I found the right
condition to see the interaction. However, considering the chaperone nature of the
14-3-3s and the amount of material I used for the experiments, it is likely that the
interaction between the partners could easily have occurred. Since it did not happen,
it is unlikely that the 14-3-3s are the exporting factors interacting with MacroD2.
Finally, I compared the recruitment dynamics at the DNA lesion of MacroD2 full-
length, macrodomain and C-terminus fragment. While the whole protein is both able
to recruit and export from the nucleus, the macrodomain-only construct remains at the
DNA lesion for a much longer time, due to its inability to export. This is confirmed
also by the MacroD2 full-length exporting-deficient mutant, as well as by the inhibition
of ATM activity by small inhibitor. Thus, the nuclear export of MacroD2 affects its
own residency at the DNA lesion and might impact the DNA damage response.
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3.10.1 MacroD2 C-terminus is an intrinsically disordered region
MacroD2 is a protein with a globular N-terminal macrodomain domain (56, 67). How-
ever, the C-terminal portion of the protein has not been previously annotated. My
experiments indicated that the C-terminus region is unstructured (see Figure 3.14).
The circular dichroism spectrum exhibits the features of a totally unstructured region,
with this portion likely to be unstructured also within the full-length protein context.
Surprisingly, although unstructured fragments are generally associated with insolubility
in physiological conditions, the purification of the C-terminal fragment was successful
(see Figure 3.13), likely due to the amino acidic composition of the sequence, rich in
residues that form hydrogen bonds. The composition is indeed in line with the require-
ments for the intrinsically disordered proteins and might allow the correct solubility of
the fragment (358).
Intrinsically disordered proteins are defined as having at least a region that, al-
though able to assume different conformation with various degrees of order, is still
biologically active (358). In eukaryotic proteomes, the presence of proteins with at
least a short disordered stretch seems quite important, with at least 1500 proteins
showing this feature. The presence of a disordered region makes the protein able to
bind interactors more dynamically, by lowering the free-energy barriers. For this reason,
the disordered proteins represent important hubs in signaling pathways, with p53 being
the most notorious example of disordered proteins (359). This might be connected to
the fact that intrinsically disordered proteins are on average substrate to twice as many
kinases as the structured ones (360).
The fact that the MacroD2 C-terminus is an intrinsically disordered region could
be very interesting for two reasons. First, an intrinsically disordered domain confers
augmented interacting capabilities, and could represent a fundamental source of both
positive and negative regulation of the enzymatic activity. Secondly, the disordered
proteins are underrepresented in the group of proteins involved in catalysis and biosyn-
thesis (361). Therefore, MacroD2 could represent an intriguing anomaly in the world
of the flexible proteins.
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3.10.2 MacroD2 ratio across the nuclear envelope changes upon DNA
damage
MacroD2 is a protein 448 amino acids long with a molecular weight of 50 kDa. Since
almost half of the protein is disordered, the shape of MacroD2 is more similar to a 25
kDa globular protein with a long, highly hydrated tail, than a globular protein of 50
kDa. This change in shape should be taken into account for what concerns the mode
of passage through the nuclear pore.
According to the laboratory of Dr. D Go¨rlich (Max Planck Institute for Biophysical
Chemistry, Go¨ttingen), a non-spherical probe, like a GFP-GFP fusion, although hav-
ing a mass of 54 kDa, crosses the nuclear pore faster than the globular maltose-binding
protein, which is 43 kDa in weight (mentioned as unpublished datum in (300)). This
observation is explained by the possibility that the protein could passively cross the
membrane with a preferred orientation. Even if such a concept could seem counterin-
tuitive in light of our knowledge about how proteins behave in gels and pores, it well
explains why the EGFP-tagged version of MacroD2 can be easily found in both nuclear
and cytoplasmic compartments. For this reason, when there is no DNA damage in the
cell, MacroD2 might passively diffuse across the nuclear envelope.
However, even if MacroD2 is constantly redistributing itself between the nucleus and
the cytoplasm in a passive manner, upon DNA damage the flux of MacroD2 towards
the cytoplasm is increased. The net flux out across the nuclear envelope comes from
the combination of two components: the influx and the eﬄux of the protein, the first
factor being smaller than the second (362). The net flux of MacroD2 into the cytoplasm
could be explained either by increased eﬄux and unchanged influx or by unchanged
eﬄux and decreased influx. In this second case, the influx contribution can reduce so
much to be null, due for example to the protein being anchored in the cytoplasm.
According to the Fick laws for diffusion applied to a permeable membrane (363),
the flux of of the molecule X across the membrane (Jx, n/m
2s) is the result of the
difference of concentration of the protein in the two compartments, multiplied for a
constant P , so that:
Jx = P ([X]2 − [X]1)
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where [X]1 is the concentration of the molecule X in the first compartment, while
[X]2 is the concentration in the second one. The constant P is the permeability in the
membrane of the molecule X. Thus, the increase in MacroD2 flux out might be caused
by a change in the gradient across the membrane, maybe because MacroD2 is released
by some anchoring in the nucleus (for example from chromatin) or is anchored once
it arrives in the cytoplasm. Another cause of eﬄux increase could be a change in the
permeability coefficient: for example, MacroD2 molecules might be positively regulated
to interact with the export machinery, resulting in a facilitated transport.
A fluorescence loss in photobleaching (FLIP) experiment, where cytoplasmic EGFP-
MacroD2 signal is constantly photo-bleached, allowed Dr. Timinszky to determine the
eﬄux upon control or DNA damage treatment (Dr. G. Timinszky, unpublished).
By transforming the single-exponential curve into a linear function by change in scale,
he was able to determine the P constant in the two conditions. In fact, upon DNA
damage, the constant was higher. Thus, MacroD2 eﬄux is not due to a change in
gradient across the envelope, arguing against the anchoring hypothesis. Instead, this
result supports the hypothesis that MacroD2 interacts in a regulated manner with a
component of the exporting machinery upon DNA damage.
In summary, since EGFP-tagged MacroD2 is distributed always between the nucleus
and the cytoplasm, it is possible that such a distribution is true also for the endogenous
protein. Instead of imagining MacroD2 fully nuclear or cytoplasmic, MacroD2 could
show a precise ratio between the nucleus and the cytoplasm, possibly connected with
the unknown function that it has (or has not) to perform at a certain physiological
state. However, upon DNA damage and activation of the response, the phosphorylation
shifts the equilibrium towards the cytoplasmic accumulation. Most likely it favors the
occurrence of more enzymatic reactions in the cytoplasm, while it discourages those in
the nucleus.
3.10.3 The mechanism behind MacroD2 passage through the nuclear
envelope
According to the data that I have collected, MacroD2 accumulates in the cytoplasm
upon DNA damage in a regulated manner. However, MacroD2 lacks targeting se-
quences, both for the import and for the export (see Section 3.3). As a mechanism
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underling this accumulation, the two short MacroD2 exporting sequences are phospho-
rylated, triggering the nuclear export.
One hypothesis is that this modification could induce the binding to an adaptor
protein carrying a NES: therefore, MacroD2 would export by a “piggy-back” mech-
anism. Considering the different export-deficient mutants (see Figures 3.37 and
3.38), the binding seems to require the presence of a methionine, possibly important
to form contacts with the binding pocket of the exporting adaptor. The position of
the methionine was different in the two exporting sequences. Although it is possible
to argue that the mechanism regulating the two exporting sequences might be differ-
ent, due perhaps to different partners, it is difficult to explain that the methionine is
essential in both sequences by mere coincidence. Thus, considering the phosphorylated
serines and the methionines as requirements for the binding of the exporting interactor,
I tested whether the 14-3-3 proteins can meet these requirements. Even though the
14-3-3 proteins are known phospho-binders, these candidates did not show any clear
binding upon in vitro and in vivo experiments (see Section 3.8).
Together with the direct interactor, I lack clues as to which exportin protein might
be involved in the nuclear transport. Exportin 1 is the most common transporter for
the nuclear export (303). The involvement of exportin 1 is generally tested by use of
leptomycin B, a compound that blocks exportin 1 interaction with cargoes by modifying
the binding pocket (364). When Dr. Timinszky used this compound, MacroD2 nuclear
export was only partially blocked, thus arguing against its exclusive involvement (Dr.
G. Timinszky, unpublished). More data should be collected to have an exhaustive
picture about the involvement of other exportins.
An alternate hypothesis is that the phosphorylation might confer increase MacroD2
affinity for the components of the NPC, allowing MacroD2 to cross the membrane more
often. In fact, a study showed that nucleoporins contains hydrophobic residues yet are
overall positively charged, which well matches with the overall negative charge of the
nuclear transport receptors (365). This would be also compatible with the overall
negative charge of the C-terminal portion of MacroD2.
As mentioned previously, the mutation of a methionine within both MacroD2 ex-
porting sequences completely inhibits the nuclear export. Since the methionine is a very
hydrophobic residue, it could be important for the interaction with the hydrophobic
residues of the nucleoporins. After all, the loss of binding due to methionine oxidation
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in few cases of protein-protein interaction studies shows how essential the methionine
can be in such a situation (366, 367, 368). Also, this hypothesis would better explain
why the methionine does not have the same position in the two MacroD2 exporting
sequences, since the successful interaction for the export would not require a fixed con-
sensus sequence, but only the position of hydrophobic residues in a negatively charged
patch. Therefore, it could be possible that the phosphorylation of the serines shifts the
balance towards an even more unfolded and negatively charged sequence, allowing the
methionine to directly bind the FG repeats of the nucleoporins present in the NPC. It
would probably be the first case of “regulated passive diffusion”.
Therefore, according to this hypothesis, the phosphorylation would allow faster
translocation through the nuclear pore, regardless of the direction of the transport.
To assure the directionality from the nucleus to the cytoplasm, the phosphorylation
step must be assumed to take place within the nucleus, while MacroD2 should be
preferentially dephosphorylated in the cytoplasm. In support to this hypothesis, the
mutation of the MacroD2 exporting serines into glutamate did not show any net nuclear
export of MacroD2 (Dr. G. Timinszky, unpublished).
However, mutation of the methionine into other strongly hydrophobic residues
(isoleucine and phenylalanine) impairs the nuclear export (see Figure 3.39). Al-
though all are hydrophobic residues, such a result argues for a specific role of the me-
thionine, that cannot be mediated just by its hydrophobic nature. This result indeed
argues against this alternative hypothesis.
Nonetheless, the methionine is an important element for the accomplishment of
MacroD2 nuclear export. Such an important role of the methionine could then explain
a little conundrum that involves MacroD2 and oxidative stress: at the beginning of
my PhD, I tested MacroD2 nuclear export upon H2O2 treatment, and although be-
ing preliminary experiments, both Dr. Timinszky and I found that MacroD2 nuclear
export was minimal (Figure 3.47). Although more experiments and more controls
are needed to transform this preliminary observation into a result, the results I have
successively collected might explain this anomalous behavior. In fact, now we know
that the methionine is necessary for the MacroD2 nuclear export and it is generally
oxidized upon oxidative stress (366).
Oxidative stress is a powerful inducer of ADP-ribosylation and ARTD1 activity.
However, a set of studies showed that, beside DBSs, oxidative stress can also activate
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Figure 3.47: Oxidative stress fails to trigger MacroD2 nuclear export - Quan-
tification of live-cell imaging of U2OS-mEGFP-MacroD2 C-terminus+mCherry-H2B cells
treated with H2O2, 600 µM. 50−100 cells were quantified analyzed from one experiment.
Nuclear/cytoplasmic ratio was calculated using CellProfiler 2.0 (331), and the mCherry
signal was used for the nuclei segmentation. Error bars, 95 %CI.
ATM kinase (275). Therefore, the activity of ATM should lead to MacroD2 nuclear
export, but this does not happen. A first explanation could be the absence of MacroD2
phosphorylation, because ATM might change its substrate subset according to the type
of DNA damage type and activation mode, although it is still not clear whether it is
true (263). On the other hand, the lack of export may not be due to a change in the
modification of the MacroD2 C-terminus region, but because of impaired interaction
with the export machinery. The oxidation of the methionine, as a consequence of the
oxidative stress, could be thus a mechanism to override ATM regulation and still keep
MacroD2 within the nucleus to perform its activity. Such a mechanism would be then
negatively regulated by the activity of the methionine sulfoxide reductase A, which can
restore the native state of the methionines (368).
3.10.4 ATM kinase regulates MacroD2 nuclear export
In my experiments, I showed that ATM is the primary kinase that induces MacroD2
nuclear export (see Section 3.4). But MacroD2 may not be the only export target of
ATM: ATM activation has been shown to induce changes in the localization of several
proteins. In some cases, a direct intervention of ATM has been shown to affect the
nuclear export of some factors (226, 324, 369). The NF-κB essential modulator, NEMO,
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requires three sequential post-translational modifications for its nuclear export and
ATM phosphorylation is the second; ATM is also shown to cross the nuclear envelope
together with NEMO (226). COP1, instead, is the E3 ubiquitin ligase that targets p53
for degradation (369). ATM-induced nuclear export of COP1 is important to stabilize
p53 and activate it.
ATM modifies a vast number of proteins (42, 44). Many of these targets have more
than one site modified and contain a stretch of 100 residues with three phosphorylated
SQ/TQ motifs, called a SQ/TQ cluster domain (SCD) (370). In a recent meta-study,
among the proteins with SCDs, unexpected cellular processes were enriched, such as
“gene regulation”, “vesicle-mediated traffic”, “cytoskeletal components” and “neural
development” (371). However, I realized that in this meta-study, MacroD2 did not
appear, even though it does meet the definition (S345+S415+S426). This is explained
by the fact that the first isoform annotated on Genbank, which the authors of the study
used for their study, contains only one of the three SQ motifs. The S415 and S426 are
in fact included in an exon that is likely spliced in alternative ways, considering all
the splice variants annotated on Uniprot (Figure 3.48). The exon sequence is very
conserved among vertebrates.
350 360 370 380 390 400 410 420 430 440 448
* *
Figure 3.48: Comparison of the sequence 350-448 in the different annotated
MacroD2 isoforms - The sequence between 350 and 448 amino acids of all the isoforms
of MacroD2 present on Uniprot database is shown. On the bottom line is the consensus
sequence for the alignment. The stars indicate the position of the two SQ motifs. Alignment
performed with MultAlin (372)
Such a hypothesis would represent an interesting mode of regulation of the protein.
Since the two SQ motifs S345 and S415 have an additive effect on the nuclear export
of MacroD2 (see Figure 3.33), the regulated exclusion of one of them could impact
on the dynamics of MacroD2 nuclear export. I can thus imagine the possibility of
differential splicing according to cell types or environmental stimuli.
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When testing the involvement of ATM, I showed the complete blockage of MacroD2
export upon inhibitor treatment in the case of UV-laser microirradiation with medium
energy and etoposide treatment, as well as in ATM-/- HT-144 cell line treated with
etoposide (see Section 3.4). The preliminary work with camptothecin also suggest
the exclusive involvement of ATM (see Figure 1.15). In the other conditions that I
tested, such as RNAi-mediated ATM knock-down or HT-144 cells treated with UV-laser
microirradiation, the inhibition of MacroD2 nuclear export was only partial.
The RNAi-mediated knock-down of ATM showed only a partial if not minimal effect
on the MacroD2 nuclear export dynamics (see Figures 3.18, 3.19 and 3.20). This
result could be explained first of all by the partial depletion of ATM kinase, whose
residual amount might still suffice to accomplish the kinase functions, although with
a decreased rate. On the other hand, the partial impact of the ATM depletion on
MacroD2 export rate could be due to the activation of other kinases that replace ATM
when its presence in cells is drastically decreased, as shown also in the case of the
ATM knock-out cell line, where DNA-PK clearly activates MacroD2 nuclear export
(see Figure 3.23). Nonetheless, the fact that the absence of ATM might allow other
kinases to modify non-physiological substrates could represent either a back-up pathway
or the occurrence of unwanted interactions with possible pathological consequences.
Lastly, the impact that the siRNA treatment has on the two MacroD2 constructs
(full-length or C-terminal region) is different. While the C-terminus export is reduced
by half its maximum level upon ATM depletion, the full-length protein export is affected
only marginally (see Figures 3.18, 3.19 and 3.20). It is possible that the presence
of the macrodomain favors the interaction between the kinase and the substrate, lim-
iting the effect of the ATM depletion in this specific case. Indeed, the presence of a
functioning macrodomain shows to have an impact, even if minimal, on the nuclear
export dynamics when comparing the MacroD2 full length wild-type protein with the
mutant deficient in ADP-ribose binding (G188E) (see Figure 3.26).
However, the EGFP-EGFP-MacroD2 C-terminus, which has a comparable size to
the EGFP-MacroD2 full-length construct but lacks the macrodomain, shows likewise
a minimal change in export rate upon ATM depletion, supporting the idea that the
presence of the macrodomain cannot answer for this reduced effect of the knock-down
(see Figures 3.28). Most likely, it is the size of the protein in the first place that
defines the speed of translocation across the nuclear envelope. For slower translocators,
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such as EGFP-MacroD2 full-length and EGFP-EGFP-MacroD2 C-terminus, crossing
the nuclear envelope, not the phosphorylation event, may be the limiting step of the
process.
3.10.5 ADP-ribosylation meets ATM signaling
ADP-ribosylation is a very dynamic post-translational modification, broadly involved
in the regulation of DNA damage repair. Similarly, ATM is activated by a number of
genotoxic stimuli and its main function is to oversee the correct repair and survival of
the cell, or to induce its programmed death, if damage is beyond repair (336). It is not
a surprise that these two signaling pathways show a number of connections. Several
factors involved in homologous recombination and ATM signaling, including ATM itself,
recruit to DNA breaks thanks to PAR-binding modules (8, 156). For example, both
Nbs1 and Mre11 initial recruitment depend on ARTD1 activation, and subsequently
the Mre11-Rad50-Nbs1 (MRN) complex induces increased levels of ATM activation
(155).
In general, the recruitment of the repair factors employs modules that recognize
poly-ADP-ribosylation, since a vast platform of PAR molecules offers a better sub-
strate for the formation of a three-dimensional network (6). The negative regulation
of this recruiting platform is thus bestowed mainly on PARG activity, as shown by the
change in recruitment dynamics in the presence and absence of RNAi-mediated PARG
depletion (56).
While the role of PARylation in DNA damage response is well established (see
Section 1.2.6), more evidence continues to be collected about the contribution of
MARylation in DNA repair regulation. ARTD3 is a MART that is involved in DNA
damage repair, namely in the choice between HR and NHEJ pathways (373, 374).
ARTD10, the prototypical MART, is instead involved in the regulation of trans-lesion
DNA synthesis, which occurs when the replication fork encounters a DSB site (175).
In my study, while inhibition of the recruitment of MacroD2 to DNA lesions did
not have any impact on its nuclear export dynamics, the nuclear export did affect the
recruitment dynamics (see Figure 3.45). The recruitment to the DNA damage site
is a feature of the macrodomain (see Figure 3.44), and it is quite clear that the
fluorescent signal persists for 30 minutes at the damage focus if not promptly removed
by the nuclear export (see Figures 3.44 and 3.45).
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Furthermore, inhibition of ATM or mutation of the SQ motifs result in the failure
of MacroD2 nuclear export and its persistence within the nucleus. Indeed, a longer
presence of MacroD2 in the nucleus means a longer presence at the DNA lesion (see
Figure 3.45), which might easily be a source of misregulation of the repair pathway.
Thus, the ATM-induced nuclear export of MacroD2 could represent another case sup-
porting the role played by MARylation in the regulation of the DNA repair process.
In particular, MacroD2 might negatively regulate the DNA damage response.
3.11 Future directions
3.11.1 Regarding the location of MacroD2 and the mechanism of ex-
port
While I could show that endogenous MacroD2 still exports from the nucleus upon
etoposide treatment using an immunofluorescence approach (see Figure 3.10), I could
not define its cellular localization in the two conditions. It would be important to
address this question in order to understand whether the whole pool of protein relocates
or just a fraction. As the antibody used in this study has limits, as previously discussed,
it is essential to develop new immunological tools. Currently, a PhD student in our
lab, G. Mo¨ller, is preparing and testing new monoclonal antibodies developed together
with the “Monoclonal Antibodies” facility of the Helmholtz Zentrum, Munich. Once
the tool has been developed, it is possible to test the real localization of the endogenous
MacroD2 upon control and DNA damage condition. I hypothesize that MacroD2 will
most likely be present in both the nuclear and cytoplasmic compartment in the control
condition, showing a common behavior with the EGFP-tagged MacroD2. However,
whether there will be residual MacroD2 left in the nucleus upon DNA damage or if
the nuclear export will be complete, remains unclear. If the endogenous MacroD2
is generally present in both nuclear and cytoplasmic compartments, except during the
DNA damage response, this result would argue for the continuous shuttling of MacroD2
across the nuclear envelope.
To rule out that MacroD2 signal is distributing across the nuclear envelope be-
cause of a form of active transport, it would be necessary to test the distribution of
MacroD2 upon RNAi-mediated knock-down of importins or exportins. When such an
experiment is performed in the absence of DNA damage, it can discriminate between
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passive diffusion and active transport: if the depletion of at least one importin or ex-
portin changes the nuclear-cytoplasmic ratio, it suggests that MacroD2 distribution is
mediated by a form of active transport dependent on importin/exportin cycles. If the
ratio is unchanged, it means that in the absence of DNA damage MacroD2 moves via
passive diffusion between the two compartments.
Since the depletion of the importins and exportins using RNA-interference might
be only partial, interfering with the formation of a more definite phenotype, the use of
knock-out cell lines for the different factors would probably be the ideal way to define
whether MacroD2 distribution is indeed due to a regulated active transport. Nonethe-
less, the results of such experiments might still show a confusing output, since the
nuclear transport receptors are essential factors for the healthy localization of cellular
components and their absence may generate pleiotropic effects.
The mechanism of transport of MacroD2 upon DNA damage could be different
from the mechanism with which MacroD2 crosses the nuclear envelope in the absence
of stress. If MacroD2 exports upon DNA damage by an active transport mechanism,
it will most likely be through a “piggy-back” mechanism, where phosphorylation of
MacroD2 enables it to bind another protein that contains a NES. MacroD2 protein, in
fact, lacks annotated or predicted NES sequences. Since it is a matter of finding the
right interactor, the best option is to adopt a pull-down approach coupled with mass
spectrometry. This is indeed what I did and I will describe it in the next chapter (see
Chapter 4).
The second hypothesis I formulated consists of a “regulated passive diffusion”. Ac-
cording to this hypothesis, MacroD2 would be intrinsically able to bind the nucleoporins
without any intermediary and to cross the nuclear envelope. Upon DNA damage, the
phosphorylation of its intrinsically disordered region would further favor the interaction
with the nuclear pore complex. The interaction may take place due to the presence
of negativly charged residues and few hydrophobic residues, positioned in strategic po-
sitions: among them, the two methionines (M350 and M413) would be important for
the interaction with the FG-rich motifs of the nucleoporins. This hypothesis could be
refuted by the fact that the MacroD2 fragment in which the methionine 413 has been
mutated to phenylalanine or isoleucine showed no nuclear export. Nonetheless, it could
still be interesting to perform the in vitro pull-down using the MacroD2 exporting
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fragments and nucleoporin FG-rich tail fragments in the presence and absence of DNA
damage, to test if the two proteins can directly interact.
Regardless from the mechanism of the translocation of MacroD2, my experiments
showed the importance of the methionine for the accomplishment of the nuclear export
of MacroD2. Since the oxidation of the methionine has been shown to affect protein-
protein interactions, I wonder if the oxidation of MacroD2 methionines upon H2O2
treatment could be a way to override ATM-induced nuclear export and to keep MacroD2
within the nucleus to perform its function. First of all, more experiments are needed to
define whether MacroD2 nuclear export is responsive or not to oxidative stress. Also, I
would test the PAR levels in the cells upon H2O2 treatment, in order to test the export
in a condition where the oxidative stress response is active.
Once the anomalous behavior of MacroD2 is confirmed, I would test if the MacroD2
exporting fragments would be phosphorylated also upon oxidative stress. In adopting
the same protocol that I used for the experiments with the radioactive γ-ATP (see
Figures 3.29 and 3.36), the Benzonase nuclease and the ATM inhibitor could be
used as positive and negative controls, respectively. If these fragments are still phos-
phorylated by ATM, I would then test if the methionine is oxidized. To this end, it
could be possible to analyze the same fragments with mass spectrometry, looking just
for the oxidation of these residues. Since the oxidation of the methionine residues fre-
quently occurs during sample preparation for mass spectrometry, it is vital to perform
the experiment also with the control sample, without DNA damage, and to evaluate the
difference in oxidation. Then, once it is determined if MacroD2 exports by interacting
with a specific adaptor protein or with the nucleoporins, if upon H2O2 the methionines
are indeed more oxidized, the efficiency of the interaction between MacroD2 exporting
fragments and the counterpart should be tested in the presence of either the unmodified
or oxidized methionine. Addition of reducing agents in the unmodified samples should
help increase the difference in binding between the two conditions.
3.11.2 Regarding ATM and the regulation of MacroD2 nuclear export
Upon DNA damage, ATM is activated and phosphorylates MacroD2. This event trig-
gers the nuclear export of the ADP-ribosylhydrolase. While the most studied activa-
tion mode of ATM is the induction by DSBs, the literature shows many other ways by
which ATM can be activated (see Section 1.3.3). It would be interesting to screen
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for MacroD2 nuclear export in many other conditions: hypotonic stress, cloroquine
treament for the ATMIN-dependent activation, or hypoxia.
Additionally, many targets of ATM have more than one modifiable site, such as
MacroD2, as it has been defined by this study. However, two of the three SQ motifs
in MacroD2 that could form a SQ/TQ cluster domain are present on a putative alter-
natively spliced exon (see Figure 3.48). The alternative splicing of this exon might
confer an additional layer of regulation to MacroD2 nuclear export and its dynamics,
since it could define how fast MacroD2 should be exported from the nucleus. However,
to test this hypothesis it is necessary to know the function of MacroD2, in order to
define the conditions to compare and to design the experiments accordingly.
For example, one of the probable functions of MacroD2 is the negative regulation of
PARylation at DNA lesions, which avoids hyper-activation of ARTDs and subsequent
parthanatos. Thus, MacroD2 splicing could be tested in a context prone to parthanatos.
Indeed, the generation of a MacroD2 isoform that exports more slowly from the nucleus
would generate a bigger barrier against this type of programmed death. There are in-
deed physiological situations where high intrinsic production of reactive oxygen species
is reported, such as activation from quiescence in hematopoietic stem cells or neural
development (375, 376). Since these tissues suffer from substantial oxidative stress, the
activation of PARylation is expected. Moreover, oxidative stress is also able to activate
ATM, although it would be important to confirm the activation of the kinase also in
these study models. Then, specific probes for the whole protein and for the specific
exon should be designed in order to perform real-time quantitative PCR, in order to
define both the expression levels of MacroD2 in these tissues and to answer for the
possible exon exclusion.
3.11.3 Regarding the role of MacroD2 upon DNA damage
The nuclear export of MacroD2 and its ATM-dependent regulation upon DNA dam-
age response suggests that MacroD2 might be involved in the DNA damage response.
Moreover, this behavior negatively correlates with the residency time of MacroD2 at
the DNA lesions (see Figures 3.44 and 3.45). For this reason, it would be interesting
to test if MacroD2 is able to affect the DNA repair.
To test this hypothesis, one could compare the wild-type and MacroD2 knock-out
cell lines previously used (see Figure 3.10) in specific DNA repair pathway assays. By
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transiently transfecting GFP-based reporter plasmids, it is possible to easily monitor
the efficiency of specific repair pathways, such as homologous recombination (HR), c-
NHEJ, single-strand annealing (SSA) and alt-EJ (377). Such reporter plasmids contain
sequence for a GFP molecule divided into two parts and, between them, the site for a
very rare restriction enzyme, Isce-I. The reporters are designed so that upon cutting
with the specific enzyme, the GFP gene is successfully generated if the specific DNA
repair pathways has been used. To this end, it is possible to monitor the amount of
cells that underwent the specific repair by cell sorting.
If there is any difference between the control and the knock-out cell lines in a
specific pathway, the experiment should be completed with the rescue of the phenotype.
Transfecting the MacroD2 knock-out cells with MacroD2 wild-type, MacroD2 ADP-
ribose binding-deficient or MacroD2 export-deficient constructs will help defining the
function of MacroD2 needed for the repair pathway. I would expect that when wild-type
or export-deficient mutant MacroD2 are transfected, the pathways that require ATM
activation, like HR, would show a decrease in their repair efficiency, since the export
is likely a mechanism to decrease the presence of MacroD2 at the DNA lesion and the
export is activated by ATM itself. The binding-deficient mutant, instead, should act
like the negative control. However, for those pathways where MacroD2 seems not to
be exported from the nucleus and its activity could be welcome at the DNA lesion,
like c-NHEJ (dependent on DNA-PK) or alt-EJ (dependent on ARTD1), the repair
efficiency might not be affected.
The only caveat in this plan is that the transfection of MacroD2 constructs rep-
resent a strong over-expression compared to the endogenous: MacroD2 is a protein
of lowly abundance, whose expression is regulated at transcriptional and possible
post-transcriptional level, given the anti-sense non-coding RNA overlapping its gene
(MacroD2 gene surroundings: http://www.ncbi.nlm.nih.gov/gene/140733). Since
MacroD2 has an enzymatic activity, I cannot exclude that its over-expression might shift
the system towards other deleterious effects. Therefore, the output of the experiment
should be carefully evaluated considering these two aspects. Ultimately, this problem
could be solved by restoring the endogenous promoter in the mCherry-construct, al-
though this might only ameliorate the transcriptional regulation but not the possible
post-transcriptional regulation.
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However, if MacroD2 shows an impact on some DNA repair pathways, the next
step would be to determine which factor can be ADP-ribosylated and are a tar-
get of MacroD2 enzymatic activity. The increasing number of publications on mass
spectrometry-associated pull-downs of ADP-ribosylated proteins could be a further
source of candidates to test. The recently generated online database of ADP-ribosylated
proteins could be the suitable starting point for this search (378). In vitro experiments
to test the functional activity or structural status of the substrate, with and without the
modification, will be necessary to characterize the role of MacroD2 regulatory activity
in the DNA repair pathway.
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4MacroD2 interactome in control
and genotoxic condition
4.1 Introduction
Chapter 3 detailed the nuclear export of MacroD2 upon DNA damage. While phospho-
rylation by ATM and PI3K-like kinases was shown to induce the export, the exporting
mechanism and the related machinery were not identified. If the most likely “piggy-
back” mechanism for the nuclear transport indeed occurrs, the name of an interactor
able to drive MacroD2 across the nuclear envelope is missing. Instead of painstackingly
searching for the whole genome looking for possible candidates on hypothesis-driven
experiments, the most time and cost-effective strategy at this point would consist of a
unbiased approach on proteomic scale.
Moreover, MacroD2’s real cellular function is still unidentified and the current list
of MacroD2 interactors is so short that it is not helpful in answering this question.
The few interactors of MacroD2 already published are mostly shown to bind in in
vitro experiments: ARTD1 (56, 67), ARTD10 (56, 67), GSK3β (67). Other studies
involving MacroD2 suggest functional roles in carcinogenesis and neural development,
but they are mainly based on genome-wide association studies and fail to show any
mechanistic insight behind the association (see Section 1.2.5). Thus, knowing the
complete interactome of MacroD2 and possibly the substrates of its enzymatic activity
could be an important step to unlock its cellular role.
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To this end, I chose to perform co-immunoprecipitation (co-IP) experiment com-
bined with peptide mass fingerprinting to define the MacroD2 interactome in the
presence and absence of DNA damage. I therefore employed two different treat-
ments: DMSO and etoposide. Also, I used three different baits: MacroD2 full-length,
macrodomain and C-terminal region fragments, in order to define differential enrich-
ments caused by the two halves of MacroD2. The experiment was performed in collab-
oration with Dr. A. Schmidt from the Zentrallabor fu¨r Proteinanalytik, LMU.
By defining the interactome of MacroD2 with and without genotoxic stress, I aimed
to address two points: first, I aimed to identify the proteins involved in MacroD2
regulated export. Morover, I aimed to define the areas of cellular life that are regulated
by MacroD2 enzymatic activity.
4.2 Setup of the co-immunopurification experiment
4.2.1 Generation of stable cell lines
For the co-IP, I decided to use stable cell lines expressing the constructs of interest, thus
avoiding possible inconsistencies due to transfection efficiency (see Methods 6.17.1).
To this end, we used HEK293 Flp-InTM T-RExTM by Thermofisher. There are several
advantages associated with using this cell line. Firstly, HEK293 achieve much higher
yield of cell-lysate relate to the amount of growing surface compared to our other cell-
lines of use, U2OS and HeLa. Also, these commercial cells allowed us to obtain stable
cell-lines with the gene integrated in the same spot, avoiding differences in expression
or genetic background. Lastly, the promoter is normally repressed by a TetR protein,
allowing inducible expression upon administration of doxycyclin.
I created four cell lines with the help of S. Grau and J. Preißer, each expressing one
of the following:
• EGFP-MacroD2 full-length
• EGFP-MacroD2 macrodomain (aa 1-243)
• EGFP-MacroD2 C-terminus (aa 237-448)
• EGFP
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The use of the EGFP tag allows for easy screening of colonies that successfully
integrated the genes by directly checking with a bench-top microscope, followed by
immunoblotting. EGFP is 25 kDa, which is quite large for being used as a tag. This
is the same approximate size of the macrodomain or the C-terminus alone. Therefore,
I cannot exclude that such a tag might impair possible binding events, even if EGFP
is considered to be an inert protein and less prone to interactions. While the size
of EGFP may prevent interactions due to steric impairment, EGFP-tagged MacroD2
constructs are still able to recruit to the DNA lesion and to export from the nucleus,
suggesting that the binding ability is not affected. Moreover, one of the generated cell
lines expresses only the EGFP alone, in order to exclude possible interactors accounted
to the tag and not to MacroD2.
The Flp-InTM T-RExTM system is very convenient. The HEK293 cells obtained
directly from Thermofisher present two integrated constructs, one with the FRT site,
selected through a zeocin-selection marker, and one with the TetR gene expressing
the repressor and presenting the blasticidin-selection marker. Growing cells in zeocin-
blasticidin selection medium ensures the maintenance of the FRT site in the cell popu-
lation. The genes of interest were cloned into a pcDNATM5/FRT/TO plasmid, which
has a hygromycin-selection marker. After seeding the cells, the hygromycin-selected
plasmid is transfected together with the pOG44 plasmid containing the Flp recombi-
nase: in the cells that acquire both plasmids, the transiently expressed Flp recombinase
leads to the integration of the gene of interest to the specific point in the genome where
the FRT site is located. Also, the integration makes the cells resistant to hygromycin
but sensitive to zeocin, thus allowing the proper selection of the cells that have correctly
performed the integration. After two weeks in selection media with hygromycin and
blasticidin, single-cells colonies showing expression of green fluorescence were isolated
before amplifying them for immunoblots and functional testing.
Before each experiment, the cells were tested for induction of protein expression
upon doxycyclin treatment (Figure 4.1). In order to confirm the identity of the cells
used for the pull-down experiments, induced cells were also tested for their functional
behavior upon laser microirradiation. Each induced protein preserved the same be-
haviors and even kinetics in HEK293 cells. EGFP-expressing cells did not show any
change in the protein localization upon UV-laser microirradiation. EGFP-MacroD2
full-length showed both export from the nucleus and recruitment to the DNA lesion
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with a peak at 2.5 minutes, similar to what previously shown for HeLa cells (see Fig-
ure 3.44). Likewise, EGFP-MacroD2 macrodomain recruits to the DNA lesion while
the EGFP-MacroD2 C-terminus exports from the nucleus.
0 min 2.5 min 5 min 10 min 15 min
EGFP
EGFP
MacroD2
full length
EGFP
MacroD2
macrodomain
EGFP
MacroD2
C-terminus
Figure 4.1: Induction and functional check of HEK293 stable cell lines -
The four HEK293 stable cell lines (EGFP; EGFP-MacroD2 full-length; EGFP-MacroD2
macrodomain; EGFP-MacroD2 C-terminus) are induced with doxycyclin 1mg/mL. After
one day of incubation, cells were checked for the proper induction of the constructs expres-
sion and tested upon UV laser microirradiation for recruitment and/or export. The focus
of laser micro-irradiation is indicated with yellow arrowhead. Scale bar, 10 µm.
4.2.2 Protocol for the co-immunopurification
The co-immunopurification was optimized and the final conditions were as follows.
RIPA buffer was used for the generation of whole-cell lysates, as described in Methods
6.17.2. The incubation of the cell lysate with the GFP-trapping resin was performed
for 2 hours at 4 ◦C and the wash of the resin was performed once with RIPA buffer and
twice with PBS. All buffers were supplemented with protease inhibitor and phosphatase
inhibitors cocktails, to prevent protein degradation and dephosphorylation, which may
induce loss of interactors. Moreover, the whole procedure was performed at 4 ◦C, so
that the enzymatic activity of MacroD2 was inhibited (56).
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In order to increase the chances of detecting also weak interactors, I chose to use
large amount of cell lysate. Therefore, the experiment required similarly large amounts
of GFP-trap beads to achieve a satisfactory pull-down. Therefore, I evaluated whether
to use the homemade agarose-coupled GFP-trap, prepared by G. Jankevicius and Dr.
A. Bowman, or a commercially available product (agarose-coupled GFP-trap by Chro-
motek). I tested the two for the efficiency of pull-down of purified EGFP (10 µg)
(Figure 4.2). Although the commercial resin showed its superiority in the efficiency
of pull-down, possibly due to a much higher density of coupled GFP-trap, I decided to
use the home-made GFP-trap for the first replicate, with an increased amount of beads
used in each sample.
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Figure 4.2: Comparison in pull-down efficiency between commercial and home-
made GFP-trap - 10 µg of purified EGFP was used to a compared purification using
10 µL of commercial GFP-trap (Chromotek) or 20 µL of in-house made GFP-trap (G.
Jankevicius and A. Bowman). Elution was performed with Laemmli buffer and purification
efficiency was tested by Coomassie staining (loaded 2.5 % of the material in each lane).
For the purification steps, see Methods 6.17.2.
Finally, to test the efficiency of the purification, I performed the co-IP with 6 mg of
cell-lysate from cells expressing EGFP-MacroD2 full-length and 50 µL of home-made
GFP-trap. This setup allowed an enrichment of bait by 1.6-fold compared to the input
(Figure 4.3). The Coomassie staining of the same samples, showed the sequential
reduction of the unspecific bands within the series of washes. In the elution with
Laemmli buffer, the patterns of residual bands is very different from the one present in
the washes, suggesting the purification of specific interactors of MacroD2.
The elution step of my preliminary experiments was performed with Laemmli buffer
in order to collect all the material attached to the beads and to have a better estimation
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Figure 4.3: Pull-down efficiency test with EGFP-MacroD2 full-length - HEK293
EGFP-MacroD2 full-length cells were plated and induced with doxycyclin 1mg/mL. After
one day, cells were collected and cell lysate was prepared. 6 mg of cell lysate was then
purified with 50 µL of in-house made GFP-trap. Elution was performed with Laemmli
buffer and purification efficiency was tested by western-blot with anti-GFP (loaded 2.5
% of the material in each lane) and Coomassie staining. For the purification steps, see
Methods 6.17.2
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of the immuno-purification efficiency. When the co-immunopurification experiments
were coupled to mass spectrometry detection, the initial steps in the preparation for
the mass spectrometry run were performed directly on beads by Dr. A. Schmidt. For
the detailed protocol, see Methods 6.17.2.
4.3 Co-immunopurification experiment
Four biological replicates of co-immunipurification experiment were performed. For
each replicate, the doxycyclin-mediated induction of the protein expression in the four
cell line was tested using live-cell imaging coupled with UV-laser microirradiation, as
shown in Figure 4.1. Once the correct induction was confirmed, the four cell lines were
seeded in non-selective media. The three MacroD2 cell lines were plated in two distinct
dishes, while the EGFP was plated once. Doxycyclin (1 mg/mL) was added to the
plates 4 hours after plating. After 24 hours from induction, I treated the MacroD2
cell lines with DMSO or etoposide 10 µM for one hour in order to obtain the following
conditions:
1. EGFP
2. EGFP-MacroD2 full-length DMSO
3. EGFP-MacroD2 full-length etoposide
4. EGFP-MacroD2 macrodomain DMSO
5. EGFP-MacroD2 macrodomain etoposide
6. EGFP-MacroD2 C-terminus DMSO
7. EGFP-MacroD2 C-terminus etoposide
The co-IP was complated as described in Methods 6.17.2. The first biological repli-
cated was performed with home-made GFP-trap beads, while the commercially avail-
able resin was used for the remaining three replicates, due to the certified reproducibility
in their performance compared to the home-made beads. The preparatory steps for the
mass-spectrometry run and the runs themselves were performed by Dr. Schmidt (see
Methods 6.17.2 and 6.17.3).
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4.4 Analysis and quality controls
The collected the data from the mass spectrometer were treated in order to transform
a series of spectra into a usable output (see Methods 6.17.4). The final output of a
co-IP-peptide mass fingerprinting experiment should be a list of protein names, which
represent the group of most probable interactors of the bait protein in a particular
condition. From these protein lists it is then possible to perform statistical analysis to
determine interesting patterns in the cellular functions and pathways.
For the peptide mass fingerprinting, the identification step is essential, yet delicate.
Each peptide that flew in the machine has a specific mass/charge ratio (m/z). The
MaxQuant software that we used is able to identify the protein of origin for each peptide
by using the mass/charge ratio. The algorithm compares the mass/charge ratio of one
experimentally-measured peptide with the values of all the peptides generated in silico
from the human proteome. Therefore, the software can assign each detected peptide to
a protein peptide. Such a process is bound to generate some error, which can be reduced
by the optimized definition of the parameters available in the software. Dr. Schmidt
chose the best parameters according to his personal experience and the knowledge of
the instrument. The identification process is also performed at the same time for all
the samples, so that the parameters used are exactly the same.
The identification step generates a table in which associates each peptide with its
protein of origin and its specific signal intensity. The MaxQuant-embedded algorithm
calculates the intensity of each protein in a sample by considering the peak intensity of
all the found peptides related to the protein in the mass spectrometry spectra (379).
To have a first view of the quality of the different replicates, Dr. Schmidt compared
the average of the signal intensities and the missing values in the four replicates. In
fact, as error is normally generated upon mass spectrometry detection and/or peptide
identification, from the total subset of protein detected in the whole experiment, not all
the proteins are found in all the samples. These proteins that have not been detected
are defined as missing values and are generated either by the loss of the signal at
the detection or for a possible incorrect identification. For example, the protein A is
present in replicate 1 and 3 but not in replicate 2 of the same condition. Therefore, in
the replicate 2 a missing value is present for that protein. This initial analysis allowed
Dr. Schmidt to realize that the first biological replicate was behaving very differently
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compared to the others in terms of signal intensities and number of peptides associated
per each protein (which are also known as spectral counts) (Figure 4.4). Also, all the
samples of replicate 1 presented many more missing values than the other replicates.
Since this replicate was the only one performed with the home-made beads, we decided
to exclude it from the analysis.
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Figure 4.4: Comparison in intensities and missing values between the four
biological replicates - a) Intensities of the EGFP and MacroD2 protein signals showed
as LFQ (label-free quantitation) value, which are raw intensities normalized on multiple
levels to reflect the relative amounts of the proteins (380); b) Missing values (red) of each
protein (row) in every condition (column).
We thus proceeded in the analysis of the last three biological replicates. The signal
intensity of all proteins needed to be corrected, as the overall amount of detected protein
might differ between one sample and the other due to technical error generated upon
the co-IP step or the mass spectrometry run.
First of all, we chose to work with the intensity-based absolute quantification
(iBAQ) values: for each protein in a specific sample, the iBAQ signal is the sum of
all the peptides intensities divided by the number of the peptides of the protein that
could be observed. Therefore, the iBAQ represents a weighted intensity, which intro-
duce a measure of reliability of this signal in the quantification. Then, to even out
the technical error due to sample processing, the iBAQ value of every protein in each
sample was normalized according to a coefficient defined per each sample. To obtain
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the sample-specific coefficient, Dr. Schmidt identified the proteins that are present in
most samples. He then calculated the median iBAQ of these proteins for each sample
and each median was normalized against the highest median value among all samples.
Due to the very nature of the mass spectrometry technique, where random pep-
tides are sampled, the normalized iBAQ signals showed a number of missing values as
expected. Missing values are always generated, since peptides might be not present,
not detected or not correctly identified. In order to avoid considering proteins with
too many missing values in the statistical tests, which might generate additional noise,
all the proteins that were not present in all three biological replicates for at least one
condition were filtered out. For example, protein X is present in the three replicates of
EGFP condition but nowhere else, thus protein X is retained in the analysis; protein Y
is present only in two replicates of the EGFP condition, but nowhere else, thus protein
Y is excluded from further analyses. This step was important in removing from the
analysis noise generated from stochastic sampling of the mass spectrometry run.
Once the proteins were filtered, in order to determine the similarities of the different
conditions across the biological replicates, I performed a hierarchical clustering test as
an additional quality control. The clustering algorithm that I adopted performed a
single-linkage approach: with this algorithm, the clustering proceeds by reiteratively
combining two groups that contains the closest pair of elements, still not close enough
to be part of the same group. This method is also called the nearest neighbor clustering.
In the ideal case, all the samples of one condition in different replicates should cluster
together. However, the test on my data showed differences between different biological
replicates (Figure 4.5).
Most strikingly, all the samples from the fourth biological replicate clustered to-
gether. This feature is shared also using other clustering algorithm outputs (data not
shown). Such a behavior indicates that the fourth biological replicate is in same ways
different from the other two, since each condition of this replicate is more similar to
different conditions of the same replicate than to the same condition in the other repli-
cates. On the other hand, the other two biological replicates mostly cluster according
to the condition. The only exception is the C-terminus-associated samples, which are
located quite far away from each other.
In order to totally eliminate missing values from further analyses, after having
filtered the proteins I imputed the iBAQ signal in place of the missing values by mean
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Figure 4.5: Hierarchical clustering of the different co-IP samples - Hierarchical
clustering performed with single-linkage algorithm on Perseus 1.5.3.2 software.
of a normal distribution. The imputation step, thus, substitutes the null values with
values that are similar to background signal so that they do not generate an important
bias in the analysis, but yet can be used to perform the enrichment tests.
4.5 Enrichments and generation of protein lists
In the previous steps, the iBAQ signals have been corrected and filtered. At this point
they are ready to be used for the generation of the protein lists for my six conditions
of interest:
1. “MacroD2 full-length DMSO”
2. “MacroD2 full-length etoposide”
3. “MacroD2 macrodomain DMSO”
4. “MacroD2 macrodomain etoposide”
5. “MacroD2 C-terminus DMSO”
6. “MacroD2 C-terminus etoposide”
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The following steps were performed in order to determine the list of significantly
enriched proteins for each condition. To this end, I first compared the protein intensities
of all the samples, two by two. In each comparison, I performed Student’s t-tests in
order to identify the proteins that are specifically enriched in one of two samples.
Each t-test was performed by using 0.1 as value for the S0 coefficient and 0.08 for
the false discovery rate (FDR) on the Perseus software. The FDR value of 0.08 is
more lenient than the default 0.05, which was too stringent for some enrichments. For
example, by comparing MacroD2 full-length DMSO and MacroD2 full-length etoposide
protein intensities, I could define the 10 − 20 protein enriched in the first sample and
the similar number of proteins enriched in the second (Figure 4.6). The comparison
between two samples with a T-test and the generation of specific protein lists is referred
as enrichment.
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Figure 4.6: An example of enrichment between two different samples - Graphic
representation of the Student’s t-test between two samples, in this example MacroD2 full-
length DMSO versus MacroD2 full-length etoposide. The t-test was performed with 0.1 as
S0, which defines the importance of the pvalue over the difference in enrichment, and 0.08
as FDR. In red, the genes that are significantly enriched in the two samples. On the right
part of the graph, the genes are enriched in the MacroD2 full-length DMSO sample, on
the left side the genes are more present in the MacroD2 full-length etoposide sample. In
gray are all the genes that are not significantly enriched in either of the two samples. The
graph was generated with Perseus 1.5.3.2 software.
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Per each condition that I wanted to define, such as “MacroD2 full-length DMSO” or
“MacroD2 C-terminus etoposide”, I perfomed an enrichment of the omonimous sample
against each of those samples that could be considered negative controls: the negative
control sample should present proteins that are not enriched in the main sample, and
viceversa. Therefore, for each condition, there are as many protein enrichments as
negative controls (Table 4.1). For example, for the “MacroD2 full-length DMSO”
condition, I performed one enrichment between the MacroD2 full-length DMSO and
the EGFP sample and another enrichment between the the MacroD2 full-length DMSO
and the MacroD2 full-length etoposide sample. Or, in case of the “MacroD2 C-terminus
etoposide” condition, the negative controls were EGFP, MacroD2 C-terminus DMSO,
MacroD2 macrodomain DMSO and MacroD2 macrodomain etoposide, and thus for this
condition four protein enrichments were generated.
Condition Negative control
MacroD2 full-length DMSO EGFP
MacroD2 full-length etoposide
MacroD2 full-length etoposide EGFP
MacroD2 full-length DMSO
MacroD2 macrodomain DMSO EGFP
MacroD2 macrodomain etoposide
MacroD2 C-terminus DMSO
MacroD2 C-terminus etoposide
MacroD2 macrodomain etoposide EGFP
MacroD2 macrodomain DMSO
MacroD2 C-terminus DMSO
MacroD2 C-terminus etoposide
MacroD2 C-terminus DMSO EGFP
MacroD2 C-terminus etoposide
MacroD2 macrodomain DMSO
MacroD2 macrodomain etoposide
MacroD2 C-terminus etoposide EGFP
MacroD2 C-terminus DMSO
MacroD2 macrodomain DMSO
MacroD2 macrodomain etoposide
Table 4.1: List of enrichments - Overview of the different enrichments, divided accord-
ing to the condition and showing the relative negative controls.
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Once created these protein enrichments, I compared all the enrichments of the same
condition and defined which proteins were present in at least two out of four enrich-
ments (or in case of the full-length conditions, in both enrichments). These recurring
proteins are considered common proteins and represent the most reliable interactors of
MacroD2 in that specific condition. However, in a few cases the list of common proteins
was extremely short, which hampered the following analyses. In addition, sometimes
different components of a same complex were present in two different enrichments of
the same condition. Such a phenomenon also hinders the finding of relevant biological
terms. For this reason, I also looked in the combined list of the enriched proteins (all
proteins).
The protein lists generated from the above analysis, both common proteins and all
proteins, are shown in Appendix A. For each list, I checked the annotations of every
entry on Uniprot. This manual revision was important to define the presence of specific
proteins that could be easily connected to MacroD2 regulation by nuclear transport,
such as kinases, exportins or chaperones. However, neither kinases or exportins were
present in any of the protein lists.
Instead, in order to have a clearer understanding about the overall protein network
in each condition and to formulate hypotheses on the cellular function of MacroD2, I
analyzed the lists by looking for biological patterns. To this end, each list was analyzed
by means of the online database STRING and its associated software. This software
scrutinizes the protein lists and classifies the proteins according to the biological tags
that each protein has. Consequently, STRING finds the enriched biological terms for
functional processes, pathways or cellular localizations within a group of proteins. Each
biological term in the list is associated to a FDR value, which represents the likelihood
that this enriched term is false: the lower the FDR is, the more likely this term is
genuinely enriched in the list of terms. In my analysis only biological terms with FDR
lower than 0.05 are taken into account. The enriched biological terms lists are shown
in Appendix B.
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4.6 General overview of MacroD2 interactors and enriched
biological terms
4.6.1 MacroD2 full-length treated with DMSO
The complete list of interactors of “MacroD2 full-length DMSO” is shown in Appendix
A (Table A.1). For the MacroD2 full-length conditions, I considered as negative
controls the EGFP and the MacroD2 full-length protein with the opposite compound
treatment, in this case MacroD2 full-length etoposide sample.
When checking the common proteins to the two enrichments, only one protein
remained. This was EIF3K, an initiation factor for protein translation (Table A.2).
This means that detection of enriched biological terms was impossible.
Therefore, to have a glimpse of what might be the overall network of the MacroD2
protein in the DMSO condition, I analyzed all the proteins present in the three lists.
When analyzing all the proteins combined, the enriched biological terms showed clearly
the strong contribution of RNA-binding proteins within the MacroD2 interactome (see
Table B.1). These biological terms reflect the presence of both components of the
ribosomal complex and proteins involved in RNA splicing.
Indeed, recently the role of ADP-ribosylation in the regulation of RNA metabolism
has become clearer. Proteomic studies of PAR-binding proteins or PARylated proteins
showed enrichments in RNA biology-related classification terms (10, 118, 118, 206).
In addition, several studies showed effects of ARTDs in all the key steps of RNA
metabolism, from transcription to translation, but also in stress-dependent alternative
splicing or RNA-interference regulation (10). Thus, the presence of factors necessary
for RNA splicing among the MacroD2 interactors may indicate a direct involvement of
MacroD2 in this new branch of ADP-ribosylation-mediated regulation.
4.6.2 MacroD2 full-length treated with etoposide
The complete list of interactors of “MacroD2 full-length etoposide” is shown in Ap-
pendix A (Table A.3). The enrichments were performed against EGFP and EGFP-
MacroD2 full-length DMSO. The number of proteins that are common to the two en-
richments (common proteins) was also small (Table A.4). These proteins fail to show
any significant enrichment in the biological terms.
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When I combined all the proteins belonging to this condition, the only significant
biological terms all pertained to the binding of RNA molecules (see Table B.2). This
result is in line with the enriched biological terms of the MacroD2 full-length DMSO
condition, however it does not address the possible role of MacroD2 upon genotoxic
stress.
4.6.3 MacroD2 macrodomain treated with DMSO
The complete list of interactors of “MacroD2 macrodomain DMSO” is shown in Ap-
pendix A (Table A.5). As negative controls, I considered EGFP, MacroD2 macrodomain
etoposide, MacroD2 C-terminus DMSO and MacroD2 C-terminus etoposide samples.
The “MacroD2 macrodomain DMSO” was the condition with the highest number
of interactors (Table A.6). Consequently, the number of filtered common proteins
was 54. The annotated interactions show an intricate network (Figure 4.7). Some
members are involved in RNA metabolism and translation. Other interactions, instead,
involve proteins that have a role in transport across the different compartments, such
as 14-3-3ζ (YWAHZ) and Ran-GTPase (RAN).
The presence of the 14-3-3ζ in this enrichment was unexpected. I tested the 14-3-3s
as possible candidates for MacroD2-regulated nuclear export, since the 14-3-3 protein
appeared in the first biological replicate of the co-immunopurification experiment (see
Section 3.8). My experiments, however, did not show any interaction. Although I
have never tested the binding of the 14-3-3ζ with full-length MacroD2, the fact that the
protein is enriched with the macrodomain fragment indicates that, even when it binds,
the 14-3-3ζ is not likely to be involved in the regulated nuclear export of MacroD2.
Likewise, the C-terminus-dependent MacroD2 nuclear export would suggest that
a possible interaction with the Ran-GTPase should occur either with the full-length
protein or the C-terminus fragment. Instead, the Ran-GTPase is immunoprecipi-
tated by the MacroD2 macrodomain. However, this result is consistent with the fact
that Ran-GTPase is MARylated by bacterial toxins as well as by ARTD10 in vitro
(381). Therefore, this interaction represents another indirect validation for the co-
immunopurification approach.
When checking the enriched biological terms for the list of common interactors
in the MacroD2 macrodomain DMSO condition (see Table B.3), the presence of
many membrane-associated terms, among them the endoplasmic reticulum (ER), can
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Figure 4.7: Annotated interactions within the common proteins present in the
four EGFP-MacroD2 macrodomain DMSO enrichments - Annotated interactions
shown with the help of STRING software. Edges of different colors according to the type
of interaction and the experimental proof: cyan) known interaction from curated database;
fucsia) known interaction experimentally determined; green) gene neighborhood; red) gene
fusions; blue) gene co-occurrence; yellow) text-mining; black) co-expression; light blue)
protein homology.
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be connected to the role of MARylation in the regulation of the Unfolded Protein
Response by ARTD15/PARP16 (see Section 1.2.7).
Moreover, the “intracellular steroid hormone receptor signaling pathway” term sug-
gests that MacroD2 might be involved in the signaling pathway responsive to steroid
hormones. Indeed, MacroD2 itself was shown to interact with the estrogen-receptor
α (ERα) in a functional way (98). Even before MacroD2, MacroD1 was connected
to both the ERα and the androgen receptor as well (77, 78), while ARTD1 regulates
the transcription of estrogene-responsive genes (382). Thus, it is possible to imagine a
general role of ADP-riboylation in the steroid hormones-dependent signaling pathway.
I then performed the biological term analysis on the list of all proteins of the four
enrichments (Table B.4). When all the proteins are analyzed, the enriched biological
term “intracellular steroid hormone receptor signaling pathway” disappeared, having
lost its significance. However, other biological terms were introduced. For example,
some additional biological terms refer to carbon metabolism and energy production, like
“glycolysis/gluconeogenesis”, “citrate cycle”, “pyruvate metabolism” and even some
amino acid biosynthetic pathways.
ADP-ribosylation in general, and MacroD2 in particular, might easily have a reg-
ulatory role on the cellular energy production and metabolism in general. ADP-
ribosylation requires NAD+ as donor of the ADP-ribose and consumption of this
reagent can indirectly affect the activation level of glycolysis versus the citrate cy-
cle. On the other hand, considering a potential role of sirtuins and MacroD1 in the
regulation of the respiratory chain activity, it is possible that the regulation of the
cytoplasmic enzymes falls upon MacroD2. However, as long as we do not have a com-
plete list of MARylated proteins in the cell, it is difficult to formulate more precise
hypotheses.
4.6.4 MacroD2 macrodomain treated with etoposide
The complete list of interactors of “MacroD2 macrodomain etoposide” is shown in
Appendix A (Table A.7). The “MacroD2 macrodomain etoposide” condition includes
much fewer proteins compared to the DMSO condition. Therefore, the common proteins
are only 16 (Table A.8). ARTD1/PARP1 is present among these selected proteins. As
ARTD1 is one of the few proteins whose interaction with MacroD2 has been published
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(56, 67), its presence in the “MacroD2 macrodomain etoposide” condition provides
validity of the whole experimental setup.
Moreover, the Ras GTPase-activating protein-binding protein 2 (G3BP2) is a factor
with a RNA-binding domain, thus generally involved in the mRNA nuclear export, and
also appears in the list. Interestingly, G3BP2, together with G3BP1, has been shown
to be able to induce ADP-ribosylation-based cytoplasmic stress granules (212, 383).
When I then analyzed this list of 16 proteins on STRING, the only enriched biological
terms are related to RNA biology (Table B.5). The short list of terms is probably
determined by the short list of common interactors.
The complete list of proteins generated a longer list of enriched biological terms (see
Table B.6). A group of biological terms indicates an enrichment in factors involved
in the focal adhesion foci and adherens junctions formation, which might indicate a
possible function of MacroD2 in the regulation of fibril based structures.
Similarly, the neural progenitors-specific chromatin remodeling complex (npBAF
complex) and the neuron-specific chromatin remodeling complex (nBAF complex) are
other interesting entries of this list of biological terms. Although the presence of such
terms is quite surprising if we consider that HEK293 cells derive from kidney tissues,
these cells are indeed cancer cell lines with unstable genomes. Thus, the malignant
nature of these cells might have allowed the unexpected expression of neuron-specific
genes.
4.6.5 MacroD2 C-terminus treated with DMSO
The list of interactors for “MacroD2 C-terminus DMSO” is shown in Appendix A
(Table A.9). There are only 10 proteins, when the four enrichments of “MacroD2
C-terminus DMSO” condition are combined (Table A.10). Four out of these ten
proteins are involved in mRNA processing. In fact, the biological terms associated to
this list are strictly related to RNA biology (Table B.7).
The biological terms derived from the all the protein from the four enrichments
combined involve mainly nuclear and nucleolar compartments (see Table B.8). At
the top of the list there is an enrichment of “RNA binding” terms. Other strongly
represented terms in this condition are the “mRNA processing” and “spliceosome”
keywords. While in other conditions the presence of ribosomal proteins might have
been the major component of the RNA-binding interactors, most MacroD2 C-terminus
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interactors that bind RNA molecules may be mainly involved in RNA processing, such
as mRNA splicing and export from the nucleus, with a preferential localization within
the nuclear envelope.
4.6.6 MacroD2 C-terminus treated with etoposide
Last but not least, I performed the analysis for the “MacroD2 C-terminus etoposide”
condition. The complete list of proteins enriched in MacroD2 C-terminus etoposide
sample over the four negative controls is shown in Appendix A (Table A.11). There
are 29 proteins in common to the four enrichment lists for this condition (Table A.12
and Figure 4.8).
Among the annotated interactions, 3 proteins are connected to the DNA damage
response: p53 (TP53), RPA2 and SSBP1. The p53 protein is an important factor of
the DDR, since upon activation mediated by ATM and/or ATR, it blocks the progres-
sion of the cell cycle and decides whether the cell survives and undergoes repair or
undergoes programmed death (258). In addition, RPA2 is one of the factors involved
in the recruitment and activation of the heterodimer ATR-ATRIP (278). SSBP1 is a
mitochondrial protein, involved in the mitochondrial DNA replication and repair, al-
though localization of MacroD2 within the mitochondria is mostly excluded (384). The
enriched biological terms for the common list prevalently regard extracellular vesicles,
as cellular waste or functional secretion, and RNA binding (see Table B.9).
The analysis of the whole list of proteins, instead, greatly increases the range of
biological terms, many related to functional processes (see Table B.10). Compared
to the C-terminus DMSO condition, the localization of the factors is much more het-
erogeneous, with proteins located in compartments other than the nucleus, including
the cytosol, the mitochondria, the ER and other vesicle-based structures. The range of
functional processes is also widened, now including “mismatch repair”, “DNA replica-
tion”, “contractile fiber”, “protein regulation of protein folding”, “regulation of helicase
activity” and “carbon metabolism”.
It seems, thus, that the etoposide treatment has radically changed the types of inter-
actions that the same fragment is able to have. The nature of the change might indeed
be linked to the number of post-translational modifications that the C-terminus un-
dergoes upon genotoxic stress. This modification might augment the possible contacts
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that the C-terminus fragment can perform and possibly expand the cellular localizations
that the fragment can adopt.
4.7 Discussion
This co-immunopurification (co-IP) approach was the first attempt to uncover the
interactome of the MacroD2 full-length protein in normal physiological conditions and
under genotoxic stress. The goal of the experiment was to generate candidates that
drive MacroD2 into the cytoplasm with the regulated nuclear export. Moreover, by
uncovering the MacroD2 interactome it was possible to suggest testable hypotheses
about the functional role of MacroD2 in the cell in order to fill the gap between the
molecular activity of MacroD2 and the genome-wide association studies that concern
it (see Section 1.2.5). To achieve this, we designed the experiment with different
constructs in different conditions. In the lists of proteins false positive candidate are
further filtered out by cross-comparing the different samples.
On the other hand, the hierarchical clustering revealed problems in the quality of
the data, namely that the fourth replicate did not cluster with the others (see Figure
4.5). This is generally solved by performing another independent co-IP experiment in
the same condition and repeating the set of analyses in order to verify that the enriched
proteins and enriched biological terms do not change. However, since my host lab is
setting up other unbiased approaches to define MacroD2’s functional role, including
a BioID-based pull-down coupled with peptide mass fingerprinting (385), we chose to
use my dataset as a complementary approach to define the recurrent interactors and
functional target of MacroD2, instead of investing more time and resources on a new
replicate.
The experiment that I have presented has some limitations. First of all, MacroD2
might engage a vast array of transient interactions. The classical co-IP is not suitable
to detect interactions with labile affinity and this is possibly why I could not find any
kinases in my enrichments. To this end, the BioID approach, provided it is properly
controlled against false positives, may identify these transient interactions. Secondly,
the experiment could have been further improved by also using a cell line express-
ing MacroD2 macrodomain ADP-ribose binding-deficient (G188E) mutant. This could
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have helped define the pool of interactors that are actual MacroD2 substrates by dis-
criminating the proteins able to interact with the overall structure of the macrodomain,
from those that bind MacroD2 by means of ADP-ribosylation. However, this is a minor
limitation, since this can be easily tested during validations of the candidates.
The presence of ARTD1/PARP1 as an interactor in the “MacroD2 macrodomain
etoposide” condition acts as validation of the experimental setup. MacroD2 macrodomain
has been shown to interact with ARTD1 in vitro and in vivo, most likely mediated by
ADP-ribosylation (56, 67). Published literature also shows that etoposide treatment
can induce the activation of ARTD1 (386). Even if etoposide is not as good an inducer of
ADP-ribosylation as oxidative stress is, the treatment can still activate ARTD1 slightly
more than in the untreated state, allowing an enrichment of ARTD1 upon etoposide
treatment.
4.7.1 MacroD2 full-length protein has less interactors than its two
fragments
When comparing the number of interactors in the different conditions, the fragment
showing the largest number of interactors upon DMSO treatment was the macrodomain;
conversely, upon etoposide, the best binder was the C-terminus fragment (Figure 4.9).
MacroD2 full-length showed less interactors than the two shorter fragments in both
treatments. Considering how the experiment was designed, the pool of proteins binding
MacroD2 full-length should include both the interactors of the macrodomain and those
of the C-terminus. Therefore, I would have expected more binders for the MacroD2
full-length, both as an absolute number and in comparison to the two fragments. I
also performed all the enrichments of the six conditions against EGFP with much more
lenient parameters (0.05 as S0 and 0.5 as FDR), in order to be more inclusive (data
not shown). The result was a dramatic increase of protein shared by the macrodomain
and the C-terminus fragment. However, this probably represents increased noise in the
analysis.
The reason why MacroD2 full-length is a poor binder could be explained either
by technical error or by a proper physiological feature of the protein. In the first
case, the poor quality of the hierarchical clustering shows a problem in reproducibility
across the different biological replicates, which surely impacts on the statistical tests
that I perform for the enrichment. It might be that the full-length samples suffer
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FL DMSO common genes MD DMSO common genes
CT DMSO common genes
FL ETO common genes MD ETO common genes
CT ETO common genes
Figure 4.9: Overview of the most reliable binders for the six different conditions
- Venn diagram of the most reliable binders for the six conditions. The lists are generated
by the overlap of different enrichment of the same condition against two or four negative
controls, defined thus as common proteins. FL is full-length; MD is macrodomain; CT is
C-terminus. Generated with Venny 2.1.0.
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more than the others in the issue of reproducibility. On the other hand, the two
MacroD2 domains, the macrodomain and the unstructured C-terminus, might hinder
the binding of reciprocal interactors when they are together in the same polypeptide.
This hypothesis argues for an even stronger role in the crosstalk of the two parts of
MacroD2 in regulating the protein function.
In addition, almost 50 % of genes selected for the “MacroD2 C-terminus DMSO”
condition were shared with the “MacroD2 macrodomain DMSO”. This overlap was
not expected. However, considering that the MacroD2 macrodomain DMSO condition
presents the biggest number of proteins after the filtering, I can think of two explana-
tions: either the higher number of enriched proteins simply generated some background,
which was not corrected upon normalization, or there is a biological reason. It might
be that these interactors are part of complexes that might bind both the MacroD2
macrodomain and the C-terminus fragment, although I do not know of any published
cases in the current literature.
4.7.2 Filtering the protein shared in the macrodomain and C-terminus
conditions
Subsequently, I wanted to verify how many proteins are shared between the macrodomain
and C-terminus conditions. Considering that the common lists are generated by com-
bining the enrichments against the other three conditions, I would expect that no back-
ground gene is selected. Ideally all the final lists of common proteins should not share
any protein. However, some proteins are still shared between two or three conditions
(Figure 4.10).
“The MacroD2 macrodomain DMSO” is the condition that shares proteins with all
the other conditions, the highest commonality with “MacroD2 C-terminus etoposide”
condition. Considering that I generated the lists of common proteins by taking only
those that were enriched against at least two different conditions, these factors are
still likely to be proper interactors of MacroD2, with the shared proteins belonging to
large complexes. MacroD2 might interact with these complexes by exploiting both the
macrodomain and the C-terminus.
I then checked for the enrichments in biological keywords for the four conditions.
For each condition, the list has been filtered of all those factors that are shared with
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MD Etoposide
MD DMSO
CT DMSO
CT Etoposide
Figure 4.10: Proteins shared in the four conditions - Venn diagram of the most
reliable binders for four conditions: MD DMSO, MD etoposide, CT DMSO, CT etoposide.
The input lists are the common proteins for each condition. FL is full-length; MD is
macrodomain; CT is C-terminus. Generated via Venny 2.1.0.
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other conditions. Thus, the biological terms of the interactors specific for that certain
condition are shown (Table 4.2).
Category Term FDR
MacroD2 macrodomain DMSO
GO.0043230 extracellular organelle 3.00E-07
GO.0065010 extracellular membrane-bounded organelle 3.00E-07
GO.0070062 extracellular exosome 3.00E-07
GO.1903561 extracellular vesicle 3.00E-07
GO.0031988 membrane-bounded vesicle 1.18E-06
GO.0031982 vesicle 1.72E-06
GO.0044444 cytoplasmic part 0.000134
GO.0032991 macromolecular complex 0.000421
GO.0006457 protein folding 0.000528
GO.0044421 extracellular region part 0.000548
GO.0044822 poly(A) RNA binding 0.000712
GO.0003723 RNA binding 0.000878
GO.0044446 intracellular organelle part 0.0011
GO.0031625 ubiquitin protein ligase binding 0.00142
GO.0044389 ubiquitin-like protein ligase binding 0.00142
GO.0044422 organelle part 0.0016
GO.0016023 cytoplasmic membrane-bounded vesicle 0.00281
GO.0042470 melanosome 0.00281
GO.0005576 extracellular region 0.00388
GO.0031410 cytoplasmic vesicle 0.0047
GO.0070013 intracellular organelle lumen 0.0047
GO.0005829 cytosol 0.00474
GO.0043233 organelle lumen 0.00515
GO.0044428 nuclear part 0.00516
GO.0031974 membrane-enclosed lumen 0.00555
GO.0005634 nucleus 0.00603
GO.0005737 cytoplasm 0.0061
GO.0044297 cell body 0.0061
GO.0005832 chaperonin-containing T-complex 0.00665
GO.0002199 zona pellucida receptor complex 0.00798
GO.0012505 endomembrane system 0.00857
GO.0043209 myelin sheath 0.00857
GO.0019953 sexual reproduction 0.0111
GO.0031967 organelle envelope 0.0116
GO.0031975 envelope 0.0116
Continues on next page
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Category Term FDR
GO.0005515 protein binding 0.0118
GO.0045454 cell redox homeostasis 0.0172
GO.0005635 nuclear envelope 0.0199
GO.0061024 membrane organization 0.021
GO.0044703 multi-organism reproductive process 0.0215
GO.0043234 protein complex 0.0241
GO.0000003 reproduction 0.0243
GO.1990204 oxidoreductase complex 0.0266
GO.0043228 non-membrane-bounded organelle 0.0274
GO.0043232 intracellular non-membrane-bounded organelle 0.0274
GO.0043231 intracellular membrane-bounded organelle 0.0315
GO.1903047 mitotic cell cycle process 0.0329
GO.0005488 binding 0.0343
GO.0005739 mitochondrion 0.0365
GO.0042995 cell projection 0.0376
GO.0015630 microtubule cytoskeleton 0.0381
GO.0022402 cell cycle process 0.0414
GO.0044702 single organism reproductive process 0.0414
GO.0035770 ribonucleoprotein granule 0.0459
GO.0036464 cytoplasmic ribonucleoprotein granule 0.0459
GO.0097223 sperm part 0.0459
KEGG:04141 protein processing in endoplasmic reticulum 0.047
MacroD2 macrodomain etoposide
GO.0003723 RNA binding 0.0117
GO.0044822 poly(A) RNA binding 0.0128
MacroD2 C-terminus DMSO
GO.0022618 ribonucleoprotein complex assembly 0.0302
GO.0071826 ribonucleoprotein complex subunit organization 0.0302
MacroD2 C-terminus etoposide
KEGG:03430 mismatch repair 0.025
KEGG:03440 homologous recombination 0.025
KEGG:03030 DNA replication 0.0282
Continues on next page
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Table 4.2 – Continued from previous page
Category Term FDR
Table 4.2: Biological term enrichment for the core proteins of the four condi-
tions - Overview of enriched biological terms. Generated by STRING database
The biological terms for the “MacroD2 macrodomain DMSO” condition reveal a
very heterogeneous localization, with many references to the ER. The “regulation of
steroid hormone signaling pathway” has instead disappeared, probably as some filtered
out factors were contributing to the significance of that pathway in the enrichment.
The “MacroD2 macrodomain etoposide” condition has now only terms related to RNA
binding, while the “ MacroD2 C-terminus DMSO” is focused on ribonucleoprotein com-
plexes. These ribonuclear complexes include both ribosomes and particles belonging to
the spliceosome. Lastly, the “MacroD2 C-terminus etoposide” lost most of its enriched
biological terms, surprisingly retaining only those referring to “DNA replication” and
“mismatch repair”. “Homologous recombination” was also a surprising new entry in
the list.
4.7.3 Looking for the exporting interactor
Defining the interactors that are important for the nuclear export of MacroD2 upon
etoposide treatment was the main motivation for performing the co-immunopurification
experiment. One possibility is the interaction with a protein that present a NES, so
that MacroD2 is exported via a “piggy-back” mechanism. Such an interactor should be
able to bind the two MacroD2 phosphorylated serines, which are within SQ/TQ motifs
modified by ATM or a PI3K-like kinase upon DNA damage. Moreover, the candidate
should optimally be found among the interactors that are enriched in “MacroD2 full-
length etoposide” or “MacroD2 C-terminus etoposide” conditions.
It is possible to define which phospho-binding module will more likely recognize the
modification performed by a certain kinase by considering the sequence requirements of
the kinases and of the phospho-binders (357). The serine or threonine modified by ATM
and the PI3K-like kinases are most probably recognized by FHA and BRCT binding
modules. For this reason, I downloaded the list of human proteins possessing either a
FHA or a BRCT domain from Uniprot and I systematically compared these two lists
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with the one I have produced by analyzing the co-IP experimental data, looking for
possible factors that might be involved in the recognition of the modification.
Although 71 FHA-containing proteins and 44 BRCT-containing proteins are anno-
tated in Uniprot, out of the hundreds of proteins present in my pull-down experiment,
only ARTD1 and SMARCC1 present a BRCT domain. Both the proteins are present
in the list of common proteins of the MacroD2 macrodomain etoposide condition. Con-
sidering that the factor I am looking for should bind the C-terminus of the protein, I
would exclude their role in the MacroD2 assisted nuclear export.
4.8 Future directions
After having performed the experiment and completed its analysis, the next step for
proteomics experiments is the validation. This is normally performed by in vitro and
in vivo pull-downs, co-localization tests by immunofluorescence or more refined experi-
ments, such as BiMolecular Fluorescence Complementation, Proximity Ligation Assay
or FRET. However, after the analyses it is vital to search through the literature and
define which are the most sensible candidates, both as protein and as physiological
functions, to pursue. What follows are the most interesting hypotheses I formulated
about possible MacroD2 cellular functions and related follow-up experiments.
4.8.1 Screening for factors affecting MacroD2 nuclear export
As mentioned above, one of the reasons why I performed the co-IP coupled to peptide
mass fingerprinting upon etoposide treatment was to discover the interactors that may
lead MacroD2 across the nuclear envelope into the cytoplasm. When I compared the
list of MacroD2 interactors with the list of proteins possessing FHA or BRCT domains,
the only proteins present in both lists are ARTD1 and SMARCC1. However, both pro-
teins are highly enriched in the “MacroD2 macrodomain etoposide” condition. Also,
both proteins are described as nuclear proteins, thus it seems difficult to imagine how
these two factors may be involved. Considering instead the great number of proteins
that I compared, it is feasible to find two false positive elements in my search. Nonethe-
less, their functional involvement in MacroD2 nuclear export is easily testable. Using
an RNAi-mediated approach to knock-down ARTD1 or SMARCC1 and subsequently
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performing live-cell imaging experiment with EGFP-MacroD2 C-terminus upon UV-
laser microirradiation should be sufficient to define the actual involvement of these two
proteins to the nuclear export of MacroD2.
The discovery of the exporting interactor may have been hindered by the limita-
tions of the co-IP approach, as it might be not sufficient for the detection of tran-
sient interactions or interactors with small affinities. Therefore, the BioID-based mass
spectrometry-coupled pull-down experiment that my host lab is planning to perform
could greatly increase the pool of proteins that are interacting with MacroD2. The
technique is based on the generation of a hybrid construct with the protein of interest
attached to a promiscuous biotin ligase, that is able to mark with biotin the proteins
that get in proximity to the bait (385). Indeed, the main drawback of the technique is
the possible modification of too many proteins generating a great deal of false positives.
Therefore, the experiment requires good negative controls. For example, in the case of
MacroD2, the ADP-ribose-binding deficient mutant (G188E) and the export-deficient
mutant (S276,345,415,426A) could be useful to screen the interactor list and to find
proteins that are strictly related to these two protein features of MacroD2. This ap-
proach might hopefully be able to enlarge the list of interactors that I have shown in a
constructive manner.
Lastly, in order to discover the interactors that allow MacroD2 nuclear export, an-
other strategy would take advantage of the well-known phenotype of MacroD2: the
nuclear export itself. By employing libraries of siRNAs, it could be possible to screen
for those factors whose absence negatively affects MacroD2 nuclear export. This ex-
periment would be then based on RNAi-mediated strategy coupled to cell-imaging on
U2OS-MacroD2 C-terminus + mCherry-H2B stable cell line. Essential genes, whose
lack might impair the cellular life, should not be included in the siRNA library. Most of
the membrane proteins should also be discarded, since our interactor is most probably
soluble and itself able to shuttle between the nuclear and cytoplasmic compartments.
Moreover, the library could be mainly targeting proteins carrying a phospho-binding
domain. Consequently, these requirements should greatly decrease the number of genes
of interest, making the library generation and the experiment itself more feasible. An
alternative to the classical siRNA library could be instead a genome-wide CRISPR/Cas-
mediated knock-out strategy (387). By generating the all possible knock-out mutants
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from a specific cell line, this approach would definitely solve the interferences generated
by the partial depletion of target proteins that the siRNA strategy produces.
Considering the microscopy-related aspects, such a high-throughput experiment
excludes the adoption of a live-cell imaging strategy. However, it is advisable to perform
not just an end-point assay, since the kinetics of the export might be affected more in the
initial phase and somehow recovered in the late stage, when maybe the activation of the
kinase decreases. This is even more true when multiple factors redundantly cooperate
for the nuclear export of MacroD2. Lastly, if the knock-out strategy would solve the
problem of the incomplete depletion, the siRNA strategy instead will only strongly
decrease the expression of the candidate factor. Therefore, an imaging assay with four
time points (0, 5, 30 and 60 minutes) should be enough to indicate perturbations in
different phases of the nuclear export of MacroD2 and avoid false negative cases even
with the siRNA strategy approach.
4.8.2 RNA biology regulation
By checking the most common biological terms found in my co-IP experiment, RNA-
related keywords appeared for every condition analyzed. While RNA-binding proteins
are generally regarded as particularly “sticky” in pull-down experiments (388), ADP-
ribosylation has been associated to many processes where RNA molecules are involved
(see Section 1.2.7).
As mentioned above, factors involved in both constitutive and alternative splicing
contain ADP-ribose binding modules, and ADP-ribosylation of splicing factors can
impact the maturation of the transcripts (118, 206, 389). Indeed, both constitutive
and alternative splicing factors have been found in my enrichment lists. Moreover,
among the enriched proteins from my co-IP experiments, many ribosomal proteins
appeared. These proteins are also classified as RNA-binding factors. Translation itself
can be modulated by ADP-ribosylation, as shown by the physiological mono-ADP-
ribosylation of eukaryotic elongation factor-2 (eEF-2) (209, 210, 211). Therefore, the
question is whether these interactions are just due to sample preparation or whether
MacroD2 has a physiological role in the regulation of RNA biology.
The validation of the interaction is essential and requires the additional control with
the addition of RNAse, as RNA-binding proteins tend to be considered as contaminant
in pull-down experiments. Such a control would exclude the possibility that large
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complexes containing RNA molecules have been indeed purified and question a direct
role of MacroD2 in the regulation of splicing. If however, the binding of MacroD2 and
the splicing factors is validated and is indeed mediated by an RNA molecule, it could
be interesting to define which fragment of MacroD2 sequence possesses this binding
property. Performing in vitro pull-down experiments with purified MacroD2 fragments
and the candidate splicing factor, in the presence and absence of a RNA molecule will
be useful in assessing this hypothesis. Moreover, if MacroD2 binds the splicing factor,
it might perform its enzymatic activity on the factor as well: thus, the splicing factor
should be tested to see whether it undergoes any MARylation or PARylation, If the
factor is modified, the modification might be able to hinder its splicing performance,
which could be tested by means of an in vitro splicing experiment in cell-extract.
Lastly, PAR is shown to be required for the formation of cytoplasmic stress gran-
ules, where RNA-binding proteins accumulate together with mRNA molecules and
Argonaute proteins in order to temporally block their translation (212). G3BP2, which
was enriched in the “MacroD2 macrodomain etoposide” condition, was shown to be an
inducer of the cytoplasmic stress granules (383).
The localization of the MacroD2 can be tested with arsenite treatment, the most
classical method to induce the stress-granule formation. If MacroD2 is indeed able
to relocate to the stress granules, a screen for MacroD2 substrates within the stress
granules could define which proteins might have their ADP-ribosylation reversed by
MacroD2. Afterwards, these proteins might be studied for the impact that the ADP-
ribosylation has on their structure or their functional activity.
4.8.3 The neuron-specific remodeling complex, nBAF
Among the enriched biological terms for the “MacroD2 macrodomain etoposide” condi-
tion, the “SWI/SNF superfamily-type complex”, “npBAF complex”, “SWI/SNF com-
plex” and “nBAF complex” terms were present. These are all terms referring to the
BRG1- and BRM-associated factor (BAF) remodelling complex, an ATP-dependent
SWI/SNF-like complex (390). BAF complexes are formed with up to 15 factors, where
the ATP-ase subunit is generally either BRG1 or BRM. The composition of the complex
changes according to the cell type, creating hundreds of different possible complexes in
humans. The only complexes that are referred to in my list are the neural progenitor
BAF (npBAF) and neural BAF (nBAF). Two proteins, SMARCC1 and SMARCE1,
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are found in different enrichments of the same condition and the two factors are present
in both npBAF and nBAF.
npBAF and nBAF complexes are essential for the development of the nervous sys-
tem, by helping the maintenance or the establishment of the required expression pattern
(390). In neural progenitors, npBAF activity maintains the expression of the pluripo-
tency factors and represses the neuron-specific genes in order to preserve the identity
of the progenitors. However, upon commitment for the neural differentiation, some
factors of npBAF are replaced by nBAF-specific proteins and the switch from npBAF
to nBAF complex is tightly regulated (391).
Mutations in the different members of the complexes affect the neural development:
loss of npBAF specific factors, for example, impairs the proliferation of the pool of pro-
genitors, leading to microcephaly (392). However, de novo mutations on npBAF/nBAF
factors are associated with non-familial autism (393, 394). In fact, since autism causes
defects in neural circuit formation, authors have suggested that a failure in npBAF
or nBAF-mediated regulation of dendritic outgrowth could be one of the causes of
this syndrome (395, 396). Therefore, an interaction between np/nBAF complex and
MacroD2 could be a starting point to explore the mechanism behind MacroD2’s as-
sociation to autism. While the co-IP has been performed in kidney-derived HEK293
cells, where neural-specific genes are not expected to be expressed, as it is a cancer
cell-line, the possible ectopic expression of neural factors might be an explanation for
this incongruity.
The association between MacroD2 and npBAF/nBAF is interesting because of the
amount of studies that associate MacroD2 to autism and other neural development
syndromes, although without offering any mechanistic insight (see Section 1.2.5). If
the physical interaction between MacroD2 and the np/nBAF complexes is confirmed,
it would be interesting to proceed in this line of research. In fact, I can imagine two
scenarios that might link MacroD2 to this chromatin remodeler complex. In the first
scenario, the ADP-ribosylation is important for the recruitment of the complexes on
the correct promoters. Thus, MacroD2 might interact with the remodelling complex
due to their common recruitment to the same region through ADP-ribosylated factors
present on the promoters of neural genes. In the second scenario, MacroD2 could have
a role in the modulation of the catalytic activity of the npBAF/nBAF complex or even
its assembly.
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In support of the first scenario, the ATP-ase unit BRG1 was already found associ-
ated to ARTD1 at the chromatin, even though in a completely different context (397).
ChIP-sequencing experiments could maybe show that BRG1 interacts on the chromatin
with MacroD2 as well, provided having an anti-MacroD2 antibody with high specificity.
However, the ultimate outcome of these experiments would be to test whether ADP-
ribosylation is important for the targeting of the npBAF and nBAF complexes to the
correct neural gene promoters.
In support of the second scenario, SMARCC1 was shown to increase the stability
of SMARCE1 by impairing its ubiquitination (398). The authors indicated TRIP12 to
be the E3-ligase enzyme, which contains a WWE domain. Therefore, ARTDs might
regulate SMARCE1 levels by PARylation-dependent degradation. Thus, the levels
of SMARCE1 protein could be tested in the presence and the absence of oxidative
stress, when ARTD1 should be mostly active. I would also employ a siRNA-mediated
approach and look for the increase of expression levels of SMARCE1 in order to test if
other ARTDs are involved. Neuronal cell lines, such as differentiated SH-SY5Y or NT2,
should be used to be sure that SMARCE1 is properly expressed. If the hypothesis holds
true and an ARTD is found to regulate SMARCE1 protein levels, the role of MacroD2
in the system can be tested, by checking the influence that the over-expression or its
depletion have in SMARCE1 levels.
Moreover, MARylation may be a modification that regulates the activation level
or the structure of the whole complex. By screening for ADP-ribosylated or even
MARylated proteins in neuronal cell lines, it may be possible to find proteins whose
activity is modulated by such a modification, and, thus, to test possible interactions of
MacroD2 with neuronal proteins.
4.8.4 Regulation of the cytoskeletal dynamics
Various types of cytoskeletal components were enriched with all the three MacroD2
constructs, mainly upon etoposide treatment. Two proteins associated to the cy-
toskeletal structure of the focal adhesion (FA) foci, TRIP6 and SNX9, were found
to be enriched in the “MacroD2 full-length etoposide” condition (399, 400) (see Table
A.4). “Microtubule cytoskeleton” and “cytoskeleton” biological terms were enriched
in the “MacroD2 macrodomain DMSO” condition (see Table B.4). Also more biolog-
ical terms related to cytoskeletal structures appeared in the “MacroD2 macrodomain
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etoposide” condition, such as “focal adhesion”, “cell-substrate adherens junction”,
“cell-substrate junction”, “intermediate filament cytoskeleton”, “adherens junction”
and “anchoring junction” (see Table B.6). Lastly, the enriched biological terms in
the “MacroD2 C-terminus etoposide” condition included “sarcomere”, “contractile fiber
part”, “myofibril”, “cuticular plate”, “I band”, “anchoring junction”, “spectrin ”, “Z
disc” and “adherens junction” (see Table B.10). Although the structures defined
by these different term are functionally distinct, they all present as common feature
the presence of protein filaments, like F-actin, intermediate filaments or tubulin-made
microtubules.
FAs and other cytoskeletal elements can be very important for generating morpho-
logical structures with special functions. These structures are even more important
when set in the context of special cell-types that have a peculiar morphology and
function, such as the neurons. Recent literature shows that the interaction between
cytoskeleton and neural function is an expanding research field (401). F-actin are, for
example, necessary for the correct formation of dendritic spines, the membrane struc-
ture forming one part of the synapse (402). Disruption of the morphology brings a
disruption in the neural functionality. How everything is ultimately connected with
neurological disorders is still an open question.
The above-mentioned association of MacroD2 with autism and other neurological
disorders (see Section 1.2.5) could also be explained by a dysfunction in cytoskeletal
organization. The imperfect formation of synapses may affect the general neural net-
work. In fact, impairment of brain connectivity has been associated also with a locus
nearby to the MacroD2 gene (97). In my co-IP experiment, the MacroD2 constructs
purified cytoskeletal factors above all upon etoposide treatment, arguing that the hypo-
thetical regulation of the cytoskeletal dynamics by MacroD2 is activated upon genotoxic
stress. Moreover, as described in Chapter 3, ATM substrates possessing the SQ/TQ
cluster domain (SCD) in the sequence were analyzed for biological term enrichment.
In this case cytoskeleton-related terms were surprisingly overrepresented (371).
To proceed in this direction, I could take advantage of microscopy techniques and
analyze the co-localization of MacroD2 with cytoskeletal components. As the focal
adhesion biological terms appeared frequently in the analysis, examining the changes
in foci formation in MacroD2 knock-out cells compared to wild-type cells would give
an indication into MacroD2’s role. Alternatively, testing neural cells for dendritic spine
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formation in the presence and the absence of MacroD2 would also indicate MacroD2
function in this process. When a clear phenotype is linked to MacroD2 depletion, it is
possible to study the mechanism behind it. It would be important to understand what
protein directly interacts with MacroD2 and whether this protein is ADP-ribosylated.
In fact, I imagine that even a single ADP-ribosylation moiety, at a specific site on the
protein surface, can have important consequences on its activity and function.
4.8.5 NF-κB signaling pathway
The NF-κB pathway is activated either upon interleukines binding at the cell mem-
brane or from the nucleus in response to genotoxic stimuli. Its activation increases the
expression of the genes involved in inflammation by the release of the transcription
factors NF-κB from the cytoplasmic inhibitory complex and by their translocation into
the nucleus. The NF-κB pathway is connected with both ATM signaling and mono-
ADP-ribosylation. In fact, upon genotoxic stress, ATM induces the activation of the
NF-κB pathway by modifying and escorting the positive regulator of NF-κB signaling,
NEMO, out of the nucleus (226). On the other side, NEMO activity is inhibited by
ARTD10-mediated MARylation (194).
Several factors involved in the NF-κB signaling in different ways were found in
several of my protein lists: NKAP, TRIP6, PRDX4 and G3BP2. The NF-κB activating
protein (NKAP) is present in the “MacroD2 full-length DMSO” condition (see Table
A.1) and has been shown to induce the NF-κB pathway (403). The peroxiredoxin-4
(PRDX4), instead, was present in the “MacroD2 macrodomain DMSO” condition (see
Table A.5), and it is a thioredoxin specifically able to activate the NF-κB pathway
(404). In this study the authors first showed the cytoplasmic localization of the PRDX4
and suggested that it is involved in NF-κB regulation by affecting the phosphorylation
of the IκBα inhibitor. The thyroid receptor-interacting protein 6 (TRIP6) was enriched
in the “MacroD2 macrodomain etoposide” condition (see Table A.8). It has been
shown to reside at the promoters of the NF-κB-responsive genes and to mediate either
the activation, when the NF-κB transcrition factors are binding, or the repression,
when the glucocorticoid receptor is binding those same genes (405). Last but not least,
the Ras GTPase-activating protein-binding protein 2 (G3BP2) was also enriched in the
“MacroD2 macrodomain etoposide” condition (see Table A.8). G3BP2 is able to
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retain the NF-κB-IκBα complex in the cytoplasm, acting as repressor of the pathway
(406).
Therefore, MacroD2 could accumulate in the cytoplasm upon ATM activation and
help remove the last “break”, the MARylation performed by ARTD10 on NEMO,
which would be necessary for the full activation of the NF-κB pathway. In order to test
this hypothesis, in vitro assays for the removal of MARylation on NEMO by MacroD2
are the necessary starting point. Subsequently, the activation of the NF-κB pathway
must be determined in vivo, by comparing wild-type cells to MacroD2-/- cells. This
can be performed by testing the phosphorylation levels of the inhibitor IκBα. IκBα’s
inhibitory action is mediated through trapping the transcription factors within the cyto-
plasm. After its ATM-induced nuclear export, NEMO activates the complex of the IκB
kinase (IKK), which phosphorylates IκBα and forces the disassembly of the inhibitory
complex (226). Thus, if NEMO is a substrate of MacroD2, the NF-κB translocation
into the nucleus and activation of the gene expression should be less in MacroD2-/-
cells than their wild-type counterpart. In case of decreased activation of the NF-κB
pathway, the phenotype should be further verified by a rescue experiment, for example,
by transiently transfecting MacroD2 wild-type, MacroD2 ADP-ribose binding-deficient
mutant (G188E) or MacroD2 export-deficient mutant (S276,345,415,426A). The ADP-
ribose binding-deficient mutant should not be able to rescue the phenotype and the
export-deficient mutant should do it only partially.
In conclusion, the possible interaction between MacroD2 and the NF-κB pathway
would be particularly interesting as it would give more relevance to the regulatory
role of the nuclear export of MacroD2. In normal conditions, the NF-κB factors are
cytoplasmic, blocked by the inhibitory complex, while MacroD2 presence in the nucleus
avoid its overwhelming presence in the cytoplasm. Upon genotoxic stress, ATM would
shift the balance towards the cytoplasm for both NEMO and MacroD2. MacroD2
would then allow the full release of the NF-κB transcription factors by ensuring the
total activity of NEMO. In such a story, many passages across the nuclear envelope
would hinder the overexpression of genes involved in the inflammatory response.
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The work I have performed in these years of research contributed to a deeper un-
derstanding of the ADP-ribosyl-hydrolase world. In fact, I show in this thesis that
the ADP-ribosyl-hydrolase MacroD2 exports from the nucleus upon DNA damage.
Although most of my experiments are performed with EGFP-tagged version of the
protein, I could also show that the endogenous MacroD2 shares this behavior. The
nuclear export of MacroD2 is induced by double-strand breaks via ATM activation.
The kinase phosphorylates two serines that are located in the intrinsically disordered
region of MacroD2.
MacroD2 nuclear export can be easily considered a mechanism to regulate its en-
zymatic activity, as shown by the change in recruitment dynamics at the DNA lesion
caused by the block of the nuclear export. However, the regulation might have other
possible outcomes. To help define the range of consequences, as well as the exact mech-
anism that allows MacroD2 to cross the nuclear envelope, I decided to start uncovering
the MacroD2 interactome, by means of a co-IP experiment coupled with protein mass
fingerprinting. The different hypothesis I proposed could be considered when proceed-
ing with the validation step.
This work underlines the importance of the integration between the different sig-
naling pathways, above all upon extraordinary conditions, such as for DNA damage.
Many times, ATM signaling and ADP-ribosylation have been shown to cross each oth-
ers’ paths regarding modulation of the DNA damage response. But never before had
the interaction shown such a clear and incontrovertible effect, like the nuclear export
of an enzyme. Moreover, although ATM and ARTD1 are suggested to be directly in
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contact, my work shows in a definitive way that the interaction between these two sys-
tems does happen and it can have a visible output. Now, uncovering MacroD2 cellular
functions, its interacting network and its specific subset of substrates, is the next step
needed to really understand the reasons for the interaction between the two signaling
pathways.
With this study, the uniqueness of MacroD2 is revealed. MacroD2, in fact, is the
only human ADP-ribosyl-hydrolase so far described to be regulated in its localization.
Experiments with both full-length MacroD1 and TARG1 show localization at the mi-
tochondria or only recruitment to the DNA lesion, respectively. Neither of them is
exported from the nucleus upon DNA damage. This specific feature of MacroD2 sug-
gests that the activity of this enzyme requires a fast and tight regulation, which is not
required for the other two proteins. And enzymatic activity undergoing a complicated
regulation could easily point to important functions or interactions so far neglected.
Another interesting finding is the double nature of MacroD2. Although it is an
enzyme, MacroD2 has a C-terminus fragment that is an intrinsically disordered re-
gion. Intrinsically disordered proteins are underrepresented among enzymes, and still
MacroD2 belongs to both groups. However, these two features may be combined in
MacroD2 because they are well confined within the two portions of the proteins se-
quence: the N-terminus macrodomain can perform its enzymatic activity and keep its
ordered folding, while the C-terminus region keeps its disordered structure, more apt
to address its signaling functions. This unique “schizophrenic” nature of MacroD2
probably underlies the importance that it has in the regulation of cellular functions.
Remarkably, MacroD2 has been associated several times to autism syndrome and
other neurodevelopmental diseases. However, we don’t know yet how this phenotype
can be connected to its enzymatic activity. We are surely getting closer to solve the
riddle, but more effort should be put into filling the gap between MacroD2 molecu-
lar activity and its consequences on the whole organism, by understanding the one or
many functions that this protein might have. Considering the consequences that disin-
formation on the alleged connection between autism and vaccination has caused for the
public health of many western countries, the understanding of a possible mechanism
inducing this syndrome should be one of the top priorities of research on MacroD2.
Another conclusion I draw from my work is that we need to develop a more compre-
hensive understanding of the different signaling mechanisms ongoing in the cell. So far,
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partially due to technical limitations, the research on ADP-ribosylation has focused on
the transferases and their activation. It is now important to pay attention to the whole
cycle, by understanding also the mechanisms that induce the destruction of the specific
signal when the emergency phase is over. ADP-ribosylation is a very dynamic signal,
and the accurate regulation of its mechanisms must be a challenging task. But, as this
is true within the regulation of the sole ADP-ribosylation signaling, it is also true when
considering the many signaling pathways in action at the same time all together. Upon
each condition, several signaling pathways are activated to various extents.
Although it is quite a daunting task, our knowledge of what is happening in the
cell at every moment is still very fragmented. But the real understanding comes with
the knowledge of all the factors contributing to a system and the ability of generating
successful predictions. With my experience, I can say that in biology we are not there
yet. Still, the path in front of us does not seem so long anymore.
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6Material and methods
6.1 Reagents
DMSO (Dimethyl sulfoxide) (D2438; Sigma)
Etoposide (E1383; Sigma)
Aphidicolin (A0781; Sigma)
Camptothecin (7689-03-4; Sigma)
PARP inhibitor Olaparib (AZD2281; Selleckchem)
ATM kinase inhibitor (KU55933; Selleckchem)
ATR kinase inhibitor (VE-821; Selleckchem)
DNA-PK kinase inhibitor (NU7441; Selleckchem)
(32P)γATP (FP-301; Hartmann Analytic)
GFP-trap homemade (from Dr. A. Bowman and G. Jankevicius)
GFP-trap (gta; Chromotek)
bisBenzimide H 33342 trihydrocloride (Hoechst; Sigma)
Peptides (Metabion)
Oligos (Metabion)
6.2 Antibodies
Anti-MacroD2 (#494-7, rabbit polyclonal, from in-house facility)
Anti-GFP antibody (goat polyclonal, lab stock)
Anti-GST antibody (rat monoclonal from Dr. Kremmer of Helmholtz Zentrum Mu-
nich)
163
6. MATERIAL AND METHODS
Anti-ATM [Y170] (ab32420, rabbit monoclonal, Abcam)
Anti-GAPDH (rat monoclonal #5C4 from Dr. Kremmer of Helmholtz Zentrum Mu-
nich)
Anti-beta actin antibody (rabbit polyclonal, ab8227, Abcam)
Alexa-488 goat anti-rabbit (Invitrogen)
Goat anti-rabbit IgG-HRP conjugated (BIO-RAD)
Goat anti-rat IgG-HRP conjugated (Jackson ImmunoResearch)
6.3 Buffers
RIPA buffer
50 mM Tris-Cl, pH 7.5
150 mM NaCl
0.1% Sodium Deoxycholate
1 mM EDTA
1% NP-40
SDS protein sample loading buffer 4x
250 mM Tris-HCl pH 6.8
10% dithiothreitol
5% SDS
40% glycerol
0,005% Bromphenol Blue
4x upper/stacking gel SDS buffer
500 mM Tris-HCl pH 6.8
0.1% SDS
4x lower/separating gel SDS buffer
1.5 M Tris-HCl; pH 8.7
0.1% SDS
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1x Western Blot transfer buffer
25 mM Tris buffer
192 mM Glycine
20% Methanol
0.0375% SDS (added only for transferring ATM protein)
Ponceau S
0.1% Ponceau S (Sigma)
1% Acetic acid
1x Coomassie blue R-250
40% Methanol
10% Acetic acid
0.1% Coomassie Brilliant Blue R-250 (Sigma)
for destaining, the buffer was prepared without Coomassie dye
6.4 Cell culture media
Normal culture medium
DMEM - high glucose (#5671 - Sigma)
10 % FBS (Gibco)
2 mM L-glutamine (Sigma)
100 U mL-1 penicillin + 100 g mL-1 streptomycin (Sigma)
McCoy’s-based culture medium
McCoy’s 5a (Sigma)
10 % FBS (Gibco)
2 mM L-glutamine (Sigma)
100 U mL-1 penicillin + 100 g mL-1 streptomycin (Sigma)
Imaging medium
Phenol Red-free Leibovitz’s L-15 (21083027 - Life Technologies)
10 % FBS (Gibco)
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2 mM L-glutamine (Sigma)
100 U mL-1 penicillin + 100 g mL-1 streptomycin (Sigma)
6.5 Kits
The list of commercial kits used during the study is shown in the Table 6.1.
Item Manifacturer
Plasmid preparation Miniprep Metabion
Plasmid preparation Midiprep Promega
PCR purification Metabion
Gel extraction Kit Metabion
NuPAGE (precast gels and buffers) Invitrogen
Table 6.1: Kits - Overview of the commercial kits used during the study.
6.6 Plasmids
The list of plasmid used during the study is shown in the Table 6.2.
Plasmid Database location
pmEGFP-C1 CL1036
pmEGFP-C1-MacroD2 full-length CL2251
pmEGFP-C1-MacroD2 macrodomain (aa 1-234) CL1977
pmEGFP-C1-MacroD2 C-terminus (aa 236-448) CL1978
pmEGFP-C1-MacroD2 G188E CL3521
pmEGFP-C1-MacroD2 G100E+I189R+Y190N CL3760
pmEGFP-C1-EGFP-MacroD2 C-terminus (aa 236-end) CL3758
pmEGFP-C1-MacroD2 S276,345,415,426A CL3714
pmEGFP-C1-MacroD2 S276,345,415A CL3715
pmEGFP-C1-MacroD2 S276,345,426A CL3716
pmEGFP-C1-MacroD2 S276,415,426A CL3717
pmEGFP-C1-MacroD2 S345,415,426A CL3718
pmEGFP-C1-MacroD2 S276,426A CL3759
pmEGFP-C1-MacroD2 (aa410-418) CL3503
pmEGFP-C1-MacroD2 (aa402-418) CL3742
pmEGFP-C1-MacroD2 (aa382-418) CL3552
pmEGFP-C1-MacroD2 (aa382-418) D410A CL3540
Continues on next page
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Plasmid Database location
pmEGFP-C1-MacroD2 (aa382-418) V411E CL3543
pmEGFP-C1-MacroD2 (aa382-418) E412A CL3544
pmEGFP-C1-MacroD2 (aa382-418) M413A CL3546
pmEGFP-C1-MacroD2 (aa382-418) N414A CL3547
pmEGFP-C1-MacroD2 (aa382-418) S415A CL3548
pmEGFP-C1-MacroD2 (aa382-418) Q416A CL3549
pmEGFP-C1-MacroD2 (aa336-372) CL3729
pmEGFP-C1-MacroD2 (aa336-372) S345A CL3736
pmEGFP-C1-MacroD2 (aa336-372) Q346A CL3737
pmEGFP-C1-MacroD2 (aa336-372) M350A CL3741
pETMCN-6His-TEV-MacroD2 full-length CL3528
pETMCN-6His-TEV-V5-MacroD2 macrodomain (aa 1-234) CL3053
pETMCN-6His-TEV-MacroD2 C-terminus (aa 244-448) CL3529
pETMCN-6His-TEV-EGFP-MacroD2 (aa 1-448) CL3720
pETMCN-6His-TEV-EGFP-MacroD2 C-terminus (aa 236-448) CL3743
pGEX-6P1-GST-EGFP-MacroD2 (aa 382-418) CL3721
pETMCN-6His-TEV-EGFP-MacroD2 (aa 382-418) CL3745
pETMCN-6His-TEV-EGFP-MacroD2 (aa 382-418) D410A CL3722
pETMCN-6His-TEV-EGFP-MacroD2 (aa 382-418) V411E CL3723
pETMCN-6His-TEV-EGFP-MacroD2 (aa 382-418) E412A CL3724
pETMCN-6His-TEV-EGFP-MacroD2 (aa 382-418) M413A CL3725
pETMCN-6His-TEV-EGFP-MacroD2 (aa 382-418) N414A CL3726
pETMCN-6His-TEV-EGFP-MacroD2 (aa 382-418) S415A CL3727
pETMCN-6His-TEV-EGFP-MacroD2 (aa 382-418) Q416A CL3728
pGEX-4T1-GST-14-3-3  CL3747
pGEX-4T1-GST-14-3-3  K49E CL3748
pGEX-2TK-GST-14-3-3 σ CL3749
pGEX-4T1-GST-14-3-3 ζ CL3750
pGEX-2TK-GST-14-3-3 β CL3751
pGEX-6P1-GST-14-3-3 η CL3752
pGEX-6P1-GST-14-3-3 τ CL3753
pGEX-4T2-GST-14-3-3 γ CL3754
pcDNA5-FRT/TO-EGFP CL3553
pcDNA5-FRT/TO-EGFP-C1-MacroD2 (aa 1-448) CL3538
pcDNA5-FRT/TO-EGFP-C1-MacroD2 (aa 1-243) CL3761
pcDNA5-FRT/TO-EGFP-C1-MacroD2 (aa 237-448) CL3554
pOG44 Flippase CL3640
Continues on next page
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Plasmid Database location
Table 6.2: Plasmids - Overview of the plasmids used during the study.
6.7 Cell culture and treatments
6.7.1 Cell lines used
The lists of the used cell lines is shown in the Table 6.3.
Cell lines Media
U2OS Normal
U2OS MacroD2-/- (GM09) Normal
U2OS mYFP-MacroD2 (aa 1-448) + mCherry-H2B Normal
U2OS mEGFP-MacroD2 (aa 237-448) + mCherry-H2B Normal
U2OS mEGFP-MacroD2 (aa 1-448) Normal
U2OS mEGFP-MacroD2 (aa 237-448) Normal
U2OS mEGFP-MacroD2 (aa 1-448) G188E Normal
U2OS mEGFP-mEGFP-MacroD2 (aa 237-448) Normal
HeLa Kyoto mCherry-H2B Normal
G-361 McCoy’s-based
HT-144 McCoy’s-based
HEK293 Flp-InTM T-RExTM Normal
HEK293 Flp-InTM T-RExTM EGFP Normal
HEK293 Flp-InTM T-RExTM EGFP-MacroD2 (aa 1-448) Normal
HEK293 Flp-InTM T-RExTM EGFP-MacroD2 (aa 1-243) Normal
HEK293 Flp-InTM T-RExTM EGFP-MacroD2 (aa 237-448) Normal
Table 6.3: Cell lines - Overview of the cell lines used during the study.
6.7.2 Cell culture
Human U2OS stable cell lines were grown in normal cell culture medium supplemented
with 200 µg mL-1 G418 (Gibco). For maintenance of the mCherry-H2B construct, 2
µg mL-1 Puromycin (Sigma) may have been added to the medium. HEK293 stable
cell lines were grown in normal cell culture medium supplemented with 15 µg mL-1
blasticidin and 100 µg mL-1 hygromycin. For transient transfections, HeLa Kyoto cell
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line stably expressing mCherry-H2B were mainly used. Transient transfections were
also performed on U2OS and HT-144 cell lines.
Cells were plated in borosilicate 8-well Lab-Tek chambered cover glasses (Thermo-
Scientific) for imaging experiments. For other types of experiments, different plastic
supports were used: 6-well plates, 12-well plates. 24-well plates, 60-cm2 dishes or
150-cm2 dishes (TPP).
6.7.3 Transfections and treatments
For transient transfections, cells were plated in a number that was adjusted according
to the cell line, the day of use and the surface of plating (for example, 20000 U2OS
cells were plated in one Lab-Tek well to be used on the next day).The next day, DNA
transfection was performed by means of Xfect (Clontech) according to the manufac-
turer’s recommendations. For example, regarding the most used setup, for one single
Lab-Tek well, 500 ng of plasmid was used together with 0.3 µL of X-fect reagent. Cells
were tested the day after transfection.
For siRNA-mediated MacroD2 and ATM depletion, Negative Control #2, s44380
and s1708 Silencer Select siRNA oligonucleotides (Ambion) were used in combination
with Lipofectamine RNAiMAX (ThermoFisher) according to the manufacturers proto-
col. Cells were tested 72 hours post transfection.
Small molecule inhibitors were added to the culture medium 30 minutes before
imaging in the concentration indicated. For DNA damage-induction upon microscopy
experiments, camptothecin (50 µM) or etoposide (10 µM) were added during the imag-
ing session. For protein lysates, cells were incubated with etoposide (10 µM) for 1 hour
before collection.
6.7.4 Synchronization with Aphidicolin
To synchronize the cells, a protocol with Aphidicolin (Sigma) was used. On the first
day, 20000 cells of U2OS mEGFP-MacroD2 (aa 237-448) + mCherry-H2B were plated
in each 8-well Lab-Tek well. After 4 hours, Aphidicolin to a final concentration of 5
µg mL-1 was added. After 16 hours, the reactivation process was performed by means
of a wash in PBS, a wash in normal medium and an incubation of 10 minutes in the
incubator. These three steps were performed twice. Then imaging medium was added
and cells were ready for the experiment.
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6.8 Microscopy experiments
6.8.1 Microscope setup and imaging
During the experiments, cells were kept at 37 ◦C in Imaging medium. Imaging was
performed on a Zeiss AxioObserver Z1 confocal spinning-disk microscope equipped with
an AxioCam HRm CCD camera (Zeiss) through a Zeiss C-Apochromat 40x/1.2 water-
immersion objective or a Zeiss Plan-Apochromat 63x/1.2 water-immersion objective.
For laser microirradiation, we used a 355-nm wavelength, diode-pumped, solid-state,
pulsed laser (DPSL-355/14, Rapp OptoElectronics). DNA damage was induced by
focusing the laser to a point or a line in the nucleus or by adding camptothecin or
etoposide. Cells were imaged every 10 seconds for 30 minutes.
6.8.2 Detection of endogenous MacroD2 by immunofluorescence
U2OS cells were plated in borosilicate 8-well Lab-Tek chambered cover glasses (Ther-
moScientific). Treatment with etoposide 10 M was performed for one hour. Cells were
then fixed and permeabilised with Methanol/Acetone 1:1 solution for 10 minutes at
-20 ◦C. Blocking was performed with PBS-Tween 0.1% with BSA 5%. Cells were incu-
bated with the antibody anti-MacroD2 antibody (1:500), diluted in PBS-Tween 0.1%
- BSA 3%, for one hour at room temperature. Incubation with Alexa-488-conjugated
antibody (1:500) was performed for one hour at room temperature. Lastly, cells were
incubated with Hoechst 33342 (Sigma) at 200 ng mL-1 final concentration for 10 min-
utes.
6.8.3 Analysis of MacroD2 export
The time-lapse and the immunofluorescence images were analysed with CellProfiler 2.0
(331). The mCherry-H2B or Hoechst images were used for the segmentation of the
nucleus. To quantify protein export upon treatment, background was first subtracted
and the ratio of nuclear intensity over cytoplasmic intensity of MacroD2 in each cell
was calculated. For the time-lapse images, the ratio of each time point was normalized
to the first time point. Only the cells properly segmented in the first time-point of the
time laps were selected for the calculation of the average. Igor Pro (WaveMetrics) was
used for analyzing and plotting the data.
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6.8.4 Comparison between nuclear and cytoplasmic signal change
To compare nuclear signal depletion with cytoplasmic signal increase, HeLa cells stably
expressing mCherry-H2B and transfected with mEGFP-MacroD2 were used for UV-
laser experiments, as described before. The analysis was performed in Fiji (http:
//fiji.sc/Fiji) and consisted of manually segmenting the whole cell, the nucleus and
the cytoplasm. The mean intensity of each object was subtracted of the background.
The nuclear mean intensity over the total cell mean intensity was compared to the
cytoplasm mean intensity over the total cell mean intensity. Igor Pro (WaveMetrics)
was used for plotting the data.
6.8.5 Analysis of MacroD2 recruitment
To quantify the amount of protein recruited to DNA damage site, cells were registered
by means of the MultiStackReg plugin (http://bradbusse.net/sciencedownloads.
html) in Fiji (http://fiji.sc/Fiji). The mean intensity of the recruitment area was
subtracted with the background and normalized over the mean intensity of the total
cell. Then, the obtained ratio at each time point was normalized to the intensity of
the initial time point. Igor Pro (WaveMetrics) was used for analyzing and plotting the
data.
6.8.6 Automatized analysis of MacroD2 export
For the experiments 3.24 and 3.28, changes to the normal setup have been introduced.
Cells were plated in black cycloolefin-covered 96-well plates (Greiner) with a number
of cells per well adjusted according to the experiment and the cell line. Before exper-
iment, cells were treated for 10 minutes with Hoechst, in order to allow nuclei seg-
mentation upon analysis. During the experiments, cells were kept at 37 ◦C in Imaging
medium. Imaging was performed on a Zeiss AxioObserver Z1 confocal spinning-disk
microscope equipped with an AxioCam HRm CCD camera (Zeiss) through a Zeiss
Plan-Apochromat 20x/0.8 lens. Cells were imaged while treated with etoposide 10 µM,
every 5 minutes for 80 or 85 minutes. Each well was imaged in 18 positions.
The time-lapse and the immunofluorescence images were analysed with CellProfiler
2.0 (331). The Hoechst images were used for the segmentation of the nucleus. To
quantify protein export upon treatment, background was first subtracted and the aver-
age nuclear intensity and the average cytoplasmic intensity of all MacroD2 cells in the
condition were calculated. The ratio of nuclear intensity over cytoplasmic intensity of
MacroD2 was then calculated. The ratio of each time point was normalized to the first
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time point. Igor Pro (WaveMetrics) was used for analyzing and plotting the data.
6.9 Immunoblotting
RIPA buffer was used to obtain whole cell lysate. Samples were also sonicated to shear
genomic DNA and incubated at 4 ◦C for 30 minutes. Afterwards, supernatant was
cleared from cellular debris by centrifugating for 30 minutes at 11000 g. The cleared
lysate concentration was after determined via a Bradford assay on strongly diluted
samples. Proteins were resolved either on 12% or 6%+12% SDS-PAGE, if detecting
MacroD2 or ATM, respectively. The transfer was performed onto nitrocellulose mem-
brane (Whatman Protran). Transfer efficiency was checked with Ponceau S solution.
The membrane was blocked in PBS-Tween 0.05% buffer supplemented with 5%
non-fat milk. Proteins were detected with the appropriate primary antibodies (anti-
MacroD2 antibody 1:1000; anti-ATM antibody 1:1000; anti-GAPDH antibody 1:10;
anti-GST 1:10; anti-14-3-3 1:1000) and secondary antibodies coupled to horseradish
peroxidase (1:10000). Detection was performed with Immobilon Western Blotting de-
tection reagent (GE Healthcare).
6.10 Ciclohexamide chase
U2OS mYFP-MacroD2 full-length + mCherry-H2B cells were plated in two 6-well
plates (TPP) with 300000 cells per well. On the next day, ciclohexamide (300 µg mL-1)
was added in all the wells, but the two control wells with ethanol only. After one hour,
the timepoint 0 cells were collected and placed on ice. In the meantime, the chase
was started by adding DMSO or etoposide (10 µM) in either of the two plates. Then,
following timepoints were collected at the times: 45 minutes, 2 hours, 4 hours, 24 hours.
Also the control with ethanol was collected at 24 hours.
All the samples were prepared with RIPA buffer, as described before. For the
western blot, anti-GFP (1:1000) and anti-actin (1:5000) were used. The different signal
bands were quantified. The signal of the GFP band was normalized over the actin band
and each time point was normalized over time 0. The ratios were then averaged and
analyzed with unpaired non-parametrical Mann-Whitney.
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6.11 Affinity-purification of anti-MacroD2 serum
Column buffer
100 mM NaHCO3, pH 8.3
500 mM NaCl
Acid buffer
100 mM acetate, pH 4.0
500 mM NaCl
Basic buffer
100 mM Tris, pH 8.0
500 mM NaCl
Loading buffer
10 mM Tris, pH 7.5
1mM PMSF
Washing buffer
10 mM Tris, pH 7.5
500 mM NaCl
This protocol has been provided by Dr. D. Mokranjac. Firstly, the purified 6His-
TEV-V5-MacroD2 macrodomain (1-243) was digested by a TEV protease during the
first dialysis over night. Afterwards, the protein was further purified by mean of a
size-exclusion column loaded on the FPLC. 5 mg of V5-MacroD2 macrodomain (1-
243) was then dyalized into column buffer by means of a PD-10 column (17-0851-01;
GE-Healthcare).
For the preparation of the resin, CNBr-Sepharose 4B beads powder (GE Healthcare)
was used. The powder was incubated for 30 minutes with 1 mM HCl, for hydration.
Further washes were performed with 1 mM HCl. Afterwards, the beads were transfered
into a disposable plastic column (Bio-Rad). The protein solution was added, a part
from an aliquot that works as input for the coupling efficiency. The column was then
rolled for 1 hour at room temperature. Unbound material was collected for checks of the
coupling efficiency. The column was then washed with column buffer and the remaining
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active groups were blocked by loading 1M ethanolamine pH 8.0. The ethanolamine was
incubated for 2 hours at room temperature. Then, the column was washed with three
cycles of two buffers at different pH: acetate at pH 4.0 and Tris at pH 8.0. Lastly, the
columns is washed with 0.05% NaN3 and stored at 4
◦C.
For the affinity-purification, the column was equilibrated with 10 mM Tris, pH 7.5.
The serum was prepared by diluting it with the loading buffer (6 mL + 24 mL). Then,
the diluted serum was loaded onto the column. The flow-through was collected to test
the purification efficiency. The column was then washed with 10 mM Tris, pH 7.5 and
with the washing buffer. Finally, the elution consisted with three steps.
• 0.1 M citrate buffer, pH 4.0
• 0.1 M glycine buffer, pH 2.5
For each of these two elution steps, 1 mL fractions were collected and immediately
neutralized with 100 µL 1 M Tris, pH 8.8. Then, the column was equilibrated with 0.1
M Tris, pH 8.8 and prepared for the third elution.
• 0.1 M phosphate buffer, pH 12.5
Aso in this case, the 1 mL fractions were collected and immediately neutralized with
100 µL 1 M glycine, pH 2.0.
For further usage, the column was washed with 0.1 M Tris, pH 8.8, then washed
and stored with 0.05% NaN3 at 4
◦C.
6.12 Protein purification
Lysis/wash buffer
50 mM Tris-Cl, pH 7.5
500 mM NaCl
20 mM imidazole
1mM DDT
protease inhibitor cocktail (Roche)
Elution buffer
50 mM Tris-Cl, pH 7.5
500 mM NaCl
500 mM imidazole
1mM DDT
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protease inhibitor cocktail (Roche)
Storage buffer
25 mM Tris-Cl, pH 7.5
250 mM NaCl
1 mM DTT
For His-tagged proteins, protein expression constructs were expressed in E. coli Rosetta
(DE3)pLysS cells at 18 ◦C for 16 hours after 0.2 mM IPTG induction. Cell pellets were
snap-frozen in liquid nitrogen and stored at -80 ◦C.
For histidine-tagged protein purification, the thawed pellet was resuspended in a
lysis/wash buffer. Lysates were sonicated for 20 x 18 seconds at medium setting (Bran-
son) until the lysate was not viscous and centrifuged for 45 minutes at ∼45,000 g at
4 ◦C.
The supernatant was exposed to a column with Ni-NTA agarose (Qiagen), washed
3 times with 30 mL wash buffer and eluted with 5 mL the elution buffer. The proteins
were dialyzed in storage buffer with either dialysis membranes (ZelluTrans - Roth;
MWCO 3500) over-night or PD-10 columns (17-0851-01; GE-Healthcare).
Peak fractions were confirmed by SDS-PAGE and Coomassie staining. Concentra-
tions were determined by Bradford assay (Biorad).
For GST-tagged protein purification, the procedure was as above, with the exception
that no imidazole was used, glutathione Sepharose 4 Fast Flow (GE-Healthcare) was
used as column resin and 20 mM reduced-glutathione elution buffer (GE Healthcare)
was used.
6.13 Experimental determination of MacroD2 secondary
structure composition
6His-TEV-MacroD2 full-length, 6His-TEV-V5-MacroD2 macrodomain (aa 1-234) and
6His-TEV-MacroD2 C-terminus (aa 244-448) proteins were purified as previously ex-
plained with the Ni-NTA agarose (Quiagen). Upon dialysis into storage buffer, proteins
were digested over-night with a TEV protease to remove the His-tag. Then, with the
help of G. Jankevicius and A. Bowman, the proteins were further purified by mean of
a size-exclusion column loaded on the FPLC.
The proteins were successively dyalized with 20 mM phosphate buffer (pH 7.3). For
the circular dichroism test, a sample of each protein at the concentration of 5 µM was
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used by Dr. F. Kamp for the run of the machine.
6.14 Kinase assay on MacroD2 fragments
Lysis buffer
25 mM Tris-Cl, pH 7.5
150 mM NaCl
0.5% NP-40
phosphatase inhibitor cocktail (PhosSTOP - Roche)
protease inhibitor cocktail (Roche)
Dilution buffer
25 mM Tris-Cl, pH 7.5
150 mM NaCl
0.01% NP-40
phosphatase inhibitor cocktail (PhosSTOP - Roche)
protease inhibitor cocktail (Roche)
Washing buffer
25 mM Tris-Cl, pH 7.5
500 mM NaCl
0.01% NP-40
phosphatase inhibitor cocktail (PhosSTOP - Roche)
protease inhibitor cocktail (Roche)
The purified proteins His-mEGFP-MacroD2 C-terminal (aa236-448) fragment (5 µg
(200 pmol) per sample); GST-mEGFP-tagged MacroD2 (aa382-418) fragment (52 µg (1
nmol) per sample) and His-mEGFP-tagged MacroD2 (aa382-418) fragments (wild-type
and mutants) (35 µg (1 nmol) per sample) were used.
HEK293 Flp-InTM T-RExTM cells (ThermoFisher) were collected on ice. Cells were
resuspended in lysis buffer, then incubated on ice for 30 minutes while mechanically
lysed by syringe. Where appropriate, KU55933 at the final concentration of 10 µM was
added. The cell lysate was then supplemented with 250 U Benzonase nuclease (Sigma),
MgCl2 to a final concentration of 4 mM and 2 µCi (32P)γATP (FP-301 Hartmann
Analytic).
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The lysate was incubated at 37 ◦C for 40 minutes. It was then cleared from the
chromatin with a maximum speed centrifugation, diluted by 1:5 with dilution buffer
and the input was kept. Proper amounts of GFP-trap (Chromotek), previously washed
with lysis:dilution buffer, were incubated with the supernatant for 1 hour at 4 ◦C with
agitation. The beads were then washed two times with lysis:dilution buffer and once
with washing buffer. Input and beads were boiled for 10 minutes at 95 ◦C in equal
amounts of 2x SDS protein sample loading buffer. Beads were centrifuged for 10 minutes
at maximum speed, in order to break the beads apart and release all the protein.
Samples were separated on 1 mm Bis-Tris, 4-12 % acrylamide NuPAGE gel according to
the manufacturers protocol (Invitrogen). the gel was stained with Coomassie Brilliant
blue and imaged (ImageScanner III GE Healthcare). Afterwards, the gel was destained,
dried for two hours with high temperature and exposed to imaging plates (Fuji Film).
Quantification for the kinase assay on purified C-terminal fragments was performed
by defining the intensity of every band in both the Coomassie staining and in the
autoradiography. In each case, the band signal was subtracted of the background sig-
nal present along the lane. Then, the autoradiography signal was normalized to the
Coomassie staining signal, defining per each band the ratio radioactive signal/amount.
The ratios from three different experiments were then averaged. Similarly, the quantifi-
cation for the kinase assay on purified mutant MacroD2 fragments was performed by
defining the intensity of every band and their ratio radioactive signal/coomassie signal,
as described above. Each His-construct intensity was then subtracted of the resid-
ual intensity in the His-S415A mutant, whose radioactivity signal is generated by the
degradation of the upper wild-type-containing band, when the GST-tag is lost. Then,
the adjusted His-construct intensities were normalized to the GST-construct intensity
of the same lane, normalized to the wild-type/wild-type ratio and averaged.
6.15 Phospho-peptide enrichment upon DNA damage
Lysis buffer
25 mM Tris-Cl, pH 7.5
150 mM NaCl
0.5% NP-40
10 mM NaF
1 mM Na3VO4
phosphatase inhibitor cocktail (PhosSTOP - Roche)
protease inhibitor cocktail (Roche)
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Dilution buffer
25 mM Tris-Cl, pH 7.5
150 mM NaCl
0.01% NP-40
10 mM NaF
1 mM Na3VO4
phosphatase inhibitor cocktail (PhosSTOP - Roche)
protease inhibitor cocktail (Roche)
Washing buffer
25 mM Tris-Cl, pH 7.5
500 mM NaCl
0.01% NP-40
10 mM NaF
1 mM Na3VO4
phosphatase inhibitor cocktail (PhosSTOP - Roche)
protease inhibitor cocktail (Roche)
Storage buffer
PBS
100 mM NaF
10 mM Na3VO4
phosphatase inhibitor cocktail (PhosSTOP Roche)
protease inhibitor cocktail (Roche)
Human U2OS cell lines stably expressing mYFPMacroD2 full length+mCherry-H2B
were treated with etoposide 5 M or DMSO for one hour. Cells were then collected on ice
and treated with lysis buffer. Lysates were than diluted 1:5 with dilution buffer. After
vigorous centrifugation, the supernatant was collected and the input was kept. Proper
amounts of GFP-trap (Chromotek), previously washed with lysis:dilution buffer, were
incubated with the supernatant for 1 hour at 4 ◦C with agitation. The beads were then
washed two times with lysis:dilution buffer and once with washing buffer. Beads were
then kept in storage buffer.
Further preparation, run of the machine and data analysis performed by Dr. An-
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dreas Schmidt. Proteins bound to beads were treated with 5 mM DTT to reduce
disulfide bonds and subsequently alkylated using 20 mM iodoacetamide. Proteins were
cleaved with AspN for 12 hours at 25 ◦C. Following proteolytic digest, peptide mixtures
were desalted on reverse-phase C18 stage tips. 90% of the peptide mixture was mixed
with 2 M glycolic acid for phosphopeptide enrichment on TiO2 as described in (407),
then loaded onto the prepared TiO2 resin (Glygen).
Eluted phosphopeptide mixtures and peptide mixtures were separated on an Ul-
timate 3000 nano-RP-HPLC coupled to an LTQ-Orbitrap mass spectrometer (both
Thermo-Fisher). The mass spectrometer was operated in data-dependent acquisition
mode with one survey scan for precursor mass detection and up to 6 MS/MS experi-
ments per cycle. CID-MS/MS experiments were conducted with multi-stage activation
for neutral loss masses of 32.7, 49 and 98. For MS acquisition, monoisotopic precursor
selection and dynamic exclusion for 30 seconds were enabled.
Raw data were searched with MaxQuant vs. 1.5 against a human protein database
(Uniprot, May 2015) and an in-house target database containing common target protein
and contaminants. All phosphopeptide hits for the MacroD2 were manually curated.
To quantify the phosphorylation, peak areas for the most abundant charged states for
unmodified peptides and phosphopeptides of the target protein were extracted from the
raw data of the tryptic peptide mixture before phosphopeptide enrichment and log2
normalized. Signal strength of unmodified peptides was used for normalization of the
protein amount between control and treatment experiments of each biological replicate.
6.16 Interaction assays with 14-3-3 proteins
6.16.1 14-3-3 proteins purification
All the expression plasmid of GST-14-3-3 proteins were purchased via Addgene. For
some of them, some mutagenesis steps were necessary to reproduce the sequence an-
notated on Uniprot. The GST-14-3-3 tagged proteins were purified according to the
protocol described before (see Methods 6.12), with the additional step of the size-
exclusion column purification. Proteins were stored in storage buffer.
6.16.2 Pull-down with biotinilated-MacroD2 peptides
Dilution buffer
25 mM Tris-Cl, pH 7.5
150 mM NaCl
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0.01% NP-40
phosphatase inhibitor cocktail (PhosSTOP - Roche)
protease inhibitor cocktail (Roche)
Washing buffer
25 mM Tris-Cl, pH 7.5
500 mM NaCl
0.01% NP-40
phosphatase inhibitor cocktail (PhosSTOP - Roche)
protease inhibitor cocktail (Roche)
Peptides were ordered from Metabion.
1. Biotin - G S L S Q R Q R S T S T P N V H (Control peptide - unphosphorylated)
2. Biotin - G S L S Q R Q R S T pS T P N V H (Control peptide - phosphorylated)
3. Biotin - N T P G P D V E M N S Q V D K V
4. Biotin - N T P G P D V E M N pS Q V D K V
5. Biotin - N T P G P D V E A N S Q V D K V
6. Biotin - N T P G P D V E A N pS Q V D K V
Peptides were dissolved following the instruction given by the manufacturer: 1 and 2
were dissolved in water; the other peptides were dissolved in 20% acetonitrile. Also,
to avoid the oxidation of the methionine, water and acetonitrile used for dissolve the
peptides have been previously insuﬄated with N2. All peptides were dissolved with a
concentration of 1 mg mL-1.
The peptides were then conjugated to Streptavidin Sepharose High Performance
(Sigma). 100 µg of peptide were resuspended in 400 µL PBS. In the meantime, 400 µL
of beads was washed three times with PBS + 0.1% NP-40. The beads and the peptides
were then combined and incubated on rotation over night at 4 ◦C. On the next day,
the beads were washed three times with PBS + 0.1% NP-40 to remove the unbound
peptide. The conjugated beads were then stored in PBS and kept at 4 ◦C.
Per each GST-tagged 14-3-3 recombinant protein, 2 µg of protein were resuspended
in in dilution buffer. To clear any precipitated protein from the solution, the samples
were centrifuged for 15 minutes at maximum speed and the supernatant was then
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transferred to a fresh tube. From the cleared supernatant, an aliquot was kept as
Input. At the same time, aliquots of 30 µL slurry conjugated beads were prepared and
washed three times in dilution buffer.
The protein solution was finally added to the conjugated beads and incubated with
rotation for 1 hour at 4 ◦C. Afterwards, beads were washed twice with dilution buffer
and once with washing buffer. Each sample with 15 µL beads had the supernatant
removed and was added with 20 µL 2x SDS protein sample loading buffer. The beads
were then boiled for 10 minutes at 95 ◦C and centrifuged for 10 minutes at maximum
speed, in order to break the beads apart and release all the protein.
Samples were separated on 12% acrylamide SDS-PAGE gel. For the western blot,
anti-GST (1:10) was used to probe the amount of GST-14-3-3 proteins purified by
means of the peptides.
6.16.3 Pull-down with purified MacroD2 fragments
Lysis buffer
25 mM Tris-Cl, pH 7.5
150 mM NaCl
0.5% NP-40
phosphatase inhibitor cocktail (PhosSTOP - Roche)
protease inhibitor cocktail (Roche)
Dilution buffer
25 mM Tris-Cl, pH 7.5
150 mM NaCl
0.01% NP-40
phosphatase inhibitor cocktail (PhosSTOP - Roche)
protease inhibitor cocktail (Roche)
Washing buffer
25 mM Tris-Cl, pH 7.5
500 mM NaCl
0.01% NP-40
phosphatase inhibitor cocktail (PhosSTOP - Roche)
protease inhibitor cocktail (Roche)
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The purified proteins His-mEGFP-MacroD2 C-terminal (aa236-448) fragment (2
µg) were used together with a selection of GST-14-3-3 proteins (,  K49E, ζ and β) (2
µg), with GST-EGFP as negative control. The same GST-14-3-3 proteins were used
for the next experiment, with the His-mEGFP-tagged MacroD2 (aa382-418) fragments
(wild-type, M413A and S415A) (7 µg).
HEK293 Flp-InTM T-RExTM cells (ThermoFisher) were collected on ice. Cells were
resuspended in lysis buffer, then incubated on ice for 30 minutes while mechanically
lysed by syringe. The cell lysate was then supplemented with 250 U Benzonase nuclease
(Sigma) and MgCl2 to a final concentration of 4 mM or only water as control.
The lysate was incubated at 37 ◦C for 40 minutes. It was then cleared from the chro-
matin with a maximum speed centrifugation, diluted by 1:5 with dilution buffer and the
input was kept. Proper amounts of glutathione Sepharose 4 Fast Flow (GE-Healthcare),
previously washed with lysis:dilution buffer, were incubated with the supernatant for 1
hour at 4 ◦C with agitation. The beads were then washed two times with lysis:dilution
buffer and once with washing buffer. Input and beads were boiled for 10 minutes at
95 ◦C in equal amounts of 2x SDS protein sample loading buffer. Samples were sep-
arated by 12% acrylamide SDS-PAGE gel. For the western blot, anti-GFP (1:1000)
was used to probe the amount of EGFP-MacroD2 fragments purified by means of the
GST-14-3-3 proteins.
6.16.4 Co-Immunopurification of 14-3-3 
HEK293 Flp-InTM T-RExTM stably expressing EGFP or EGFP-MacroD2 full-length
were plated and the recombinant protein expression was induced by 1mg/mL doxycy-
clin. On the next day, cells were treated for 1 hour with etoposide 10 µM and then
collected on ice. The whole cell extract was processed with RIPA buffer. In the mean-
time, aliquots of GFP-trap beads (Chromotek) were washed three times with RIPA
buffer. A part from the input aliquot, 5 mg of cell lysates were added to the beads
and incubated for 2 hours at 4 ◦C. Beads were then washed once with RIPA buffer and
twice with PBS.
Input and beads were boiled for 10 minutes at 95 ◦C in 2x SDS protein sample
loading buffer. The beads were centrifuged for 10 minutes at maximum speed, in order
to break the beads apart and release all the protein. 2.5% input and 25% beads were
loaded onto 12% acrylamide SDS-PAGE gel for separation. For the western blot, anti-
MacroD2 (1:1000) and anti-14-3-3  (1:1000) were used to interact the two perspective
interactors. Anti-GAPDH (1:10) was used as negative control for the pull-down.
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6.17 Co-immunopurification of MacroD2 interactome
6.17.1 Generation of cell lines
HEK293 Flp-InTM T-RExTM were used to generate the four cell lines:
• EGFP-MacroD2 full-length
• EGFP-MacroD2 macrodomain (aa 1-243)
• EGFP-MacroD2 C-terminus (aa 237-448)
• EGFP
HEK293 Flp-InTM T-RExTM were plated in 6-well plates, in order to have 80%
confluency on the next day. On the next day, cells were transfected with either pcDNA5-
FRT/TO-EGFP, pcDNA5-FRT/TO-EGFP-C1-MacroD2 (aa 1-448), pcDNA5-FRT/TO-
EGFP-C1-MacroD2 (aa 1-243) or pcDNA5-FRT/TO-EGFP-C1-MacroD2 (aa 237-448),
together with pOG44 Flippase in a 1:9 ratio. In one well, pmEGFP was used as positive
control for the transfection. The transfection was performed with the reagent Xfect
(Clontech), according to the manufacturer’s recommendations. On the next day, cells
from one well were plated into seven 150-cm2 dishes (TPP) in medium added with blas-
ticidin (15 µg mL-1) and hygromicin (100 µg mL-1). This strong dilution was meant to
have single colony formation in the big plates.
For two weeks, cells were grown in selecting medium, which was changed every three
days to restore the selecting capacity. After two weeks, 14 colonies were collected and
transfered into 96-well plates. As soon as cells became confluent, cells were transfered
into a support with greater surface, in order to amplify them. In each stage, slowest-
growing colonies were trashed. When reached the 6-well stage, colonies were plated
and induced with 1mg mL-1 doxycyclin. The next day, cells were collected and tested
by western blot (anti-GFP) to check for the correct size of the expressed construct.
Colonies were also screened for fluorescence intensity. The three colonies left for each
construct were then tested at the microscope for response to laser microirradiation. This
test was also performed before each biological replicate preparation. Only the colony
per each construct that was best performing for fluorescence intensity and growth rate
was used for the real experiment.
6.17.2 Co-immunopurification
Each experiment was performed in four biological replicates. The four cell lines de-
scribed above, HEK293 Flp-InTM T-RExTM expressing EGFP, EGFP-MacroD2 full-
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length, EGFP-MacroD2 macrodomain and EGFP-MacroD2 C-terminus, were grown in
normal medium, in two different plates. One day before the treatment and collection, all
cells were induced with 1 mg mL-1 doxycyclin. On the next day, EGFP-MacroD2 full-
length, macrodomain and C-terminus-expressing cells were treated either with DMSO
or etoposide 10 µM for 1 hour.
Cells were collected on ice, washed with PBS and treated with RIPA buffer, in order
to obtain the whole cell extract. In the meantime, aliquots of homemade GFP (for the
first replicate) or GFP-trap beads (Chromotek, for the second to fourth replicate) were
washed three times with RIPA buffer. A part from the input aliquot, 5 mg of cell
lysates were added to the beads and incubated for 2 hours at 4 ◦C.
1. EGFP
2. EGFP-MacroD2 full-length DMSO
3. EGFP-MacroD2 full-length etoposide
4. EGFP-MacroD2 macrodomain DMSO
5. EGFP-MacroD2 macrodomain etoposide
6. EGFP-MacroD2 C-terminus DMSO
7. EGFP-MacroD2 C-terminus etoposide
Beads were then washed once with RIPA buffer and twice with PBS. The samples
were than brought to Dr. Schmidt to perform the rest of the processing. Disulfide
bonds were reduced with dithioteitrol at 56 ◦C. Then, the free cysteines were alky-
lated with 10 mM iodoacetamide in 100 mM Tris, 6 M urea. The urea is added to
unfold the proteins and make them more accessible to both alkylation and following
digestion steps. Proteins are then pre-digested with Lys-C (200 ng/sample) at 30 ◦C
on rotation for 4 hours, in order to pre-cleave the proteins and remove the beads. Af-
ter centrifugation, the supernatant was transfered into a new vial and the beads were
washed two times with 100 mM ammonium bicarbonate. Each wash was added to the
above-mentioned supernatant, to collect all the proteins from the beads. The collected
proteins were then digested by trypsin (1 µg per sample) for 12 hours at 30 ◦C. The
output peptides of Lys-C and trypsin digestion are exactly the same, so that for in
silico peptide identification in the analysis, we could consider as only the trypsin have
been used.
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6.17.3 Mass spectrometry
After a desalting step, Dr. Schmidt performed the mass spectrometry run. Tryptic
protein digests were analyzed by nano-high performance liquid chromatography mass
spectrometry (HPLC-MS) on an Ultimate 3000 nanoLC system (Thermo-Fisher), cou-
pled to a quadrupole time-of-flight (qTOF) mass spectrometer 6600 Triple TOF (Sciex).
First, acidified peptides were injected onto a trapping column (5 x 0.3 mm) packed
with C18 material (Thermo-Fisher, Acclaim PepMap, 5 µm, 100 A˚) to remove salt and
chemicals applied during chromatography at a flow rate of 20 µL min-1 of 0.05% TFA
solution.
After the washing phase, peptides were separated on a nano-RP-C18 column (Thermo-
Fisher, Acclaim PepMap, 250 x 0.075 mm x 2.4 µm, 100 A˚) using a linear gradient from
4-35% ACN over a mixing time of 120 min. The column outlet was directly coupled
to the electrospray-source to introduce the peptides into the mass spectrometer. The
mass spectrometer was operated in data-dependent acquisition mode detecting peptides
eluting from the chromatography column in a survey scan from 300-2000 m/z. Up to
40 precursor signals were subjected to fragmentation analysis by collision-induced dis-
sociation per operation cycle of 3 seconds. Precursor ions which were fragmented in
previous cycles were excluded for 30 seconds to reduce re-analysis and obtain deeper
proteomic data.
6.17.4 Data analysis
Peptide identification was performed by mean of the Andromeda search engine inte-
grated in the MaxQuant software (408). All samples were mapped against a database
containing the amino acids sequences of human proteins (Uniprot, vs. Oct 2015). Com-
pared to the other three, the first biological replicate performed very poorly and was
then excluded from the analysis.
As intensities, a Max-Quant-embedded algorithm was used (379). For one protein,
iBAQ signal consists of the the sum of all the peptides intensities divided by the number
of theoretical peptides generated by the in silico digestion. For normalization of the
different samples, every iBAQ signal was divided by a coefficient defined per each
sample. To obtain the sample-specific coefficient, the peptides that are present in most
samples were identified. The median iBAQ for each sample was then calculated and
each median was normalized against the highest median value.
The normalized iBAQ signals of the different proteins were then filtered in order
to keep only those proteins that were present in all the biological replicate of one
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specific condition (for example, protein present in replicate 2, 3 and 4 for MacroD2
macrodomain DMSO were kept, even if missing in all others conditions). Then, in
place of the missing values, the iBAQ values were inputed by mean of a normal dis-
tribution. Successively, t-tests between different samples were performed. Each t-test
was performed by using 0.1 as minimal fold enrichment and 0.08 as false discovery
rate (FDR). For the full-length conditions, the enrichments were performed against the
EGFP negative control and the full-length fragment with the opposite treatment, for
a total of two enrichments per condition. For the macrodomain and C-terminus frag-
ments, the enrichments were performed against the EGFP negative control, the same
fragment with the opposite treatment and the opposite fragment in both treatment,
for a total of four enrichments per condition.
Having these series of enrichments, two protein list types were generated. The first
list, the common proteins, is generated by selecting the proteins shared by at least two
enrichments for the same condition. The second list is the pool of all the proteins found
enriched in all the enrichments of a condition. Each of the two lists was then analyzed by
means of the STRING database and its embedded software (http://string-db.org/).
The common lists were further checked for the amount of overlap, by means of the
Venny 2.1.0 (http://bioinfogp.cnb.csic.es/tools/venny/). The filtered common
lists were again analyzed with the STRING associated software.
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Lists of MacroD2 interactors
A.1 MacroD2 full-length DMSO protein list
Protein name Gene name
MacroD2 full-length DMSO over EGFP
Costars family protein ABRACL ABRACL
Apoptotic chromatin condensation inducer in the nucleus ACIN1
T-complex protein 1 subunit epsilon CCT5
Cx9C motif-containing protein 4 CMC4
Elongation factor 1-beta EEF1B2
Eukaryotic translation initiation factor 3 subunit K EIF3K
Fragile X mental retardation syndrome-related protein 1 FXR1
Heat shock 70 kDa protein 12A HSPA12A
Leucine-rich repeat-containing protein 59 LRRC59
O-acetyl-ADP-ribose deacetylase MACROD2 MACROD2
Microtubule-associated protein RP/EB family member 1 MAPRE1
Phosphatidylethanolamine-binding protein 1 PEBP1
Ran-specific GTPase-activating protein RANBP1
60S ribosomal protein L31 RPL31
40S ribosomal protein S10 RPS10
Tubulin-specific chaperone A TBCA
Treacle protein TCOF1
Nucleolysin TIAR TIAL1
MacroD2 full-length DMSO over full-length etoposide
Continues on next page
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Table A.1 – Continued from previous page
Protein name Gene name
Aminoacyl tRNA synthase complex-interacting protein 2 AIMP2
ATPase family AAA domain-containing protein 3A ATAD3A
Calmodulin-like protein 5 CALML5
Cystathionine beta-synthase CBS
Eukaryotic translation initiation factor 3 subunit C EIF3C
Eukaryotic translation initiation factor 3 subunit K EIF3K
Guanine nucleotide-binding protein (...) subunit beta-1 GNB1
Histone H2A.V H2AFV
Histone H2A type 1-J HIST1H2AJ
Galectin-7 LGALS7
NF-kappa-B-activating protein NKAP
Poly(U)-binding-splicing factor PUF60 PUF60
RNA-binding protein 3 RBM3
Iporin RUSC2
Ubiquitin carboxyl-terminal hydrolase 5 USP5
Table A.1: MacroD2 full-length DMSO - Overview of enriched proteins in MacroD2
full-length DMSO sample, when compared with EGFP and MacroD2 full-length etoposide
samples.
Protein name Gene name
MacroD2 full-length DMSO common proteins
Eukaryotic translation initiation factor 3 subunit K EIF3K
Table A.2: MacroD2 full-length DMSO, common proteins - Overview of the pro-
teins that are in common among the different “MacroD2 full-length DMSO” enrichments.
A.2 MacroD2 full-length etoposide protein list
Protein name Gene name
MacroD2 full-length etoposide over EGFP
Apoptotic chromatin condensation inducer in the nucleus ACIN1
Continues on next page
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Table A.3 – Continued from previous page
Protein name Gene name
Sodium/potassium-transporting ATPase (...) alpha-1 ATP1A1
Cx9C motif-containing protein 4 CMC4
Elongation factor 1-beta EEF1B2
Protein FAM98A FAM98A
Leucine zipper putative tumor suppressor 3 LZTS3
O-acetyl-ADP-ribose deacetylase MACROD2 MACROD2
Microtubule-associated protein RP/EB family member 1 MAPRE1
28S ribosomal protein S23 (mitochondrial) MRPS23
Myotrophin MTPN
Phosphatidylethanolamine-binding protein 1 PEBP1
Proteasome subunit alpha type-6 PSMA6
RNA-binding protein 26 RBM26
60S ribosomal protein L31 RPL31
40S ribosomal protein S10 RPS10
Splicing factor 3B subunit 5 SF3B5
Sorting nexin-9 SNX9
Spermidine synthase SRM
Single-stranded DNA-binding protein (mitochondrial) SSBP1
Thyroid receptor-interacting protein 6 TRIP6
Tumor susceptibility gene 101 protein TSG101
MacroD2 full-length etoposide over full-length DMSO
Leucine zipper putative tumor suppressor 3 LZTS3
Myotrophin MTPN
Ornithine aminotransferase (mitochondrial) OAT
RNA-binding protein Raly RALY
RNA-binding protein 26 RBM26
Splicing factor 3B subunit 5 SF3B5
Serine hydroxymethyltransferase (mitochondrial) SHMT2
Sorting nexin-9 SNX9
Single-stranded DNA-binding protein (mitochondrial) SSBP1
Thyroid receptor-interacting protein 6 TRIP6
Tubulin beta-2B chain TUBB2B
Table A.3: MacroD2 full-length etoposide - Overview of enriched proteins in
MacroD2 full-length etoposide sample, when compared with EGFP and MacroD2 full-
length DMSO samples.
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Protein name Gene name
EGFP-MacroD2 full-length etoposide common proteins
Leucine zipper putative tumor suppressor 3 LZTS3
Myotrophin MTPN
RNA-binding protein 26 RBM26
Splicing factor 3B subunit 5 SF3B5
Sorting nexin-9 SNX9
Single-stranded DNA-binding protein (mitochondrial) SSBP1
Thyroid receptor-interacting protein 6 TRIP6
Table A.4: MacroD2 full-length etoposide, common proteins - Overview of the
proteins that are in common among the different “MacroD2 full-length etoposide” enrich-
ments.
A.3 MacroD2 macrodomain DMSO protein list
Protein name Gene name
MacroD2 macrodomain DMSO over EGFP
ATP-citrate synthase ACLY
Acidic leucine-rich nuclear (...) 32 family member E ANP32E
Sodium/potassium-transporting ATPase (...) alpha-1 ATP1A1
Calreticulin CALR
T-complex protein 1 subunit epsilon CCT5
T-complex protein 1 subunit zeta CCT6A
T-complex protein 1 subunit eta CCT7
Chromatin target of PRMT1 protein CHTOP
Dihydrolipoyl dehydrogenase (mitochondrial) DLD
DnaJ homolog subfamily A member 1 DNAJA1
Aspartyl aminopeptidase DNPEP
Enoyl-CoA hydratase (mitochondrial) ECHS1
Elongation factor 1-beta EEF1B2
Eukaryotic translation initiation factor 2 subunit 1 EIF2S1
Eukaryotic peptide chain release factor subunit 1 ETF1
Peptidyl-prolyl cis-trans isomerase FKBP4 FKBP4
Fragile X mental retardation syndrome-related protein 1 FXR1
Glutathione S-transferase omega-1 GSTO1
Continues on next page
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Table A.5 – Continued from previous page
Protein name Gene name
Histidine triad nucleotide-binding protein 1 HINT1
Importin subunit beta-1 KPNB1
L-lactate dehydrogenase B chain LDHB
Protein ERGIC-53 LMAN1
Leucine-rich repeat-containing protein 59 LRRC59
O-acetyl-ADP-ribose deacetylase MACROD2 MACROD2
MARCKS-related protein MARCKSL1
39S ribosomal protein L12 (mitochondrial) MRPL12
Myosin light polypeptide 6 MYL6
Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase NOP2
tRNA (cytosine(34)-C(5))-methyltransferase NSUN2
Protein disulfide-isomerase P4HB
Proliferation-associated protein 2G4 PA2G4
28 kDa heat- and acid-stable phosphoprotein PDAP1
Programmed cell death protein 5 PDCD5
Phosphatidylethanolamine-binding protein 1 PEBP1
ATP-dependent 6-phosphofructokinase. platelet type PFKP
Prohibitin PHB
DNA-directed RNA polymerases I and III subunit RPAC1 POLR1C
DNA-directed RNA polymerase II subunit RPB3 POLR2C
26S proteasome non-ATPase regulatory subunit 7 PSMD7
RNA-binding protein Raly RALY
Ran-specific GTPase-activating protein RANBP1
RNA-binding protein 4 RBM4
60S ribosomal protein L31 RPL31
40S ribosomal protein S10 RPS10
40S ribosomal protein S14 RPS14
40S ribosomal protein S21 RPS21
RuvB-like 1 RUVBL1
SUMO-activating enzyme subunit 1 SAE1
Endophilin-A1 SH3GL2
Phosphate carrier protein (mitochondrial) SLC25A3
Staphylococcal nuclease domain-containing protein 1 SND1
Small nuclear ribonucleoprotein F SNRPF
Sorting nexin-9 SNX9
Superoxide dismutase [Cu-Zn] SOD1
Spermidine synthase SRM
Serine/arginine-rich splicing factor 5 SRSF5
Tubulin-specific chaperone A TBCA
Transcription elongation regulator 1 TCERG1
Nucleolysin TIAR TIAL1
Mitochondrial import inner (...) translocase TIM50 TIMM50
Continues on next page
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Table A.5 – Continued from previous page
Protein name Gene name
Transketolase TKT
Translation machinery-associated protein 16 TMA16
Thioredoxin domain-containing protein 5 TXNDC5
UBX domain-containing protein 1 UBXN1
14-3-3 protein beta/alpha YWHAB
14-3-3 protein zeta/delta YWHAZ
MacroD2 macrodomain DMSO over macrodomain etoposide
Multidrug resistance protein 3 ABCB4
Actin-like protein 6A ACTL6A
Acidic leucine-rich nuclear (...) 32 family member E ANP32E
Rho GDP-dissociation inhibitor 1 ARHGDIA
Sodium/potassium-transporting ATPase (...) alpha-1 ATP1A1
ATP synthase subunit gamma (mitochondrial) ATP5C1
ATPase inhibitor (mitochondrial) ATPIF1
BAG family molecular chaperone regulator 2 BAG2
Complement C1q tumor necrosis factor-related protein 8 C1QTNF8
Calreticulin CALR
T-complex protein 1 subunit theta CCT8
Corneodesmosin CDSN
Chromatin target of PRMT1 protein CHTOP
Density-regulated protein DENR
Dihydrolipoyl dehydrogenase (mitochondrial) DLD
Enoyl-CoA hydratase (mitochondrial) ECHS1
Emerin EMD
Peptidyl-prolyl cis-trans isomerase FKBP3 FKBP3
Peptidyl-prolyl cis-trans isomerase FKBP4 FKBP4
Protein FRG1 FRG1
Far upstream element-binding protein 1 FUBP1
Glutathione S-transferase omega-1 GSTO1
Histidine triad nucleotide-binding protein 1 HINT1
Ig alpha-2 chain C region IGHA2
Protein lin-7 homolog C LIN7C
Leucine-rich repeat-containing protein 59 LRRC59
Malate dehydrogenase (mitochondrial) MDH2
39S ribosomal protein L12 (mitochondrial) MRPL12
mRNA turnover protein 4 homolog MRTO4
Myotubularin-related protein 4 MTMR4
Myosin-10 MYH10
Myosin-9 MYH9
Myosin regulatory light chain 12A MYL12A
Continues on next page
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Table A.5 – Continued from previous page
Protein name Gene name
Nuclear autoantigenic sperm protein NASP
Protein disulfide-isomerase P4HB
Proliferation-associated protein 2G4 PA2G4
28 kDa heat- and acid-stable phosphoprotein PDAP1
Phosphatidylethanolamine-binding protein 1 PEBP1
Serine/threonine-protein phosphatase PGAM5 (mitochondrial) PGAM5
DNA-directed RNA polymerase II subunit RPB3 POLR2C
Peroxiredoxin-4 PRDX4
Phosphoribosyl pyrophosphate synthase-associated protein 2 PRPSAP2
GTP-binding nuclear protein Ran RAN
Arginine–tRNA ligase. cytoplasmic RARS
RNA-binding protein 4 RBM4
60S ribosomal protein L28 RPL28
60S ribosomal protein L37a RPL37A
40S ribosomal protein S23 RPS23
SUMO-activating enzyme subunit 1 SAE1
Endophilin-A1 SH3GL2
Staphylococcal nuclease domain-containing protein 1 SND1
U4/U6.U5 small nuclear ribonucleoprotein 27 kDa protein SNRNP27
Sorting nexin-9 SNX9
Spermidine synthase SRM
Serine/arginine-rich splicing factor 1 SRSF1
Serine/arginine-rich splicing factor 5 SRSF5
Stathmin STMN1
Suppressor of G2 allele of SKP1 homolog SUGT1
Transgelin-2 TAGLN2
Tubulin-specific chaperone A TBCA
Tubulin-folding cofactor B TBCB
Transcription elongation regulator 1 TCERG1
Nucleolysin TIAR TIAL1
Mitochondrial import inner (...) translocase subunit TIM50 TIMM50
Transketolase TKT
Transmembrane protein 178A TMEM178A
DNA topoisomerase 1 TOP1
Tubulin beta-2B chain TUBB2B
Ubiquitin-conjugating enzyme E2 S UBE2S
Cytochrome b-c1 complex subunit 1 (mitochondrial) UQCRC1
Voltage-dependent anion-selective channel protein 3 VDAC3
14-3-3 protein zeta/delta YWHAZ
MacroD2 macrodomain DMSO over C-terminus DMSO
Continues on next page
193
A. LISTS OF MACROD2 INTERACTORS
Table A.5 – Continued from previous page
Protein name Gene name
Acidic leucine-rich nuclear (...) 32 family member A ANP32A
Acidic leucine-rich nuclear (...) 32 family member E ANP32E
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 ATP2A2
T-complex protein 1 subunit zeta CCT6A
T-complex protein 1 subunit theta CCT8
Corepressor interacting with RBPJ 1 CIR1
DnaJ homolog subfamily A member 1 DNAJA1
Eukaryotic peptide chain release factor subunit 1 ETF1
Peptidyl-prolyl cis-trans isomerase FKBP1A FKBP1A
Guanine nucleotide-binding protein (...) subunit beta-1 GNB1
Histidine triad nucleotide-binding protein 1 HINT1
Ig alpha-2 chain C region IGHA2
Protein lin-7 homolog C LIN7C
Protein ERGIC-53 LMAN1
Prelamin-A/C;Lamin-A/C LMNA
mRNA turnover protein 4 homolog MRTO4
Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase NOP2
tRNA (cytosine(34)-C(5))-methyltransferase NSUN2
Phosphatidylethanolamine-binding protein 1 PEBP1
26S proteasome non-ATPase regulatory subunit 7 PSMD7
GTP-binding nuclear protein Ran RAN
Serine hydroxymethyltransferase (mitochondrial) SHMT2
U4/U6.U5 small nuclear ribonucleoprotein 27 kDa protein SNRNP27
Stathmin STMN1
Tubulin-specific chaperone A TBCA
Triosephosphate isomerase TPI1
Thioredoxin domain-containing protein 5 TXNDC5
Voltage-dependent anion-selective channel protein 3 VDAC3
14-3-3 protein zeta/delta YWHAZ
MacroD2 macrodomain DMSO over C-terminus etoposide
Acidic leucine-rich nuclear (...) 32 family member E ANP32E
BAG family molecular chaperone regulator 2 BAG2
Calmodulin CALM1
T-complex protein 1 subunit zeta CCT6A
Cleavage and polyadenylation specificity factor subunit 2 CPSF2
Putative ATP-dependent RNA helicase DHX30 DHX30
DnaJ homolog subfamily A member 1 DNAJA1
Emerin EMD
Far upstream element-binding protein 1 FUBP1
Glutamine synthetase GLUL
Continues on next page
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Protein name Gene name
Ig heavy chain V-III region KOL IGHV3-23
Prelamin-A/C LMNA
mRNA turnover protein 4 homolog MRTO4
Myosin-10 MYH10
Phosphatidylethanolamine-binding protein 1 PEBP1
Serine/threonine-protein phosphatase PP1-gamma (...) PPP1CC
Peroxiredoxin-4 PRDX4
26S proteasome non-ATPase regulatory subunit 4 PSMD4
Tyrosine-protein phosphatase non-receptor type 11 PTPN11
RNA-binding protein 4 RBM4
60S ribosomal protein L28 RPL28
U5 small nuclear ribonucleoprotein 200 kDa helicase SNRNP200
Serine/arginine-rich splicing factor 5 SRSF5
Transcription elongation regulator 1 TCERG1
Thioredoxin domain-containing protein 5 TXNDC5
UBX domain-containing protein 1 UBXN1
Cytochrome b-c1 complex subunit 1 (mitochondrial) UQCRC1
Table A.5: MacroD2 macrodomain DMSO - Overview of enriched proteins
in MacroD2 macrodomain DMSO sample, when compared with EGFP, MacroD2
macrodomain etoposide, MacroD2 C-terminus DMSO and MacroD2 C-terminus etoposide.
Protein name Gene name
MacroD2 macrodomain DMSO common proteins
Acidic leucine-rich nuclear (...) 32 family member E ANP32E
Sodium/potassium-transporting ATPase (...) alpha-1 ATP1A1
BAG family molecular chaperone regulator 2 BAG2
Calreticulin CALR
T-complex protein 1 subunit zeta CCT6A
T-complex protein 1 subunit theta CCT8
Chromatin target of PRMT1 protein CHTOP
Dihydrolipoyl dehydrogenase (mitochondrial) DLD
DnaJ homolog subfamily A member 1 DNAJA1
Enoyl-CoA hydratase (mitochondrial) ECHS1
Emerin EMD
Eukaryotic peptide chain release factor subunit 1 ETF1
Peptidyl-prolyl cis-trans isomerase FKBP4 FKBP4
Far upstream element-binding protein 1 FUBP1
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Glutathione S-transferase omega-1 GSTO1
Histidine triad nucleotide-binding protein 1 HINT1
Ig alpha-2 chain C region IGHA2
Protein lin-7 homolog C LIN7C
Protein ERGIC-53 LMAN1
Prelamin-A/C;Lamin-A/C LMNA
Leucine-rich repeat-containing protein 59 LRRC59
39S ribosomal protein L12 (mitochondrial) MRPL12
mRNA turnover protein 4 homolog MRTO4
Myosin-10 MYH10
Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase NOP2
tRNA (cytosine(34)-C(5))-methyltransferase NSUN2
Protein disulfide-isomerase P4HB
Proliferation-associated protein 2G4 PA2G4
28 kDa heat- and acid-stable phosphoprotein PDAP1
Phosphatidylethanolamine-binding protein 1 PEBP1
DNA-directed RNA polymerase II subunit RPB3 POLR2C
Peroxiredoxin-4 PRDX4
26S proteasome non-ATPase regulatory subunit 7 PSMD7
GTP-binding nuclear protein Ran RAN
RNA-binding protein 4 RBM4
60S ribosomal protein L28 RPL28
SUMO-activating enzyme subunit 1 SAE1
Endophilin-A1 SH3GL2
Staphylococcal nuclease domain-containing protein 1 SND1
U4/U6.U5 small nuclear ribonucleoprotein 27 kDa protein SNRNP27
Sorting nexin-9 SNX9
Spermidine synthase SRM
Serine/arginine-rich splicing factor 5 SRSF5
Stathmin STMN1
Tubulin-specific chaperone A TBCA
Transcription elongation regulator 1 TCERG1
Nucleolysin TIAR TIAL1
Mitochondrial import inner (...) translocase subunit TIM50 TIMM50
Transketolase TKT
Thioredoxin domain-containing protein 5 TXNDC5
UBX domain-containing protein 1 UBXN1
Cytochrome b-c1 complex subunit 1 (mitochondrial) UQCRC1
Voltage-dependent anion-selective channel protein 3 VDAC3
14-3-3 protein zeta/delta YWHAZ
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Table A.6 – Continued from previous page
Protein name Gene name
Table A.6: MacroD2 macrodomain DMSO, common proteins - Overview of the
proteins that are in common among the different “MacroD2 macrodomain DMSO” enrich-
ments.
A.4 MacroD2 macrodomain etoposide protein list
Protein name Gene name
MacroD2 macrodomain etoposide over EGFP
Acidic leucine-rich nuclear (...) 32 family member E ANP32E
Cx9C motif-containing protein 4 CMC4
Fragile X mental retardation syndrome-related protein 1 FXR1
Keratin. type I cytoskeletal 18 KRT18
Programmed cell death protein 6 PDCD6
60S ribosomal protein L31 RPL31
Survival of motor neuron-related-splicing factor 30 SMNDC1
MacroD2 macrodomain etoposide over macrodomain DMSO
Alpha-aminoadipic semialdehyde dehydrogenase ALDH7A1
Annexin A7 ANXA7
Calmodulin-like protein 5 CALML5
Coiled-coil domain-containing protein 80 CCDC80
Bifunctional coenzyme A synthase COASY
Coronin-1C CORO1C
dCTP pyrophosphatase 1 DCTPP1
DnaJ homolog subfamily C member 2 DNAJC2
Four and a half LIM domains protein 1 FHL1
Ras GTPase-activating protein-binding protein 2 G3BP2
Histone H2A type 1-J HIST1H2AJ
Heat shock 70 kDa protein 12A HSPA12A
Isocitrate dehydrogenase [NAD] subunit beta (mitochondrial) IDH3B
Keratin. type I cytoskeletal 18 KRT18
Keratin. type II cytoskeletal 6B KRT6B
Methylated-DNA–protein-cysteine methyltransferase MGMT
Poly [ADP-ribose] polymerase 1 PARP1
Proteasome subunit alpha type-3 PSMA3
SWI/SNF complex subunit SMARCC1 SMARCC1
Continues on next page
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Protein name Gene name
SWI/SNF-related (...) regulator of chromatin subfamily E 1 SMARCE1
Stomatin-like protein 2 (mitochondrial) STOML2
Nesprin-1 SYNE1
Vacuolar protein sorting-associated protein 28 homolog VPS28
MacroD2 macrodomain etoposide over C-terminus etoposide
Alpha-aminoadipic semialdehyde dehydrogenase ALDH7A1
Acidic leucine-rich nuclear (...) 32 family member B ANP32B
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 ATP2A2
T-complex protein 1 subunit delta CCT4
Putative ATP-dependent RNA helicase DHX30 DHX30
Enoyl-CoA hydratase (mitochondrial) ECHS1
Protein FAM98B FAM98B
Ras GTPase-activating protein-binding protein 2 G3BP2
Glutamine synthetase GLUL
Ig heavy chain V-III region KOL IGHV3-23
mRNA turnover protein 4 homolog MRTO4
Polyadenylate-binding protein 2 PABPN1
Poly [ADP-ribose] polymerase 1 PARP1
26S proteasome non-ATPase regulatory subunit 4 PSMD4
40S ribosomal protein S29 RPS29
Survival of motor neuron-related-splicing factor 30 SMNDC1
Signal recognition particle subunit SRP68 SRP68
Transcription elongation factor SPT5 SUPT5H
UBX domain-containing protein 1 UBXN1
Cytochrome b-c1 complex subunit 1 (mitochondrial) UQCRC1
Vacuolar protein sorting-associated protein 28 homolog VPS28
MacroD2 macrodomain etoposide over C-terminus DMSO
Acidic leucine-rich nuclear (...) 32 family member A ANP32A
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 ATP2A2
Coiled-coil domain-containing protein 80 CCDC80
dCTP pyrophosphatase 1 DCTPP1
Protein FAM98B FAM98B
Guanine nucleotide-binding protein (...) subunit beta-1 GNB1
Histidine triad nucleotide-binding protein 1 HINT1
Histone H2A type 1-J HIST1H2AJ
Keratin. type I cytoskeletal 18 KRT18
Prelamin-A/C;Lamin-A/C LMNA
Methylcrotonoyl-CoA carboxylase beta chain (mitochondrial) MCCC2
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Protein name Gene name
mRNA turnover protein 4 homolog MRTO4
Poly [ADP-ribose] polymerase 1 PARP1
Programmed cell death protein 6 PDCD6
26S proteasome non-ATPase regulatory subunit 7 PSMD7
Histone-binding protein RBBP7 RBBP7
Serine hydroxymethyltransferase (mitochondrial) SHMT2
SWI/SNF-related (...) regulator of chromatin subfamily E 1 SMARCE1
Survival of motor neuron-related-splicing factor 30 SMNDC1
Transcription elongation factor SPT5 SUPT5H
Nesprin-1 SYNE1
Vacuolar protein sorting-associated protein 28 homolog VPS28
Table A.7: MacroD2 macrodomain etoposide - Overview of enriched proteins
in MacroD2 macrodomain etoposide sample, when compared with EGFP, MacroD2
macrodomain DMSO, MacroD2 C-terminus etoposide and MacroD2 C-terminus DMSO.
Protein name Gene name
MacroD2 macrodomain etoposide common proteins
Alpha-aminoadipic semialdehyde dehydrogenase ALDH7A1
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 ATP2A2
Coiled-coil domain-containing protein 80 CCDC80
dCTP pyrophosphatase 1 DCTPP1
Protein FAM98B FAM98B
Ras GTPase-activating protein-binding protein 2 G3BP2
Histone H2A type 1-J HIST1H2AJ
Keratin. type I cytoskeletal 18 KRT18
mRNA turnover protein 4 homolog MRTO4
Poly [ADP-ribose] polymerase 1 PARP1
Programmed cell death protein 6 PDCD6
SWI/SNF-related (...) regulator of chromatin subfamily E 1 SMARCE1
Survival of motor neuron-related-splicing factor 30 SMNDC1
Transcription elongation factor SPT5 SUPT5H
Nesprin-1 SYNE1
Vacuolar protein sorting-associated protein 28 homolog VPS28
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Protein name Gene name
Table A.8: MacroD2 macrodomain etoposide, common proteins - Overview of
the proteins that are in common among the different “MacroD2 macrodomain etoposide”
enrichments.
A.5 MacroD2 C-terminus DMSO protein list
Protein name Gene name
MacroD2 C-terminus DMSO over EGFP
Uncharacterized protein C9orf43 C9orf43
Calnexin CANX
Cx9C motif-containing protein 4 CMC4
Dihydrolipoyl dehydrogenase (mitochondrial) DLD
Aspartyl aminopeptidase DNPEP
Elongation factor 1-beta EEF1B2
Eukaryotic translation initiation factor 3 subunit K EIF3K
Fragile X mental retardation syndrome-related protein 1 FXR1
Non-POU domain-containing octamer-binding protein NONO
Proliferation-associated protein 2G4 PA2G4
28 kDa heat- and acid-stable phosphoprotein PDAP1
Phosphatidylethanolamine-binding protein 1 PEBP1
60S ribosomal protein L31 RPL31
Protein SET SET
Splicing factor 1 SF1
U1 small nuclear ribonucleoprotein C SNRPC
Small nuclear ribonucleoprotein F SNRPF
Spermidine synthase SRM
Tubulin-specific chaperone A TBCA
Transcription elongation regulator 1 TCERG1
Translation machinery-associated protein 16 TMA16
NEDD8-conjugating enzyme Ubc12 UBE2M
MacroD2 C-terminus DMSO over C-terminus etoposide
Probable ATP-dependent RNA helicase DDX11 DDX11
Eukaryotic translation initiation factor 3 subunit K EIF3K
Far upstream element-binding protein 1 FUBP1
Ig heavy chain V-III region KOL IGHV3-23
Continues on next page
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Protein name Gene name
Serine/threonine-protein phosphatase PP1-gamma (...) PPP1CC
RNA-binding protein 4 RBM4
Transcription elongation regulator 1 TCERG1
Tubulin alpha-1C chain TUBA1C
UBX domain-containing protein 1 UBXN1
MacroD2 C-terminus DMSO over macrodomain DMSO
Uncharacterized protein C9orf43 C9orf43
Bifunctional coenzyme A synthase COASY
Probable ATP-dependent RNA helicase DDX11 DDX11
Protein FAM133B FAM133B
Heterogeneous nuclear ribonucleoprotein H2 HNRNPH2
LanC-like protein 2 LANCL2
Methylated-DNA–protein-cysteine methyltransferase MGMT
Polymerase delta-interacting protein 3 POLDIP3
Pre-mRNA-splicing factor 38B PRPF38B
Splicing factor 1 SF1
U1 small nuclear ribonucleoprotein C SNRPC
MacroD2 C-terminus DMSO over macrodomain etoposide
Rho GDP-dissociation inhibitor 1 ARHGDIA
Probable ATP-dependent RNA helicase DDX11 DDX11
Density-regulated protein DENR
Isochorismatase domain-containing protein 2 (mitochondrial) ISOC2
39S ribosomal protein L12 (mitochondrial) MRPL12
Myotubularin-related protein 4 MTMR4
28 kDa heat- and acid-stable phosphoprotein PDAP1
Arginine–tRNA ligase (cytoplasmic) RARS
RNA-binding protein 4 RBM4
Splicing factor 1 SF1
U1 small nuclear ribonucleoprotein C SNRPC
Spermidine synthase SRM
Tubulin-specific chaperone A TBCA
Transcription elongation regulator 1 TCERG1
Nucleolar protein of 40 kDa ZCCHC17
Zinc finger CCHC domain-containing protein 3 ZCCHC3
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Table A.9: MacroD2 C-terminus DMSO - Overview of enriched proteins in MacroD2
C-terminus DMSO sample, when compared with EGFP, MacroD2 C-terminus etoposide,
MacroD2 macrodomain DMSO and MacroD2 macrodomain etoposide.
Protein name Gene name
MacroD2 C-terminus DMSO common proteins
Uncharacterized protein C9orf43 C9orf43
Probable ATP-dependent RNA helicase DDX11 DDX11
Eukaryotic translation initiation factor 3 subunit K EIF3K
28 kDa heat- and acid-stable phosphoprotein PDAP1
RNA-binding protein 4 RBM4
Splicing factor 1 SF1
U1 small nuclear ribonucleoprotein C SNRPC
Spermidine synthase SRM
Tubulin-specific chaperone A TBCA
Transcription elongation regulator 1 TCERG1
Table A.10: MacroD2 C-terminus DMSO, common proteins - Overview of the
proteins that are in common among the different “MacroD2 C-terminus DMSO” enrich-
ments.
A.6 MacroD2 C-terminus etoposide protein list
Protein name Gene name
MacroD2 C-terminus etoposide over EGFP
Fructose-bisphosphate aldolase A ALDOA
Calreticulin CALR
T-complex protein 1 subunit epsilon CCT5
Chromatin target of PRMT1 protein CHTOP
Spliceosome RNA helicase DDX39B DDX39B
Dihydrolipoyl dehydrogenase. mitochondrial DLD
Enoyl-CoA hydratase. mitochondrial ECHS1
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Eukaryotic peptide chain release factor subunit 1 ETF1
Fatty acid-binding protein. epidermal FABP5
Protein FAM98A FAM98A
Peptidyl-prolyl cis-trans isomerase FKBP4 FKBP4
Glutathione S-transferase omega-1 GSTO1
Heat shock 70 kDa protein 12A HSPA12A
Importin subunit beta-1 KPNB1
Protein ERGIC-53 LMAN1
Leucine-rich repeat-containing protein 59 LRRC59
Leucine zipper putative tumor suppressor 3 LZTS3
Microtubule-associated protein RP/EB family member 1 MAPRE1
DNA helicase MCM9 MCM9
Myotrophin MTPN
Phosphatidylethanolamine-binding protein 1 PEBP1
DNA-directed RNA polymerase II subunit RPB3 POLR2C
Proteasome subunit alpha type-6 PSMA6
Ran-specific GTPase-activating protein RANBP1
Histone-binding protein RBBP4 RBBP4
Replication protein A 32 kDa subunit RPA2
Ribosomal RNA processing protein 1 homolog B RRP1B
Staphylococcal nuclease domain-containing protein 1 SND1
U1 small nuclear ribonucleoprotein A SNRPA
Small nuclear ribonucleoprotein F SNRPF
Superoxide dismutase [Cu-Zn] SOD1
Spectrin beta chain. non-erythrocytic 1 SPTBN1
Spermidine synthase SRM
Lupus La protein SSB
Single-stranded DNA-binding protein (mitochondrial) SSBP1
Tubulin-specific chaperone A TBCA
Transketolase TKT
Translation machinery-associated protein 16 TMA16
Cellular tumor antigen p53 TP53
NEDD8-conjugating enzyme Ubc12 UBE2M
MacroD2 C-terminus etoposide over C-terminus DMSO
Eukaryotic peptide chain release factor subunit 1 ETF1
Peptidyl-prolyl cis-trans isomerase FKBP1A FKBP1A
Guanine nucleotide-binding protein (...) subunit beta-2 GNB2
Heat shock 70 kDa protein 12A HSPA12A
Protein lin-7 homolog C LIN7C
Protein ERGIC-53 LMAN1
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28S ribosomal protein S22. mitochondrial MRPS22
Membrane-associated progesterone receptor component 1 PGRMC1
Proteasome subunit alpha type-6 PSMA6
U4/U6.U5 small nuclear ribonucleoprotein 27 kDa protein SNRNP27
Spermidine synthase SRM
Single-stranded DNA-binding protein (mitochondrial) SSBP1
MacroD2 C-terminus etoposide over macrodomain etoposide
Rho GDP-dissociation inhibitor 1 ARHGDIA
ATP synthase subunit gamma (mitochondrial) ATP5C1
ATPase inhibitor (mitochondrial) ATPIF1
Complement C1q tumor necrosis factor-related protein 8 C1QTNF8
Calreticulin CALR
Corneodesmosin CDSN
Chromatin target of PRMT1 protein CHTOP
Enoyl-CoA hydratase (mitochondrial) ECHS1
Eukaryotic translation initiation factor 1A. X-chromosomal EIF1AX
Peptidyl-prolyl cis-trans isomerase FKBP3 FKBP3
Peptidyl-prolyl cis-trans isomerase FKBP4 FKBP4
Guanine nucleotide-binding protein G(s) subunit alpha GNAS
Guanine nucleotide-binding protein (...) subunit beta-2 GNB2
Heterogeneous nuclear ribonucleoprotein H2 HNRNPH2
Heat shock protein beta-1 HSPB1
Isochorismatase domain-containing protein 2 (mitochondrial) ISOC2
Protein lin-7 homolog C LIN7C
Protein ERGIC-53 LMAN1
Microtubule-associated protein RP/EB family member 1 MAPRE1
28S ribosomal protein S22. mitochondrial MRPS22
Myotrophin MTPN
Myosin regulatory light chain 12A MYL12A
Cytosolic Fe-S cluster assembly factor NARFL NARFL
Proliferating cell nuclear antigen PCNA
Phosphatidylethanolamine-binding protein 1 PEBP1
Serine/threonine-protein phosphatase PGAM5 (mitochondrial) PGAM5
DNA-directed RNA polymerase II subunit RPB3 POLR2C
Peroxiredoxin-4 PRDX4
Histone-binding protein RBBP4 RBBP4
Replication protein A 32 kDa subunit RPA2
60S ribosomal protein L35a RPL35A
60S ribosomal protein L38 RPL38
SUMO-activating enzyme subunit 1 SAE1
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Staphylococcal nuclease domain-containing protein 1 SND1
U4/U6.U5 small nuclear ribonucleoprotein 27 kDa protein SNRNP27
Spectrin alpha chain. non-erythrocytic 1 SPTAN1
Spermidine synthase SRM
Serine/arginine-rich splicing factor 1 SRSF1
Single-stranded DNA-binding protein (mitochondrial) SSBP1
Suppressor of G2 allele of SKP1 homolog SUGT1
Transgelin-2 TAGLN2
Tubulin-specific chaperone A TBCA
Transketolase TKT
Cellular tumor antigen p53 TP53
Tumor susceptibility gene 101 protein TSG101
Voltage-dependent anion-selective channel protein 3 VDAC3
Zinc finger CCHC domain-containing protein 3 ZCCHC3
MacroD2 C-terminus etoposide over macrodomain DMSO
Annexin A7 ANXA7
Arginase-1 ARG1
Corneodesmosin CDSN
Coronin-1C CORO1C
Desmocollin-1 DSC1
Protein FAM133B FAM133B
Heat shock 70 kDa protein 12A HSPA12A
Leucine zipper putative tumor suppressor 3 LZTS3
Methylated-DNA–protein-cysteine methyltransferase MGMT
Myosin regulatory light chain 12A MYL12A
PITH domain-containing protein 1 PITHD1
DNA-directed RNA polymerase II subunit RPB3 POLR2C
Histone-binding protein RBBP4 RBBP4
Replication protein A 32 kDa subunit RPA2
Staphylococcal nuclease domain-containing protein 1 SND1
Stomatin-like protein 2 (mitochondrial) STOML2
Transgelin-2 TAGLN2
Zinc finger CCHC domain-containing protein 3 ZCCHC3
Table A.11: MacroD2 C-terminus etoposide - Overview of enriched proteins in
MacroD2 C-terminus etoposide sample, when compared with EGFP, MacroD2 C-terminus
DMSO, MacroD2 macrodomain etoposide and MacroD2 macrodomain DMSO.
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Protein name Gene name
MacroD2 C-terminus etoposide common proteins
Calreticulin CALR
Corneodesmosin CDSN
Chromatin target of PRMT1 protein CHTOP
Enoyl-CoA hydratase (mitochondrial) ECHS1
Eukaryotic peptide chain release factor subunit 1 ETF1
Peptidyl-prolyl cis-trans isomerase FKBP4 FKBP4
Guanine nucleotide-binding protein (...) subunit beta-2 GNB2
Heat shock 70 kDa protein 12A HSPA12A
Protein lin-7 homolog C LIN7C
Protein ERGIC-53 LMAN1
Leucine zipper putative tumor suppressor 3 LZTS3
Microtubule-associated protein RP/EB family member 1 MAPRE1
28S ribosomal protein S22. mitochondrial MRPS22
Myotrophin MTPN
Myosin regulatory light chain 12A MYL12A
Phosphatidylethanolamine-binding protein 1 PEBP1
DNA-directed RNA polymerase II subunit RPB3 POLR2C
Proteasome subunit alpha type-6 PSMA6
Histone-binding protein RBBP4 RBBP4
Replication protein A 32 kDa subunit RPA2
Staphylococcal nuclease domain-containing protein 1 SND1
U4/U6.U5 small nuclear ribonucleoprotein 27 kDa protein SNRNP27
Spermidine synthase SRM
Single-stranded DNA-binding protein (mitochondrial) SSBP1
Transgelin-2 TAGLN2
Tubulin-specific chaperone A TBCA
Transketolase TKT
Cellular tumor antigen p53 TP53
Zinc finger CCHC domain-containing protein 3 ZCCHC3
Table A.12: MacroD2 C-terminus etoposide, common proteins - Overview of
the proteins that are in common among the different “MacroD2 C-terminus etoposide”
enrichments.
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Appendix B
Lists of enriched biological terms
B.1 MacroD2 full-length DMSO
The list for the enrichment of biological terms for all proteins of “MacroD2 full-length
DMSO” is enlisted below (Table B.1).
Category Term FDR
GO.0044822 poly(A) RNA binding 1.95E-05
GO.0003723 RNA binding 2.61E-05
GO.0043230 extracellular organelle 0.00688
GO.0065010 extracellular membrane-bounded organelle 0.00688
GO.0070062 extracellular exosome 0.00688
GO.1903561 extracellular vesicle 0.00688
GO.0005852 eukaryotic translation initiation factor 3 complex 0.0241
GO.0043227 membrane-bounded organelle 0.0241
GO.0005730 nucleolus 0.0366
GO.0016282 eukaryotic 43S preinitiation complex 0.0366
GO.0031982 vesicle 0.0366
GO.0031988 membrane-bounded vesicle 0.0366
GO.0033290 eukaryotic 48S preinitiation complex 0.0366
GO.0070993 translation preinitiation complex 0.0383
GO.0030529 ribonucleoprotein complex 0.0403
GO.0044421 extracellular region part 0.0403
Table B.1: Biological term enrichment for all “MacroD2 full-length DMSO”
proteins - Overview of enriched biological terms. Generated by STRING database.
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B.2 MacroD2 full-length etoposide
The list for the enrichment of biological terms for all proteins of “MacroD2 full-length
etoposide” is enlisted below (Table B.2).
Category Term FDR
GO:0003723 RNA binding 1.22E-05
GO:0044822 poly(A) RNA binding 5.58E-05
GO:0003676 nucleic acid binding 0.0174
Table B.2: Biological term enrichment for all “MacroD2 full-length etoposide”
proteins - Overview of enriched biological terms. Generated by STRING database.
B.3 MacroD2 macrodomain DMSO
The list for the enrichment of biological terms for common proteins of “MacroD2
macrodomain DMSO” is enlisted below (Table B.3).
Category Term FDR
GO.0044822 poly(A) RNA binding 3.93E-12
GO.0003723 RNA binding 6.30E-11
GO.0043230 extracellular organelle 2.00E-10
GO.0065010 extracellular membrane-bounded organelle 2.00E-10
GO.0070062 extracellular exosome 2.00E-10
GO.1903561 extracellular vesicle 2.00E-10
GO.0031988 membrane-bounded vesicle 2.82E-08
GO.0006457 protein folding 3.90E-08
GO.0031982 vesicle 4.95E-08
GO.0032991 macromolecular complex 1.86E-06
GO.0044421 extracellular region part 2.79E-06
GO.0070013 intracellular organelle lumen 1.63E-05
GO.0044446 intracellular organelle part 1.77E-05
GO.0043233 organelle lumen 1.86E-05
GO.0031974 membrane-enclosed lumen 2.26E-05
GO.0044428 nuclear part 3.49E-05
GO.0005634 nucleus 5.59E-05
GO.0005576 extracellular region 5.83E-05
GO.0044422 organelle part 9.07E-05
GO.0003676 nucleic acid binding 0.000128
GO.0005488 binding 0.000225
GO.0005515 protein binding 0.000244
Continues on next page
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Category Term FDR
GO.0042470 melanosome 0.00052
GO.0031625 ubiquitin protein ligase binding 0.000577
GO.0044389 ubiquitin-like protein ligase binding 0.000577
GO.1901363 heterocyclic compound binding 0.000577
GO.0097159 organic cyclic compound binding 0.000585
GO.0043228 non-membrane-bounded organelle 0.000708
GO.0043232 intracellular non-membrane-bounded organelle 0.000708
GO.0044444 cytoplasmic part 0.000763
KEGG:04141 protein processing in endoplasmic reticulum 0.00109
GO.0031981 nuclear lumen 0.00132
GO.0030529 ribonucleoprotein complex 0.00176
GO.0016023 cytoplasmic membrane-bounded vesicle 0.00182
GO.0005829 cytosol 0.00194
GO.0005730 nucleolus 0.00234
GO.0043234 protein complex 0.00266
GO.0043231 intracellular membrane-bounded organelle 0.00275
GO.0043209 myelin sheath 0.00291
GO.0005737 cytoplasm 0.00317
GO.0031410 cytoplasmic vesicle 0.00321
GO.0043227 membrane-bounded organelle 0.00375
GO.0016607 nuclear speck 0.00491
GO.0015630 microtubule cytoskeleton 0.00592
GO.0044297 cell body 0.00592
GO.0051087 chaperone binding 0.00632
GO.0005832 chaperonin-containing T-complex 0.0106
GO.0005654 nucleoplasm 0.0112
GO.0005874 microtubule 0.0112
GO.0035770 ribonucleoprotein granule 0.0112
GO.0036464 cytoplasmic ribonucleoprotein granule 0.0112
GO.0097223 sperm part 0.0112
GO.0003674 molecular function 0.0114
GO.0051082 unfolded protein binding 0.0114
GO.0002199 zona pellucida receptor complex 0.0114
GO.0012505 endomembrane system 0.013
GO.0005635 nuclear envelope 0.0134
GO.0005739 mitochondrion 0.0154
KEGG:05169 Epstein-Barr virus infection 0.0183
GO.0019953 sexual reproduction 0.024
GO.0044237 cellular metabolic process 0.024
GO.0044260 cellular macromolecule metabolic process 0.024
GO.0044703 multi-organism reproductive process 0.024
Continues on next page
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Category Term FDR
GO.1902582 single-organism intracellular transport 0.0263
GO.0043170 macromolecule metabolic process 0.0289
GO.0031967 organelle envelope 0.0315
GO.0031975 envelope 0.0315
GO.0045454 cell redox homeostasis 0.0345
GO.0005783 endoplasmic reticulum 0.0382
GO.0044451 nucleoplasm part 0.0382
GO.0030518 intracellular steroid hormone receptor signaling pathway 0.0406
GO.0044702 single organism reproductive process 0.0406
GO.0051704 multi-organism process 0.0406
GO.0061024 membrane organization 0.0406
GO.0006810 transport 0.0428
GO.0046907 intracellular transport 0.0428
GO.0031090 organelle membrane 0.0433
GO.0001669 acrosomal vesicle 0.0448
GO.0016604 nuclear body 0.0456
GO.0005856 cytoskeleton 0.0479
Table B.3: Biological term enrichment for “MacroD2 macrodomain DMSO”
common proteins - Overview of enriched biological terms. Generated by STRING
database
The list for the enrichment of biological terms for all proteins of “MacroD2 macrodomain
DMSO” is enlisted below (Table B.4). Since the list of terms was extremely long,
here I show just a selection, with the lowest FDR values of each super-group, such as
cellular localization or molecular pathway.
Category Term FDR
GO.0043230 extracellular organelle 4.69E-20
GO.0065010 extracellular membrane-bounded organelle 4.69E-20
GO.0070062 extracellular exosome 4.69E-20
GO.1903561 extracellular vesicle 4.69E-20
GO.0003723 RNA binding 1.56E-16
GO.0044822 poly(A) RNA binding 1.56E-16
GO.0031988 membrane-bounded vesicle 1.05E-15
GO.0031982 vesicle 3.79E-15
GO.0044421 extracellular region part 9.04E-14
GO.0044446 intracellular organelle part 6.18E-12
GO.0006457 protein folding 2.03E-11
Continues on next page
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Category Term FDR
GO.0032991 macromolecular complex 2.24E-11
GO.0005576 extracellular region 3.58E-11
GO.0005829 cytosol 4.97E-10
GO.0044422 organelle part 9.91E-10
GO.0005488 binding 7.80E-08
GO.1901363 heterocyclic compound binding 8.43E-08
GO.0097159 organic cyclic compound binding 1.20E-07
GO.0003676 nucleic acid binding 6.86E-07
GO.0006458 de novo protein folding 2.70E-06
GO.0046907 intracellular transport 2.70E-06
GO.1902582 single-organism intracellular transport 3.05E-06
GO.0043933 macromolecular complex subunit organization 1.22E-05
GO.0061024 membrane organization 1.22E-05
GO.0051084 de novo posttranslational protein folding 1.71E-05
GO.0006413 translational initiation 6.71E-05
GO.0006605 protein targeting 6.71E-05
GO.0006810 transport 6.71E-05
GO.0016482 cytoplasmic transport 6.71E-05
GO.0032984 macromolecular complex disassembly 6.71E-05
GO.0044237 cellular metabolic process 6.71E-05
GO.0051649 establishment of localization in cell 6.71E-05
GO.0071822 protein complex subunit organization 6.71E-05
GO.0016071 mRNA metabolic process 6.79E-05
GO.0071704 organic substance metabolic process 8.13E-05
GO.0046483 heterocycle metabolic process 9.76E-05
KEGG:03010 ribosome 0.000208
KEGG:01200 carbon metabolism 0.000283
KEGG:04141 protein processing in endoplasmic reticulum 0.00392
KEGG:05169 Epstein-Barr virus infection 0.00777
KEGG:00010 glycolysis / gluconeogenesis 0.0222
KEGG:00020 citrate cycle (TCA cycle) 0.0257
KEGG:01230 biosynthesis of amino acids 0.0264
KEGG:03040 spliceosome 0.0264
KEGG:00270 cysteine and methionine metabolism 0.0362
KEGG:00620 pyruvate metabolism 0.0443
Table B.4: Biological term enrichment for all the “MacroD2 macrodomain
DMSO” proteins - Overview of enriched biological terms. Generated by STRING
database
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B.4 MacroD2 macrodomain etoposide
The list for the enrichment of biological terms for common proteins of “MacroD2
macrodomain etoposide” is enlisted below (Table B.5).
Category Term FDR
GO.0003723; RNA binding 0.00139
GO.0044822; poly(A) RNA binding 0.00139
Table B.5: Biological term enrichment for the EGFP-MacroD2 macrodomain
etoposide common proteins - Overview of enriched biological terms. Generated by
STRING database
The list for the enrichment of biological terms for all proteins of “MacroD2 macrodomain
etoposide” is enlisted below (Table B.6).
Category Term FDR
GO.0044822 poly(A) RNA binding 4.50E-06
GO.0031974 membrane-enclosed lumen 5.77E-06
GO.0044446 intracellular organelle part 5.77E-06
GO.0070013 intracellular organelle lumen 5.77E-06
GO.0043233 organelle lumen 6.13E-06
GO.0003723 RNA binding 1.96E-05
GO.0043230 extracellular organelle 2.89E-05
GO.0065010 extracellular membrane-bounded organelle 2.89E-05
GO.0070062 extracellular exosome 2.89E-05
GO.1903561 extracellular vesicle 2.89E-05
GO.0031988 membrane-bounded vesicle 4.76E-05
GO.0031982 vesicle 6.54E-05
GO.0032991 macromolecular complex 6.54E-05
GO.0044422 organelle part 6.54E-05
GO.0043227 membrane-bounded organelle 0.000252
GO.0031981 nuclear lumen 0.000363
GO.0044428 nuclear part 0.000363
GO.0044421 extracellular region part 0.000386
GO.0005634 nucleus 0.00128
GO.0043229 intracellular organelle 0.00128
GO.0005654 nucleoplasm 0.00135
GO.0044877 macromolecular complex binding 0.00155
GO.0043231 intracellular membrane-bounded organelle 0.00183
Continues on next page
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Category Term FDR
GO.0070603 SWI/SNF superfamily-type complex 0.00197
GO.0005737 cytoplasm 0.00205
GO.0005759 mitochondrial matrix 0.00205
GO.0043234 protein complex 0.0021
GO.0005635 nuclear envelope 0.00247
GO.0005515 protein binding 0.00315
GO.0044444 cytoplasmic part 0.00385
GO.0005576 extracellular region 0.0041
GO.0005622 intracellular 0.00498
GO.0044424 intracellular part 0.00744
GO.0043226 organelle 0.00768
KEGG:01230 biosynthesis of amino acids 0.00863
GO.0005925 focal adhesion 0.0135
GO.0043228 non-membrane-bounded organelle 0.0135
GO.0043232 intracellular non-membrane-bounded organelle 0.0135
GO.0005924 cell-substrate adherens junction 0.0141
GO.0030055 cell-substrate junction 0.0143
GO.0045111 intermediate filament cytoskeleton 0.0146
GO.0005739 mitochondrion 0.0155
KEGG:00280 valine, leucine and isoleucine degradation 0.0182
KEGG:03050 proteasome 0.0182
GO.0031965 nuclear membrane 0.019
GO.0071564 npBAF complex 0.0204
GO.0016514 SWI/SNF complex 0.0226
GO.0071565 nBAF complex 0.0226
GO.0005912 adherens junction 0.023
GO.0070161 anchoring junction 0.0271
GO.0031967 organelle envelope 0.0285
GO.0031975 envelope 0.0285
GO.0005829 cytosol 0.0292
GO.0044429 mitochondrial part 0.037
GO.0005838 proteasome regulatory particle 0.0399
Table B.6: Biological term enrichment for all the “MacroD2 macrodomain
etoposide” proteins - Overview of enriched biological terms. Generated by STRING
database
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B.5 MacroD2 C-terminus DMSO
The list for the enrichment of biological terms for common proteins of “MacroD2 C-
terminus DMSO” is enlisted below (Table B.7).
Category Term FDR
GO.0003723 RNA binding 0.000113
GO.0044822 poly(A) RNA binding 0.00939
GO.0003676 nucleic acid binding 0.0335
Table B.7: Biological term enrichment for “MacroD2 C-terminus DMSO” com-
mon proteins - Overview of enriched biological terms. Generated by STRING database.
The list for the enrichment of biological terms for all proteins of “MacroD2 C-
terminus DMSO” is enlisted below (Table B.8).
Category Term FDR
GO.0003723 RNA binding 3.77E-17
GO.0044822 poly(A) RNA binding 4.19E-10
GO.0003676 nucleic acid binding 5.20E-10
GO.1901363 heterocyclic compound binding 5.85E-06
GO.0097159 organic cyclic compound binding 6.45E-06
GO.0030529 ribonucleoprotein complex 2.05E-05
GO.0031981 nuclear lumen 2.05E-05
GO.0044428 nuclear part 2.05E-05
GO.0070013 intracellular organelle lumen 2.05E-05
GO.0043233 organelle lumen 2.09E-05
GO.0031974 membrane-enclosed lumen 2.27E-05
GO.0005634 nucleus 3.29E-05
GO.0005730 nucleolus 0.00107
GO.0044446 intracellular organelle part 0.00139
GO.0005654 nucleoplasm 0.00213
GO.0044422 organelle part 0.00715
GO.0032991 macromolecular complex 0.0151
GO.0043231 intracellular membrane-bounded organelle 0.0199
GO.0043603 cellular amide metabolic process 0.0295
GO.0005681 spliceosomal complex 0.0297
GO.0008380 RNA splicing 0.0306
GO.0006397 mRNA processing 0.0374
GO.0016071 mRNA metabolic process 0.0374
GO.0022618 ribonucleoprotein complex assembly 0.0374
GO.0034622 cellular macromolecular complex assembly 0.0374
GO.0071826 ribonucleoprotein complex subunit organization 0.0374
Continues on next page
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Category Term FDR
KEGG:03040 spliceosome 0.0379
GO.0005685 U1 snRNP 0.0422
GO.0006518 peptide metabolic process 0.0442
GO.0043227 membrane-bounded organelle 0.0496
Table B.8: Biological term enrichment for all the “MacroD2 C-terminus
DMSO” proteins - Overview of enriched biological terms. Generated by STRING
database
B.6 MacroD2 C-terminus etoposide
The list for the enrichment of biological terms for common proteins of “MacroD2 C-
terminus etoposide” is enlisted below (Table B.9).
Category Term FDR
GO.0043230 extracellular organelle 0.000239
GO.0065010 extracellular membrane-bounded organelle 0.000239
GO.0070062 extracellular exosome 0.000239
GO.1903561 extracellular vesicle 0.000239
GO.0051095 regulation of helicase activity 0.00295
GO.0003723 RNA binding 0.00539
GO.0044822 poly(A) RNA binding 0.00539
GO.0044421 extracellular region part 0.00607
GO.0031988 membrane-bounded vesicle 0.00924
GO.0032991 macromolecular complex 0.00924
GO.0043228 non-membrane-bounded organelle 0.00924
GO.0043232 intracellular non-membrane-bounded organelle 0.00924
GO.0031982 vesicle 0.0103
GO.0005576 extracellular region 0.0219
GO.0003676 nucleic acid binding 0.0306
Table B.9: Biological term enrichment for “MacroD2 C-terminus etoposide”
common proteins - Overview of enriched biological terms. Generated by STRING
database
The list for the enrichment of biological terms for all proteins of “MacroD2 C-
terminus etoposide” is enlisted below (Table B.10).
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Category Term FDR
GO.0043230 extracellular organelle 3.22E-12
GO.0065010 extracellular membrane-bounded organelle 3.22E-12
GO.0070062 extracellular exosome 3.22E-12
GO.1903561 extracellular vesicle 3.22E-12
GO.0044822 poly(A) RNA binding 2.35E-11
GO.0003723 RNA binding 1.56E-10
GO.0031988 membrane-bounded vesicle 1.02E-08
GO.0031982 vesicle 2.13E-08
GO.0005829 cytosol 3.59E-07
GO.0003676 nucleic acid binding 2.13E-06
GO.0005634 nucleus 2.89E-06
GO.0044421 extracellular region part 3.12E-06
GO.0032991 macromolecular complex 3.12E-05
GO.0005576 extracellular region 5.94E-05
GO.0030017 sarcomere 5.97E-05
GO.0044446 intracellular organelle part 6.94E-05
GO.0044449 contractile fiber part 8.78E-05
GO.0030016 myofibril 0.000113
GO.0031974 membrane-enclosed lumen 0.000113
GO.0043292 contractile fiber 0.000149
GO.0044428 nuclear part 0.000211
GO.0043228 non-membrane-bounded organelle 0.000215
GO.0043232 intracellular non-membrane-bounded organelle 0.000215
GO.0043233 organelle lumen 0.000215
GO.1901363 heterocyclic compound binding 0.000424
GO.0070013 intracellular organelle lumen 0.000424
GO.0097159 organic cyclic compound binding 0.000491
GO.0044422 organelle part 0.000706
GO.0043231 intracellular membrane-bounded organelle 0.000943
GO.0005739 mitochondrion 0.00122
GO.0030529 ribonucleoprotein complex 0.00159
GO.0043227 membrane-bounded organelle 0.00163
GO.0043209 myelin sheath 0.00197
GO.0043234 protein complex 0.00342
GO.0005759 mitochondrial matrix 0.00367
GO.0005488 binding 0.00412
GO.0044429 mitochondrial part 0.00441
GO.0032437 cuticular plate 0.00461
GO.0031981 nuclear lumen 0.00534
GO.0031674 I band 0.00541
GO.0070161 anchoring junction 0.0121
GO.0006457 protein folding 0.0147
Continues on next page
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Category Term FDR
KEGG:03040 spliceosome 0.0181
KEGG:03430 mismatch repair 0.0181
GO.0005527 macrolide binding 0.0194
GO.0005528 FK506 binding 0.0194
GO.0031967 organelle envelope 0.0195
GO.0031975 envelope 0.0195
GO.0022417 protein maturation by protein folding 0.0219
GO.0051095 regulation of helicase activity 0.0219
GO.0008091 spectrin 0.023
GO.0003684 damaged DNA binding 0.0293
GO.0005515 protein binding 0.0293
GO.0051087 chaperone binding 0.0293
GO.0019899 enzyme binding 0.0316
KEGG:03030 DNA replication 0.0329
GO.0005657 replication fork 0.0337
GO.0030018 Z disc 0.0337
KEGG:01200 carbon metabolism 0.0414
KEGG:05016 Huntington disease 0.0414
GO.0005912 adherens junction 0.0451
GO.0005730 nucleolus 0.0469
GO.0005685 U1 snRNP 0.0496
GO.0098827 endoplasmic reticulum subcompartment 0.0496
Table B.10: Biological term enrichment for all “MacroD2 C-terminus etopo-
side” proteins - Overview of enriched biological terms. Generated by STRING database
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